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Cancer immunotherapy is a revolutionary new method using the immune system to 
fight cancer. Immunotherapy is expected to radically change the way cancer is 
treated due to the multiple advantages it features compared to the traditional pillars 
of cancer care such as radiotherapy, chemotherapy, and surgery. Cancer 
immunotherapy “trains” the immune system in discerning and killing cancer cells, 
being more targeted and having fewer side-effects than chemo- and radiotherapy, 
and resulting in a long-lasting remission. 
Amongst the different cancer immunotherapies developed up until now, checkpoint 
blockade therapy is an important breakthrough with 5 drugs and antibodies approved 
by the American food and drug administration (FDA) and hundreds of ongoing 
clinical trials. This approach consists of inhibiting the immune escape mechanisms of 
cancer cells, unleashing the full potential of the immune system and in particular of T 
cells. However, this therapy shows a low response rate (with checkpoint blockade 
having a success rate of 10-40% in advanced melanoma patients when used as 
monotherapy). Moreover, immune-related adverse effects, development of 
resistance and late tumor relapses are emerging.  
Another possibility in cancer immunotherapy is represented by therapeutic vaccines, 
and especially the delivery of antigens and adjuvants by nanoparticles has the 
potential to improve the efficacy of such treatments. Nanoparticles can make a 
difference since they can deliver antigen and adjuvant together to the tumor site and 
lymph nodes, protect the antigen from degradation upon its administration by 
different routes and sustain the antigen release over time. Moreover, nanoparticles 
can be used to provide additional treatment modalities such as hyperthermia and 
photodynamic therapy and multimodal imaging all in a small delivery vehicle.  
The need for further developments in cancer immunotherapy led to the concept of 
combinatorial immunotherapy, where different immunotherapies cooperate together 
in order to overcome the limitations of monotherapies. A crucial element needed for 
the proper functioning of checkpoint blockade is the continuous and sustained 
generation of a population of T cells capable of recognizing the tumor, and for this 
purpose, cancer vaccines could be considered an ideal partner for immunotherapies. 
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Amongst the possible vaccine adjuvants, Toll-like receptors (TLR) ligands and in 
particular TLR4 ligands have been actively investigated due to the known crucial 
roles of TLRs. TLR4 agonists have the potential to enhance both innate and adaptive 
immunity to treat cancer; while on the other hand TLR4 antagonists can suppress 
over-stimulation, and are thus promising for the treatment of auto-immune diseases 
and sepsis. 
The best known TLR4 ligand is lipopolysaccharides (LPS), a major component of the 
cell surface of gram-negative bacteria, featuring the amphipathic domain known as 
lipid A responsible for the immunogenic activity of LPS. The FDA approved 
monophosphoryl lipid A (MPLA) and other lipid-A derivatives with reduced toxicity 
have been targets for the development of human vaccine adjuvants, with the former 
being evaluated as a cancer vaccine adjuvant in a number of clinical trials. These 
molecules achieved effective stimulation of cellular Th1 immune responses and 
CD8+ T cell responses required to mediate immunity in cancer immunotherapy. 
However, the application of TLR agonists as monotherapies and their success in 
clinical trials has been impaired by dose-limiting toxicities owing to systemic cytokine 
induction and inefficient delivery to tumors and draining lymph nodes. 
Lipooligosaccharides (LOS), LPS not possessing the O-antigen chain (also named 
rough LPS), have been investigated less for oncological applications and especially 
as adjuvants. The immune stimulatory effects and toxicity of LPS and LOS greatly 
vary due to structural differences and their “state of aggregation”. The structure of 
TLR4 ligands also plays an important role in determining whether they behave as 
TLR4 agonists or antagonists. One important aspect is the number of hydrophobic 
chains contained in the Lipid A moiety: whereas agonists are generally characterized 
by having 6 acyl chains, molecules with 4 or 5 of these chains mainly behave as 
antagonists. 
The first chapter of this thesis is a general introduction presenting the scientific 
background and some of the concepts behind this work. 
The second chapter focuses on the development of nanoplatforms loaded with 
different TLR4 ligands. The LOS from Escherichia Coli (E. coli LOS) and from the 
plant pathogen Xanthomonas campestris pv. Campestris (Xcc LOS) were used as 
anticancer vaccine adjuvants, with the hypothesis that due to the structural 
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differences from the more known LPS and MPLA they could behave differently and 
change the assembly and the characteristics of the resulting systems. Besides, IAXO 
102, a new synthetic TLR4 antagonist was loaded on nanoparticles and tested as an 
immune modulator to test the possibilities attainable by suppressing TLR4 
stimulation. 
In order to improve the delivery of these ligands, quantum dots (QDs), upconverting 
nanoparticles (UCNPs), and iron oxide nanospheres and nanocubes (IONPsp and 
IONPc) characterized by different properties, biocompatibility, complexity of 
synthesis and efficacy, were screened. By taking advantage of a self-assembly 
process and the amphiphilic character of the TLR4 modulators, several formulations 
exploiting nanoparticle encapsulation in polyethylene glycol-phospholipid micelles 
were prepared. Aiming to examine how the various TLR4 ligands could interact with 
the different nanoparticles, the pathogen-like structures derived from the hydrophobic 
interaction of ligand and nanoparticle were characterized, and amongst these, the 
best adjuvant based on in vitro results was chosen for further studies in vivo. The 
best adjuvant, mIONPsp-Xcc LOS, was generated by loading Xcc LOS onto 7 nm 
iron oxide nanospheres (IONPsp), a biocompatible and biodegradable material which 
has been already used clinically as an iron supplement, in magnetic resonance 
imaging (MRI) as contrast agent, in hyperthermia treatments and holds potential for 
use in further cancer immunotherapy approaches. Besides, the small size and the 
negative charge of the construct have the ideal characteristics for lymph-node 
delivery, and these nanoconstructs can feature multimodal imaging and boast 
intrinsic therapeutical modalities. 
The third chapter describes how the model antigen ovalbumin (OVA) was attached 
to the IONPsp by using a covalent chemistry based on a hydrazone bonding that has 
an optimal reaction yield and fast kinetics. Moreover, it works at low concentrations 
and can be monitored by UV-Vis spectroscopy to obtain live feedback. This 
approach therefore overcomes the drawbacks of the conventional conjugation 
strategies such as 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) chemistry, 
generally being cross-linking and the need for a large excess of reagents. It was also 
explored how this covalent binding strategy can be applied on the iron oxide side of 
gold-iron oxide Janus nanoparticles (JanusNPs) to exploit their unique properties 
contributing towards the development of a unique theranostic system with specific 
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applications in cancer treatment. Moreover, a system where both OVA as antigen 
and LPS as an adjuvant were loaded into a IONPsp was developed. The resulting 
nanosystems featured hydrodynamic diameters within the 20-100 nm range ideal for 
lymph node delivery. 
The fourth chapter investigates the OVA linked to mIONPsp via hydrazone bond 
(mIONPsp-HyNic-FB-OVA) formulated with the pathogen-mimicking mIONPsp-Xcc 
LOS as vaccine adjuvant in mice against B16-F10 melanoma expressing OVA, 
together with a strategy to evaluate the effect of immune checkpoint blockade for the 
immunosuppressive programmed death-ligand 1 (PD-L1). When this nanovaccine 
was administered in the mouse melanoma model combined to the checkpoint-
blockade strategy, complete rejection of the tumor and the capacity to clear a tumor 
re-challenge were observed, which could be explained by the increase in the number 
of SIINFEKL-specific CD8+ T cells. Moreover, by formulating mIONPsp-HyNic-FB-
OVA with mIONPsp-Poly(I:C)-imiquimod, an adjuvant previously developed in our 
laboratory, its antitumor activity improved compared to the same adjuvant delivered 
with the mIONPsp-OVA prepared using electrostatic adsorption.  
The importance of these results is not only related to the complete rejection of the 
tumor observed with our combined vaccine + checkpoint blockade approach, but 
also to the simple and modular assembly of the developed delivery vehicles and the 
potential applications of nanoparticles such as hyperthermia, photodynamic therapy 












Desde su descubrimiento en 1995, se espera que la inmunoterapia para el cáncer, 
un método revolucionario que utiliza el propio sistema inmunológico como arma para 
combatir el cáncer, cambie radicalmente la manera en la que se tratan los tumores. 
Esto método tiene múltiples ventajas en comparación con la radioterapia, la 
quimioterapia y la cirugía, los pilares tradicionales de la oncología. La inmunoterapia 
para el cáncer "entrena" al sistema inmunológico en el discernimiento y la 
eliminación de las células cancerosas, siendo más específica, resultando en una 
remisión duradera e induciendo menos efectos secundarios que las maneras 
tradicionales de tratamiento del cáncer. 
Un avance importante entre las diferentes inmunoterapias contra el cáncer 
desarrolladas está representado por el bloqueo de puntos de control inmunitario, un 
método que consiste en inhibir los mecanismos de escape de las células cancerosas 
desde la vigilancia del sistema inmunológico liberando todo su potencial y en 
particular el de las células T. Hasta ahora, 5 medicamentos y anticuerpos para el 
bloqueo de puntos de control inmunitario han sido aprobados por la Administración 
de Alimentos y Medicamentos de los Estados Unidos (FDA) y cientos de ensayos 
clínicos se están llevando a cabo. Desafortunadamente, esta terapia muestra una 
baja tasa de respuesta (con una tasa de éxito del 10-40% en pacientes con 
melanoma avanzado cuando se usa como monoterapia). Además, están surgiendo 
efectos adversos relacionados con el sistema inmunológico, desarrollo de 
resistencia a la terapia y recaídas tardías del tumor.  
Otra posibilidad en la inmunoterapia del cáncer está representada por las vacunas 
terapéuticas, y especialmente la administración de antígenos y adyuvantes mediante 
nanopartículas tiene el potencial de mejorar la eficacia de un tratamiento 
convencional de este tipo. Las nanopartículas pueden marcar la diferencia ya que 
pueden suministrar antígeno y adyuvante juntos al tumor y ganglios linfáticos, 
proteger el antígeno de la degradación al momento de su administración por 
diferentes vías y mantener la liberación del antígeno con el tiempo. Además, las 
nanopartículas presentan modalidades de tratamiento adicionales, como la terapia 
de hipertermia, la terapia fotodinámica y pueden ser usadas para la adquisición de 
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imagen multimodal, todo ello en un pequeño vehículo de transporte. Este concepto 
ha tomado el nombre de nanomedicina teranóstica. 
La necesidad de nuevos desarrollos en la inmunoterapia oncológica llevó al 
concepto de inmunoterapia combinatoria, en el que diferentes modalidades 
inmunoterapéuticas cooperan entre sí para superar las limitaciones de las 
monoterapias. Un elemento crucial para el éxito de la terapia de bloqueo de los 
puntos de control inmunitario es la generación continua y sostenida de una 
población de células T capaces de reconocer el tumor, y para ello, las vacunas 
contra el cáncer se consideran un socio ideal para las inmunoterapias. 
Entre los posibles adyuvantes de la vacuna, los ligandos de los receptores de tipo 
Toll (TLRs) se han investigado activamente debido a las funciones cruciales 
conocidas de los TLR y, en particular, se han investigado los que modulan el TLR4. 
Los agonistas del TLR4 son capaces de potenciar la respuesta inmune y una de sus 
posibles aplicaciones es el tratamiento del cáncer; mientras que, por otro lado, los 
antagonistas de TLR4 pueden suprimir respuestas inmunitarias demasiado fuertes y, 
por lo tanto, son prometedores para el tratamiento de enfermedades autoinmunes. 
El ligando TLR4 más conocido es el lipopolisacárido (LPS), un componente 
importante de la superficie celular de las bacterias gramnegativas, que presenta el 
dominio anfipático conocido como lípido A, responsable de la actividad 
inmunogénica del LPS. La FDA aprobó el uso del monofosforil lípido A (MPLA) como 
adyuvante en Cervarix, una vacuna contra el cáncer cervical, siendo el primer 
ligando de origen sintética de TLR aprobado para el uso en seres humanos. 
Además, el lípido A y sus derivados con toxicidad reducida han sido objetivos para 
el desarrollo de adyuvantes de vacunas humanas en una serie de ensayos clínicos. 
Estas moléculas han conseguido estimular la producción de respuestas inmunitarias 
de tipo Th1 por la inducción de citocinas proinflamatorias y moléculas 
coestimuladoras en células dendríticas (DCs). Sin embargo, han tenido un éxito 
limitado debido a su inducción sistémica de citocinas que limita la dosis 
suministrable y su incapacidad de alcanzar el tumor y los ganglios linfáticos. 
Además, nuevos estudios han demostrado que pueden inducir la producción de 
factores que inhiben la respuesta inmunológica. Por esa razón, la combinación del 
bloqueo de puntos de control inmunitario con ligandos del TLR4 representa una 
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excelente oportunidad de incrementar la eficacia terapéutica de estas moléculas en 
el tratamiento del cáncer. 
Dentro de los agonistas del TLR4, los lipooligosacáridos (LOS), LPS que no poseen 
la cadena del antígeno O, han sido menos investigados para aplicaciones en 
oncología y especialmente como adyuvantes. Los efectos inmunoestimulantes y la 
toxicidad del LPS y del LOS varían mucho debido a las diferencias estructurales y a 
su "estado de agregación". La estructura de los ligandos TLR4 también juega un 
papel importante para determinar si se comportan como agonistas o antagonistas de 
TLR4. Un aspecto importante es el número de cadenas hidrofóbicas contenidas en 
la fracción lípido A: mientras que los agonistas se caracterizan generalmente por 
tener 6 cadenas acílicas, las moléculas con 4 o 5 de estas cadenas se comportan 
principalmente como antagonistas. 
Dentro de lo posibles antígenos, la ovoalbúmina (OVA), la principal proteína 
presente en la clara de huevo de gallina, es un candidato ideal para el uso como 
antígeno modelo debido a su disponibilidad comercial y bajo coste. Varios modelos 
tumorales que expresan OVA se han desarrollado específicamente para probar la 
eficacia de diferentes estrategias inmunoterapéuticas contra el cáncer y melanomas, 
y varios trabajos han usado el antígeno OVA como prueba de concepto.  
Muchos estudios han explotado la entrega de antígenos por nanopartículas y 
diferentes estrategias han sido utilizadas para la formación de enlaces entre la 
nanopartícula y el antígeno, entre ellas la activación de la carbodiimida (por ejemplo, 
1-etil-3-(3 dimetilaminopropil)carbodiimida, o EDC). Esta estrategia sufre de pobre 
quimioselectividad, requiere un exceso de reactivos para funcionar de una manera 
adecuada, es sensible a las variaciones de temperatura y pH y sufre de reticulación, 
que resulta en agregación y perdida de la estabilidad coloidal. Adicionalmente, la 
falta de métodos analíticos adecuados para caracterizar rápidamente el producto de 
la conjugación y su estequiometría comporta que no hay respuesta directa sobre el 
progreso de la reacción y consecuentemente su optimización es complicada. Aquí 
se aplicó un enlace de bis-arilhidrazona para el acoplamiento de nanoesferas de 
hierro al antígeno modelo ovoalbúmina (OVA), usando anilina como catalizador 
nucleófilo. La reacción de formación de hidrazona se pudo monitorizar por UV-vis, 
demostró una cinética de reacción rápida, alto rendimiento químico de conjugación 
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(>85% en pocos minutos) a concentraciones micromolares (0.5- 3 μM) y pH neutro, 
produciendo nanoplataformas estables y proporcionando ventajas significativas en la 
formación de conjugados antígeno-nanopartícula. 
 
• El primer capítulo de esta tesis es una introducción general que pretende 
discutir los antecedentes científicos y algunos de los conceptos que subyacen 
a este trabajo.  
 
• El segundo capítulo se centra en el desarrollo de nanoplataformas 
funcionalizadas con diferentes ligandos TLR4. Se utilizaron los LOS de 
Escherichia Coli (E. Coli LOS) y el del patógeno vegetal Xanthomonas 
campestris pv. campestris (Xcc LOS) como adyuvantes de la vacuna contra el 
cáncer, con la hipótesis de que, debido a sus diferencias estructurales con 
respecto a los más conocidos E. Coli LPS y MPLA, podrían comportarse de 
forma diferente afectando el ensamblaje y las características de los sistemas 
resultantes. Debido a nuestro interés tanto en la estimulación como en la 
regulación de la respuesta inmune alcanzable con la modulación del TLR4, se 
probó también el ligando IAXO 102, un nuevo antagonista sintético como 
inmunosupresor del TLR4. Con el fin de mejorar la entrega de estos ligandos, 
se examinaron puntos cuánticos (QDs), nanopartículas de conversión 
ascendente (UCNPs) y nanoesferas y nanocubos de óxido de hierro (IONPsp 
y IONPc) caracterizadas por diferentes propriedades, biocompatibilidad, 
complejidad de síntesis y eficacia. Aprovechando de un proceso de 
autoensamblaje y de la hidrofobicidad de los moduladores TLR4, se 
prepararon varias formulaciones aprovechando la encapsulación de 
nanopartículas en micelas de polietilenglicol-fosfolípidos. Con el objetivo de 
examinar cómo los distintos ligandos TLR4 podrían interactuar con las 
diferentes nanopartículas, se caracterizaron las estructuras similares a 
patógenos únicas derivadas de la interacción hidrofóbica entre ligando y 
nanopartícula. Entre ellas, se eligió el mejor adyuvante basado en resultados 
"in vitro" para estudios posteriores "in vivo", basándose en la toxicidad y en 
las propiedades inmunoestimulantes, medidas por la liberación de la 
interleucina 6 (IL-6), tras administración de las nanoplataformas a los 
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macrófagos murinos J774A.1. El mejor adyuvante, mIONPsp-Xcc LOS, 
resultante de la funcionalización de IONPsp con el ligando Xcc LOS, fue 
generado usando IONPsp con un tamaño de 7 nm, un material biocompatible 
y biodegradable que ya ha sido usado clínicamente como suplemento de 
hierro, en agentes de contraste de imagen por resonancia magnética (IRM) y 
en tratamientos de hipertermia. Además, el pequeño tamaño y la carga 
negativa de los sistemas obtenidos constituyen características ideales para la 
administración en ganglios linfáticos y pueden potencialmente ofrecer 
modalidades terapéuticas intrínsecas e imagen multimodal. 
 
• El tercer capítulo describe cómo el antígeno modelo OVA se unió a las 
IONPsp utilizando la formación del enlace covalente hidrazona, rendiendo 
mIONPsp-HyNic-FB-OVA. También se exploró cómo esta estrategia de unión 
covalente puede aplicarse en el lado de óxido de hierro de nanopartículas 
Janus (JanusNPs) para explotar las propiedades únicas de estas 
nanopartículas y contribuir al desarrollo de un sistema teranóstico único con 
aplicaciones específicas en el tratamiento del cáncer. Además, también se 
desarrolló y probó in vitro un sistema en el que tanto E. Coli LPS como 
adyuvante y OVA como antígeno se unieron a una IONPsp. Todas las 
nanoplataformas resultantes fueron caracterizadas por un tamaño en el rango 
de 20-100 nm ideal para administración a los ganglios linfáticos. 
 
• El cuarto capítulo investiga la actividad antitumoral de la formulación 
compuesta por mIONPsp-HyNic-FB-OVA y mIONPsp-Xcc LOS en ratones 
contra el melanoma B16-F10 que expresa OVA (B16-F10(OVA)), junto con 
una estrategia para evaluar el efecto del bloqueo del punto de control 
inmunológico, apuntando el ligando del receptor de muerte programada 1 
(PD-L1). Cuando esta nanovacuna fue administrada en el modelo de 
melanoma de ratones y combinado con la estrategia de bloqueo de puntos de 
control, se observó un rechazo completo del tumor y la capacidad de eliminar 
un nuevo desafío tumoral, lo que podría explicarse por el aumento en el 
número de células T CD8+ específicas para el SIINFEKL. Además, la 
formulación de las mIONPsp-HyNic-FB-OVA con mIONPsp-Poly(I:C)-
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imiquimod, un adyuvante desarrollado precedentemente en nuestro 
laboratorio, consiguió mejorar el efecto antitumoral del mismo adyuvante 
formulado con mIONPsp-OVA obtenidas por anclaje electrostático.  
 
La importancia de estos resultados no sólo está relacionada con el rechazo 
completo del tumor observado con nuestro enfoque de vacuna combinada + bloqueo 
de puntos de control en modelos de melanoma cutáneo para ratones, sino también 
con el ensamblaje simple y modular de los vehículos de transporte desarrollados y 
las aplicaciones potenciales de nanopartículas como la adquisición de imágenes y 
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1.1: Cancer immunotherapy 
Immunotherapy is a new treatment modality that uses the immune system as a 
weapon to fight cancer1,2,3. This new approach holds the biggest promise for cancer 
treatment since the development of the first chemotherapies in the 1940s4 and has 
recently been reported as one of the main pillars of cancer care, alongside surgery, 
radiotherapy, and chemotherapy5 (Figure 1). 
 
Figure 1: Development timeline of specific cancer treatment modalities. 
Immunotherapy dates back to China’s third century BC Qin dynasty, where it was 
used to prevent smallpox6, but only in the second half of the 19th century the German 
physicians Busch and Fehleisen independently noticed regression of tumors in 
cancer patients after accidental infections by a pathogen7. In 1890 William B. Coley 
developed the scientific notion that tumors express specific antigens which could 
render them naturally immunogenic in case adequate immunostimulation is provided 
and reported a significant number of tumor regressions and cures in more than 1,000 
patients6. The next step in the development of cancer vaccines would take a century, 
impaired by the lack of knowledge of tumor antigens: in 1976 Morales et al. reported8 
that the bacterium known as “Bacillus Calmette-Guérin” (BCG) was effective in the 
treatment of superficial bladder cancer, and BCG was approved by the American 
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food and drug administration (FDA) 14 years later9 to treat such disease. In 1985, 
Hoover et al.10 showed that BCG could be used also to treat colorectal cancer, 
showing modest clinical benefit in a small number of patients. Important 
breakthroughs in the understanding of anticancer cancer immunity were reported 
separately by Steinman et al.11 in 1973 with the discovery of dendritic cells (DCs) 
and by van der Bruggen et al.12 in 1991, which discovered the first human tumor-
associated antigen: MAGE1. Years later, in 2010, the FDA approved the first-ever 
DC-based prostate cancer vaccine Sipuleucel-T (Provenge; Dendreon) for 
therapeutical use in humans13. More specifically targeted cancer immunotherapies 
were approved in recent times and include the first immune checkpoint inhibitors: the 
three antibodies nivolumab14, ipilimumab15, and pembrolizumab16,17, a bi-specific T- 
cell engager targeting a specific antigen (Blinatumomab)18, and an oncolytic virus to 
enhance systemic antitumor immune responses (Talimogene Laherparepvec)19. 
Consequently, immunotherapy treatments have been classified according to the 
mechanisms they follow, each of which exhibits different characteristics as well as 
advantages and disadvantages. This thesis will mainly concentrate on checkpoint 
inhibition and cancer vaccines. However there are other immunotherapy approaches 
and approved immunotherapeutic drugs5. 
1.1.1: Programmed cell death protein 1 (PD-1) and programmed death-ligand 1 
(PD-L1) checkpoint blockade strategies in cancer immunotherapy  
Targeting the programmed death protein 1 (PD-1)/ programmed death-ligand 1 (PD-
L1) axis, immune checkpoint inhibitors have been reported to reactivate CD8+ T cells 
to perform an attack against cancer cells hence “releasing the brakes” of anti-tumor 
immunity20,21,22. In fact, it has been recently reported that expression of immune-
inhibitory checkpoints such as PD-1/PD-L1 is a potent mediator for the balance and 
escape phases of cancer immune editing21. PD-1 (also called CD279) is one of the 
co-inhibitory receptors expressed on a variety of immune cells, such as monocytes, 
T cells, B cells, DCs, and tumor-infiltrating lymphocytes (TILs), and it interacts with 
two ligands, PD-L1 and PD-L223 (Figure 2). However, PD-L1 is expressed in tumor 
cells and antigen-presenting cells (APCs), and the engagement of their PD-L1 with 
the PD-1 of T cells creates T cell dysfunction, exhaustion, neutralization, and IL-10 
production in a tumor mass24. Additionally, the PD-1 inhibitory receptor is expressed 
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by T cells during long-term antigen exposure25. Therefore, the function of a tumor 
overexpressing PD-L1 is to protect itself from CD8+ T cell-mediated cell killing. 
Physiologically, the PD-1/PD-L1 pathway developed as a result of the need to control 
inflammation and secure normal tissue from damage26. 
 
Figure. 2: PD-1/ PD-L1 axis checkpoint blockade mechanism: T cell receptors (TCR) 
interact with the major histocompatibility complex (MHC) on tumor cells. On the other 
hand, PD-1 interacts with PD-L1 inhibiting T cells. Using anti-PD-1 antibodies and 
anti-PD-L1 antibodies suppresses these interactions “unleashing” the full T cell 
potential.  
Recently, many antibody-based checkpoint inhibitors targeting PD-1 or PD-L1 have 
been developed. To date five PD-1/PD-L1 inhibitors (PD-1 – nivolumab, PD-1 – 
pembrolizumab, PD-L1 – atezolizumab, PD-L1 – durvalumab, PD-L1 – avelumab)23 
have been FDA approved for the treatment of a wide spectrum of cancers including a 
large number of malignancies27. Those diseases include melanoma, non-small cell 
lung cancer (NSCLC), renal cell carcinoma (RCC), Hodgkin’s lymphoma, bladder 
cancer, head and neck squamous cell carcinoma (HNSCC), Merkel-cell carcinoma, 
and microsatellite instable-high (MSI-H) or mismatch repair-deficient (dMMR) solid 
tumors. Furthermore, as of March 2018, more than 1000 clinical trials of antibodies 
targeting the PD-1/PD-L1 axis are ongoing23. 
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Despite the huge clinical success of PD-1/PD-L1 antibodies and the improvement in 
patient outcome, some deficiencies of this therapy have been described recently. 
First of all, only a minority of patients have shown durable responses, with the 
frequency of rapid tumor shrinkage from single-agent anti-PD-1/PD-L1 antibodies 
ranging from 10–40% in advanced melanoma patients28. Moreover, intrinsic therapy 
resistance is common, and acquired resistance is emerging, suggesting that a 
broader view of cancer immunity is required29,23. Besides, anti-PD-1/PD-L1 therapy is 
limited to a few specific types of cancers, attributed to the heterogeneous and 
insufficient expression of such receptors in the tumor microenvironment21. A variety 
of factors contribute to determining whether an efficient response to the therapy 
occurs and appear to be associated with the diverse tumor phenotypes revealed by 
clinical studies. Differences between the phenotypes depend on whether the tumors 
host an inflammatory microenvironment, which can reflect variations in a number of 
cellular and other factors such as age, genetics, microbiome, viral infections, and 
immune-modifying drugs28. 
The context is key for the PD-1 pathway, with factors such as timing, location, T cell 
differentiation state, inflammation levels and antigen burden having an impact on the 
functional outcome of PD-1 engagement30. The activity of this immunotherapy 
strategy strictly depends on the generation of a population of T cells capable of 
recognizing the tumor through APCs. If this process does not occur, PD-1/PD-L1 
blockade is inefficient, because of the lack of an appropriate immune response that 
can trigger the effective killing of the tumor cells21. Therefore, even after successful 
anti-PD-1/PD-L1 therapy, a self-renewing or expanding memory T cell compartment 
may be too little to keep pace with tumor growth. In such occurrences, continued 
priming of naive T cells is necessary to replenish and support the antitumor 
response28. This is the reason for which a PD-L1 checkpoint blockade strategy was 





1.1.2: Vaccines for cancer immunotherapy 
The combination of immune checkpoint blockade approaches and vaccines offers 
intriguing opportunities to overcome their limitations and make therapies more widely 
effective amongst patients31,32. Before discussing the use of vaccines in cancer 
immunotherapy, a small introduction to the immune system together with its basic 
working principles is presented below.  
The immune system is mainly composed of two different arms, known as innate 
immunity and adaptive immunity. The former is the first line of defense and displays 
a nonspecific immune response against “danger” signals coming from external 
threats such as bacteria and toxins or internal ones such as growing tumors. Ideally, 
such conditions induce inflammation, activate innate effector cells with antitumor 
activity and stimulate professional APCs, especially DCs. These engulf tumor-
derived antigens and finally migrate to the draining lymph nodes to trigger an 
adaptive response by T and B lymphocytes, involving the adaptive immune system 
(Figure 3).  
As reported by Mellman et al., three distinct steps take part in generating effective 
antitumor immunity: 
1: Dendritic cells must sample tumor-associated antigens (TAAs), process and finally 
present them. TAAs can be either captured “in situ” or received from an external 
source such as therapeutic vaccines. These antigens might reflect one or more of 
the many mutated proteins that are typical of cancer or differentiation antigens 
associated with the cancer’s tissue of origin, but against which thymic or peripheral 
tolerance has not been completely established (for example, melanosome- 
associated proteins in melanoma)33. Antigen processing and presentation is also 
known as maturation and makes them differentiate extensively to promote immunity 




Figure 3: Innate and adaptive immune response. The former is the first line of 
defense against infection while the second is slower but more antigen-specific and 
keeps memory.  
Maturation should be performed by a stimulatory adjuvant to elicit the desired T cells. 
Activation signals for therapy could be supplied exogenously (for example, Toll-like 
receptor (TLR) ligands) or endogenously, enabling tumor antigens presentation on 
MHC class I and class II molecules. Recently, it was claimed that MHC class II 
epitopes are the driving force for cancer immunotherapy37, but discussing that is not 
the objective of this thesis. 
 
2: Tumor-antigen-loaded dendritic cells must migrate to lymphoid organs and 
promote T cell expansion38, to an extent that makes detection and elimination of 
cancer cells possible. Amongst T cells, expansion of CD81 effector T cells with 
cytotoxic potential, antibody and natural killer (NK) or natural killer T (NKT)- cell 
responses are desirable since they may contribute to antitumor immunity. 
  
3: Finally, educated cancer-specific T cells must enter the tumor bed and persist 
there long enough to kill the malignant cells. At this moment, tumors can release 
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immunosuppressive factors enabling Tregs cells to accumulate or expand, which 
could oppose the activity of effector T cells downregulating the expression of target 
tumor antigens. The tumor might also produce a variety of surface molecules (for 
example, PD-L1 or PD-L2) that engage receptors on the surfaces of activated T cells 
(PD-1), causing T cell anergy or exhaustion39. 
 
After having discussed the basis of the immune system functioning, and according to 
the current understanding of how antigen-specific immune responses are generated, 
the key components of cancer vaccines can be summarized in three components: 
tumor antigens, immune adjuvants, and delivery vehicles40,32 and will be described 
herein.  
 
But how does a vaccine work? First of all, APCs such as DCs must encounter the 
antigen, and this happens at the injection site. Antigen-loaded APCs then traffic 
through the lymphatic system to the draining lymph nodes, the main site of T cell 
priming. Here, mature DCs present the tumor-derived peptides on MHC class I 
molecules and MHC class II molecules to CD8+ and CD4+ T cells, respectively, of 
both naive and memory phenotypes. Additionally, tumor-specific responses are 
promoted by the delivery of costimulatory signals (CD80-CD28, CD86–CD28, CD70–
CD27 and CD40–CD40L interactions) and co-stimulation is increased by DC 
releasing IL-12 and type I interferons (IFNs). Finally, T cells traffic to the tumor site 
and kill tumor cells through cytotoxicity and production of effector cytokines. The 
lysed tumor cells release tumor antigen causing epitope spreading thus increasing 









1.1.2.1: Tumor antigens 
According to Coulie et al., each tumor is characterized by the presence of several 
tumor antigens31. Generally, two broad categories of antigens can be recognized: 
TAAs and tumor-specific antigens (TSAs). The former are the ones that are 
overexpressed, involved in tissue differentiation or preferentially expressed by 
cancer cells but not normal tissue. Although TAAs are commonly associated with 
malignant cells, they can also be expressed by healthy ones41. On the other hand, 
tumor-specific antigens are expressed only by cancer cells and therefore they are 
tumor specific. TSAs are profitable targets for cancer immunotherapy because they 
generate T lymphocytes-mediated responses. First, T cell responses elicited against 
such antigens in cancer patients leave normal tissues completely unharmed. 
Second, our natural tolerance mechanisms should not prevent or repress these 
responses. In fact, vaccines using these antigens have already shown efficacy in 
both preventive and therapeutic settings for HPV-associated cancers42. Amongst 
them, tumor neoantigens are generated as products of somatic mutations, and 
hence they are not only fully tumor specific but also highly immunogenic, lacking 
central tolerance. However, it should be taken into account that some procedures 
used to generate responder T cells against tumor-specific antigens do generate T 
cells that crossreact with other antigens present on normal cells. This can result in 
harmful side effects31. In general, antitumoral T cells are more likely to attack normal 
tissues when low tumoral specificity antigens are involved, such as differentiation 
antigens or overexpressed ones. Amongst the many antigens that have been 
reported in the literature, selecting an effective one was not the objective of this 
thesis, it was rather to study the efficiency of the developed vaccine. For this 
purpose, ovalbumin (OVA) was selected as a proof of concept antigen. OVA is the 
main protein present in chicken egg white and can act as a tumor neoantigen43. Its 
low cost and commercial availability make OVA an ideal candidate for use as a 
model antigenic molecule. Several OVA-expressing tumor models have been 
developed specifically to test the efficacy of different immunotherapeutic strategies 
against cancer and several papers have reported the use of OVA as a model 
antigen44,45,46,47. Moreover, several OVA-expressing tumor models have been 
developed specifically to test the efficacy in different melanomas. 
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1.1.2.2: Vaccine adjuvants 
 
Adjuvants are substances or interventions that, when combined with an antigen, 
enhance antigen immunogenicity and elicit the desired immune response40. On their 
own, adjuvants do not provide immunity, but rather stimulate the immune system to 
respond to a defined antigen and play a key role in improving the humoral and/or 
cell-mediated immune response to vaccine antigens and in eliciting protective and 
long-lasting immunity48,49 (Figure 5). Indeed, the word “adjuvant” comes from the 
Latin “adiuvare” and means “to help/aid”. Adjuvants can be classified according to 
their mode of action, as reported in 1997 by Cox et al.50: (i) immunomodulation 
(modification of cytokine networks); (ii) presentation (maintenance of antigen 
conformation); (iii) CD8+ T cells induction; (iv) targeting specific cells; (v) depot 
generation. A list of the advantages related to the use of vaccine adjuvants is given 
below48: 
1: They decrease the dose of antigen and the number of vaccine doses needed; 
2: Improve vaccine efficiency in infants, elderly and immunocompromised people; 
3: Increase functional antibody titer; 
4: Promote more rapid and long-lasting immune responses; 
5: Induce robust cell-mediated immunity; 
6: Provide broad protection (cross-reactivity); 
7: Facilitate mucosal immunity; 
8: Overcome antigen competition in combination vaccines. 
 
The discovery of adjuvants was first reported in 1926 by Alexander T. Glenny and 
colleagues, who reported that antigen precipitation onto insoluble particles of 
aluminum potassium sulfate (named “potash alum”) could improve antibody 
responses with respect to the soluble antigen alone. Aluminum salts were used in 
vaccine preparations with tetanus and diphtheria toxoids to protect against C. tetani 
and C. diphtheriae respectively, and still, nowadays insoluble aluminum salts are 
used worldwide as the principal adjuvants in clinical vaccines51. Unfortunately, 
despite aluminum-based adjuvants being capable of eliciting a good Th2-type 
response (i.e., antibody production-based response optimal for fighting extracellular 
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pathogens), they are not able to induce potent cell-mediated immunity (Th1-type 
response), which is a fundamental requisite for developing a successful anticancer 
vaccine52. On the other hand, TLR agonists such as polyinosinic: polycytidylic acid 
(Poly(I:C)), monophosphoryl lipid A (MPLA), and imiquimod (respectively TLR3, 
TLR4, and TLR7 ligands) have recently been used to enhance the immunogenicity of 
vaccines53,54,55 especially because of the Th1-type immune response that they 
stimulate. The use of TLR4-based vaccine adjuvants is part of the strategy used in 
this thesis and will be discussed later in this chapter. 
 






1.1.2.3: Delivery vehicles 
The process of developing an effective vaccine formulation requires careful selection 
of a potent antigen, efficient adjuvant and delivery vehicle.  
Traditional vaccines such as killed microbes, live attenuated microbes, or microbes’ 
components have had a main role in the past to control infectious diseases. 
However, they have many drawbacks: require multiple doses, may show side effects 
like inflammation at the site of vaccination and some do not confer good protection 
against disease. Besides, in nowadays’ society some live vaccines might not be safe 
to be used in the growing population of immunocompromised individuals. There is 
also a wide range of infectious diseases for which no licensed vaccines are 
available. An important advance is in the development of subunit vaccines, but they 
feature poor immunogenicity and inability to cross intestinal mucosal tissues due to 
degradation by metabolic enzymes56,57. It is also known that antigen and adjuvant 
should be together at the same site since APCs which process the antigen are also 
responsible for the activation of naïve T cells. This is where carriers can make a 
difference since they can deliver both antigen and adjuvant to the cell, protect the 
antigen from degradation upon its administration by different routes and sustain the 
antigen release over time58,59. Several particle-based vaccine delivery systems such 
as polymeric, lipid-based and chitosan nanoparticles have been investigated57, and 
Gregory et al. subdivided the different kinds of vaccine carriers used up until now in 5 
different categories (Table 1). This thesis will focus on the delivery of antigens and 
adjuvants with different kinds of nanoparticles with unique properties. Nanoparticles 
are attractive delivery vehicles for vaccines. Due to their unique chemical, physical 
and biological properties, nanoparticles are considered to be efficient delivery 
vectors for drugs, proteins, peptides, and nucleic acids. Besides, they can improve 
DC-mediated antigen uptake, direct DCs stimulation, stimulate cross-presentation, 
and act as an adjuvant on their own. Conjugation of antigens onto nanoparticles can 
allow presentation of the immunogen to the immune system in much the same way 
that it would be presented by the pathogen, thereby provoking a similar 
response56,60,40. Florindo et al. reported that upon associating an antigen with 
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nanoparticles, a stronger immune response is generated compared to the soluble 
antigen alone61.  
 
Table 1: Brief summary and pictorial representation of different types of carriers for 






1.1.3: Combinatorial immunotherapy 
Since the different kinds of immunotherapies have advantages and disadvantages, 
several new approaches target combinatorial immunotherapy or immunotherapeutic 
synergy, which can be defined as a therapeutic effect superior to the additive effect 
of each of the components in a combination and is nowadays seen as the most 
promising method for progress in cancer treatment62,63,64. Numerous clinical trials of 
immunotherapy combinations are ongoing and can be found in (Clinical Trials.gov). 
One of the first attempts was performed by Schwartzenruber et al.65, that used a 
combination of high-dose IL-2 and a peptide vaccine in a Phase III trial obtaining 
improved clinical responses. However, it should be pointed out that hospitalizing 
patients is required for high-dose IL-2 due to the toxicity associated with the 
administration of this therapy63. Many different combinations of checkpoint inhibitors 
have been reported, and especially combinations of checkpoint blockade with other 
strategies are very promising54,20,9. Although the drug ipilimumab, blocking Cytotoxic 
T-lymphocyte-associated protein 4 (CTLA-4) has been FDA approved for use in 
metastatic melanoma patients15 and is currently being evaluated in two Phase III 
clinical trials for the treatment of advanced castration-resistant prostate cancer66, 
CTLA-4 blockade can cause autoimmune adverse effects67,68,69. Another way to 
increment the effectiveness of cancer immunotherapy is the combined administration 
of PD-1-blocking antibodies and CTLA-4-blocking antibodies. Despite having already 
been approved for melanoma treatment and being investigated in many other 
malignancies, the combination of ipilimumab with pembrolizumab or nivolumab has a 
drawback, leading to substantially higher toxicity in both melanoma and non-small 
cell lung cancer70,9. Other possible combinatorial approaches that will be discussed 
in this thesis include the partnership between strategies targeting checkpoint 
blockade and cancer vaccines. Since cancer vaccines possess potential to both 
generate new antigen-specific T cell responses against tumor cells and amplify 
existing responses, they may be an effective combinatorial partner with checkpoint 
blockade because they can presensitize the host’s immune system to the tumor32. By 
picking suitable antigen targets, a strong tumor-specific immune response can be 
induced while minimizing autoimmunity. Recent studies have shown that tumor 
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neoantigens are key targets for adoptive cell transfer, checkpoint blockade and 
therapeutic vaccination71,72,37,73.  
1.2: Toll-like receptors-based cancer immunotherapy 
1.2.1: An introduction to Toll-like receptors (TLRs) and their importance 
TLRs are a family of transmembrane pattern recognition receptors (PRRs) capable 
of detecting conserved pathogen-associated molecular patterns (PAMPs) expressed 
on a wide array of microorganisms as well as endogenous damage-associated 
molecular patterns (DAMPs) released from stressed or dying cells. They are well-
known for the role they play in host defense against infection. Lately, there has been 
some interest in TLRs since they play a role in tissue repair and tissue injury-induced 
inflammation, and more importantly for this thesis, in activating and mediating 
antitumor immune responses74,75,76,77,78. 
The TLRs that recognize lipids and protein as ligands are localized on the plasma 
membrane (TLR1, TLR2, TLR4, TLR5, and TLR6), whereas TLRs detecting viral 
nucleic acids are expressed on endolysosomal compartments (TLR3, TLR7 and 
TLR9) (Figure 6). TLRs transmit signals through one or more of four adaptor 
proteins: myeloid differentiation factor 88 (MyD88), Toll-interleukin 1 (TIR) receptor 
domain-containing adapter-inducing interferon-β (TRIF), TIR-domain containing 
adaptor protein (TIRAP), and TIR-containing adapter molecule 2 (TICAM2). All TLRs 
signal through MyD88, except for TLR3, which signals through TICAM1, and TLR4 
signals through both the MyD88 and TRIF pathways74,79. 
TLRs are critical for the activation and maturation of the B-cell response during 
infection and vaccination due to their role to mediate the adaptive immunity80,74. 
Indeed, TLRs-mediated activation of professional antigen-presenting cells has a 
fundamental role in immunotherapy since it is necessary for processes such as 
antigen processing and presentation81, T cell activation82,83,84, activation of naive 
CD4 T cells85, and the inhibition of regulatory T cell activity86.  
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Purified TLR ligands have been demonstrated to induce potent anticancer effects 
against established tumors both in mice and humans. Amongst them, CpG 
oligodeoxynucleotide (CpG ODN), a TLR9 agonist, has been reported to induce 
strong Th1 adaptive and innate immune responses when used as a vaccine adjuvant 
and a number of CpG ODN-based vaccine adjuvants are ongoing clinical trials since 
TLR9 activation has been reported to enhance tumor vaccination in humans87. This 
thesis will mainly focus on the stimulation of TLR4 but the antitumor activity of other 
TLRs is reviewed elsewhere74. 
 
Figure 6: TLRs take part in the recognition of PAMPs and DAMPs. After ligation of 
TLR ligands either directly or with the help of accessory molecules, TLRs lead to the 
activation of a signaling cascade, which in turn activates the regulation of innate and 
adaptive immune responses, inflammation and tissue repair. 
 
 
1.2.2: Toll-like receptor 4 (TLR4) stimulation in cancer immunotherapy 
TLR4 strongly activates inflammatory pathways, thus making it an ideal target for 
therapeutic intervention and adjuvant development88. This receptor has long been 
involved in the quest for the development of antitumor therapies: at the end of the 
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19th century, Dr. William Coley reported that the injection of killed bacteria 
(Streptococcus pyogenes) into inoperable tumors reduced tumor growth in some 
patients89. However, the scientific community had to wait almost one century until 
Beutler and colleagues identified TLR4 as a receptor of Lipopolysaccharides (LPS)90. 
More recently, the mechanism of LPS binding to TLR4 has been reported91: this 
receptor heterodimerizes together with the help of his cofactors, cluster of 
differentiation 14 (CD14) and MD-2, and needs LPS to be presented by an LPS 
binding protein (Figure 7). 
 
Figure 7: Activation of TLR4 and its dimerization. LPS is taken by the LPS binding 
protein and cofactors CD14 and MD-2 are needed to activate the receptor. 
 
Nowadays, it is known that Coley’s toxin’s proinflammatory activity is due to the 
various bacterial components it contains such as the strongly immunostimulatory 
LPS and the TLR4 engagement on immune cells.   
Immunologically, the importance of TLR4 relates to the fact that upon stimulation 
with LPS, it is able to activate and promote T cell proliferation by stimulating APCs. 
Besides, it induces production of various proinflammatory cytokines such as tumor 
necrosis factor α (TNF-α), IL-6, pro-IL-1β, and IL-1274, corresponding to a Th1 type 
response88, promoting nonspecific or bystander T cell expansion and activation92. 
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Moreover, CD4+ and CD8+ T cells too can respond to TLR4 stimulation with LPS. A 
study from Vogel et al. reported that a cloned murine IL-2-dependent cytotoxic T cell 
line, CT 6, proliferated in response to LPS93. TLR4 engagement on human CD8+ T 
cells has also been proved to induce the release of TNF-α, IFN-γ, perforin and 
granzyme B94,75. An interesting paper by Bauer et al. showed that the expression of 
TLR4 on lung epithelium can have a protective effect against lung cancer 
development95. 
Some recent studies have suggested additional roles of TLRs in inducing anti-tumor 
T cell responses. Apetoh et al. have suggested that TLR4 provide an important 
contribution to chemotherapy and radiotherapy. The authors studied the effect of 
those two conventional treatment methods in TLR4- and MyD88-deficient mice and 
noted that the ability of numerous chemotherapeutic agents to kill established tumors 
was decreased. They demonstrated that the high-mobility-group box 1 alarmin 
protein (HMGB1) binds to TLR4 and that HMGB1, which is released by 
chemotherapy-induced cell death, can activate TLR4 and induce anti-tumor T cell 
immunity96. Another study by Yusuf et al. shows that C3H/HeJ mice with a TLR4 
mutation causing loss-of-function developed more tumors than wild-type mice when 
treated with 7,12-dimethylbenz(a)anthracene (DMBA) to induce skin tumors, 
probably owing to decreased activation of interferon-γ-dependent anti-tumor T cell 
responses97. Hsiao et al. found that TLR4 agonistic treatment inhibits migration and 
invasion of Hepatoblastoma HepG2 cells “in vitro” and can thus be a potential 
therapeutic target for control of this kind of tumor’s progression98.  
However, to date TLR modulators have shown modest antitumor effects in the clinic, 
and that is the reason for which it is important to improve their efficiency by different 
strategies such as combination with other agents to synergistically enhance their 
immunostimulatory capacity79. Another viable option, since TLR expression and its 
costimulatory effects on T cells depend on TCR stimulation, consists in fine-tuning 
the timing and capacity of the ligand to make it to the tumor site75, and this is what 
this thesis aims to accomplish by developing NP-based delivery vehicles for TLR4 





1.2.2.1: TLR4 agonists as vaccine adjuvants 
TLR modulators, especially TLR4 agonists, have been studied intensively in the last 
few years due to the role they play in modulating the innate and adaptive immune 
response99,100 and as a class of promising anticancer vaccines and therapeutics 
96,101,102.  
To date only MPLA (Figure 8), a TLR4 agonist and much less toxic derivative of 
LPS, has been FDA approved for use in humans. It is used as an adjuvant in 
Cervarix, a vaccine to prevent cervical cancer caused by human papillomavirus 
types 16 and 18103, and it is in phase I clinical trial for patients with colorectal 
cancer76. MPLA has also been approved in Europe as an adjuvant for a hepatitis B 
vaccine, Fendrix104. An old TLR agonist approved by the FDA for use in cancer 
patients is BCG which stimulates TLR2, TLR3 and possibly TLR9 other than TLR475. 
LPS and many of its less toxic derivatives, such as its active component Lipid A, 
aminoalkyl glucosamidine-4-phosphates (AGP) (Figure 8) and Corixa 675 (an 
aqueous formulation of Lipid A) are being extensively studied due to the strong 
inflammatory response they cause and their capacity to induce and activate 
antitumor responses105,103. Besides, also synthetic compounds mimicking the LPS 
structure like glucopyranosyl lipid A (GLA) (Figure 8) and compounds D1 and 
D7106,107 have been prepared and tested. As Cui et al. reported108, despite Lipid A 
being less toxic than LPS, the latter induces a much larger fraction of LPS-primed 
CD8+ T cells in the memory cell pool compared with the former. Unfortunately, 
despite many new adjuvants are being studied and developed109, finding an effective 
and safe one remains a challenge since many cause an unwanted systemic 
production of cytokines and toxicity110,111. To efficiently face this issue, control of the 
adjuvant’s pharmacodynamics and biodistribution will be fundamental to modulate 
and focalize its activity to further improve them112,113,114. That is why one of the 












































































1.2.2.2: The importance of Lipopolysaccharide (LPS): its characteristics and 
derivatives 
LPS, or Endotoxin, was first reported by Richard Pfeiffer in 1892 as a heat-stable, 
cell-associated material isolated from Vibrio cholerae which induced toxic reactions 
in guinea-pigs. He recognized this material to be clearly distinguishable from the 
heat-labile exotoxins which are secreted by bacteria115. However, it took 
approximately 60 years to discover the hot phenol-water procedure that allowed 
extraction of rather pure LPS116. LPS is commonly found in the outer leaflet of the 
outer membrane of most Gram-negative bacteria, (with some exceptions such as 
Treponema pallidum, Borrelia burgdorferi, B. hispanica, Sphingomonas capsulata 
and S. paucimobili, Thermus thermophilus, and Meiothermus taiwanensis)117 
covering up to 75% of the total cell surface. The remainder surface is constituted by 
integral membrane proteins such as porins that serve as channels to let small 
hydrophilic molecules enter and exit118. LPS is a fundamental macromolecule for 
growth and survival of many Gram-negative bacteria as it protects them from harmful 
bile acids, hydrophobic antibiotics, cellular host defense strategies119 and helps to 
provide the correct assembly of the outer membrane and the right positioning of 
porins111. LPS was named as such since it consists of poly-saccharides and a lipid 
part. The general structure of LPS was discovered back in 1971 by Liideritz et al.120 
which observed that different forms of LPS from different strains of bacteria have 
common features: all of them are made up by a polysaccharide or oligosaccharide 
portion covalently linked to a specific glycolipid component called Lipid A.  
 
According to the size of the saccharide portion, LPS can be subdivided into smooth-
form LPS (S-form) and rough-form LPS (R-form, also called lipooligosaccharides, 
LOS)121,122. In S-form LPS, the core saccharide portion is replaced by the O-specific 
polysaccharide. This LPS is mainly found in naturally occurring, or wild type, species 
of bacteria and composed by a structure of up to 50 repeating oligosaccharide units 
mainly formed by two to eight monomers and the core region, closest to the lipid A 





Figure 9: Schematic representation of S- form LPS from Escherichia Coli, composed 
by the Lipid A moiety, the inner core, the outer core, and the O-antigen chain. 
 
Whereas both the lipid portion and polysaccharide of LPS contribute to the 
pathogenic potential of Gram-negative bacteria, it is the lipid component (lipid A) 
which determines the endotoxic properties of LPS. As LPS are surface structures, 
they play a big part in the interaction of Gram-negative bacteria with higher 
organisms. The host's defense system recognizes invading bacteria by the LPS and 
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reacts with the formation of antibacterial antibodies directed against LPS regions. 
Therefore, they were also called O-antigens since they are immune-reactive surface 
agents. On the other hand, free LPS can be released killing the bacteria, and when 
this happens, they exhibit a broad spectrum of biological activities such as 
pyrogenicity and lethal shock. They are thus held responsible for certain Gram-
negative infection and accused as causative agents of the sepsis syndrome. Finally, 
LPS activate B lymphocytes, granulocytes and mononuclear cells and, hence, are 
potent immunostimulators. By virtue of this property, they are also believed to be 
involved in the physiological development and activation of the immune system124.  
 
1.2.2.3: LPS and its derivatives: structure-activity correlation 
It is known that molecules such as MPLA have a common feature: they include the 
chemical determinant (or pharmacophore) essential for MD-2 recognition and 
binding, a disaccharide core (GlcNAc–GlcNAc) with six lipid chains, and two 
negatively charged phosphates at positions C1 and C4 of the disaccharide. All these 
compounds are sparingly soluble and have poor pharmacokinetic in vivo125. In the 
past few years, an important effort has been made in order to study the correlation 
between the structure and the activity of LPS and parent molecules to get a deeper 
understanding of their immune-stimulating properties and sepsis-related toxicity. This 
knowledge is leading also to the development of new LPS-based immune-therapies 
for prevention and treatment of diseases such as cancer and to strengthen immune 
resistance to bacterial and viral infections. However, all the LPS derived from 
bacterial cell wall are a mixture of chemically different LPS molecules that range from 
rough LPS to LPS with varying core length to LPS having a high number of O-chain 
oligosaccharide repeats. Additionally, some might be differently substituted with acyl 
chains. This represents a problem when studying the mechanisms by which those 
molecules are recognized126. Therefore, accurate purification and characterization 
are fundamental to study their biochemical properties. It has been observed that a 
simple variation in the structure of such molecules might dramatically change the 
way they fit into the TLR4 complex and thus the way they interact with the immune 
system. Synthesizing a panel of LOS with slight structural differences using modular 
synthesis, Stöver et al.127 found that the ideal structure of an agonist LPS-like 
molecule, both to human and mouse cells, is hexa-acylated and has a secondary 
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acyl chain with a length of 10 carbon atoms. A similar study using bacterial 
enzymatic combinatorial chemistry (BECC) was done in 2017128, and could to some 
extent correlate the difference in the structure of the prepared LOS with the cytokine 
secretion induced, which in turn guided the immune response over  Th1, Th2, (Tregs) 
or Th17 cells. Choi et al.129 verified that the elongation of the oligosaccharide chain 
and the deletion of phosphorylcholine (PCho) at the Heptose I can attenuate the 
release of inflammatory cytokines such as TNF-α and IL-1β. Other examples worth 
mentioning are the variation of an ethylamine group on a synthetic analog of the lipid 
A from H. Pylori (HPLAEA).  In fact, Fujimoto et al.130 noticed that the compound 
HPLAEA was a much stronger antagonist of LPS than HPLA. The former could 
inhibit secretion of some cytokines, such as IL-6, IL-8, IL-18, IL-1β, and TNF-α up to 
10-fold with respect to the latter at a concentration of 5 µg/mL when E. Coli LPS was 
used as a stimulus at a concentration of 500 pg/mL. 
 
1.2.2.4: Lipooligosaccharides (LOS) and their structure-activity correlation 
Two different kinds of LPS have been found and isolated, R-form and S-form LPS. 
The main difference consists in the fact that R- form LPS, or LOS, show similar Lipid 
A structures but lack O-antigen units and the oligosaccharide core is limited to 
around ten units. LOS are the major glycolipids expressed on mucosal Gram-
negative bacteria such as the ones from the genera Neisseria, Haemophilus, 
Bordetella, and Branhamella. Those differences between LPS and LOS are probably 
due to the fact that different forms can benefit the survival of the pathogens in 
different conditions and environments131,132. Huber et al.133 reported that R-form LPS 
are the key to the activation of TLR4/MD-2-positive cells: they can activate mouse 
cells which lack expression of the LPS-binding protein CD14. They also stated that 
up-regulation of soluble CD14 due to S-form LPS in the course of an inflammatory 
response might provoke an enhanced risk of endotoxin shock134, or lead to acute 
allergic reactions. LOS have shown very promising results as vaccine adjuvants, 
both against pathogens and diseases. Ko et al.135 have recently explored the 
combination of a de-O-acylated lipooligosaccharide (dLOS, a TLR4 agonist derived 
from an E. Coli LPS mutant strain) combined with Alum and Liposomes as an 
adjuvant against Japanese encephalitis (JE) in a mice model. Both formulations 
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significantly increased the serum IgG antibody titers 2 weeks after a single 
vaccination and were comparable to those obtained 2 weeks after two immunizations 
with the alum-adjuvanted vaccine. Besides, dLOS combined with liposomes 
promoted both antibody and Th1-type cellular responses to JE vaccine. Notably, 
dLOS coupled to Alum and used as a vaccine against H1N1 Pandemic Influenza in 
mice stimulated Th1 cytokine release together with activating CD4+ and CD8+ T cells 
reducing mortality and morbidity of mice, as described by Ryu et al.136. Similar 
results were observed some years before by Han et al.137, which also assessed that 
dLOS has low toxicity up to a dose of 1 mg/kg of body weight in mice and is a more 
potent activator than MPLA in human monocytes and DCs. With respect to bacterial 
infections, LOS showed efficacy against P. aeruginosa infection in mice, increasing 
the survival rate up to 100% with the right immunization dosage and thus showed 
potential against other gram-negative bacteria infections138. In 2003, Hirano et al.139 
have used a LOS-based conjugate vaccine from nontypeable Haemophilus Influenza 
and administered it by the intranasal route to enhance bacterial clearance in mouse 
nasopharynx generating mainly IgA antibodies in lymphoid tissues. The most 
important result of the biological characterization of LPS fractions isolated from wild-
type E. Coli is the fact that the R-forms of LPS had a broader capacity to activate 
human macrophages in vitro compared with the isolated S-form of LPS, which 
required the presence of serum for the induction of TNF-α as a central mediator of 
the pro-inflammatory response to bacterial infection. Independently of the route of 
activation, the physicochemical properties of S-LPS (such as hydrophobicity, 
aggregate structure, and stability) are likely to be different from those of R-LPS and 
could explain the observed differences in the biologic activity126.  
Another well-known and used LOS is 3-deoxy-D-manno-octulosonic acid-lipid A 
(Kdo2-Lipid A). This molecule was first prepared by Raetz et al.140 and obtained by 
chromatographic purification from a heptose-deficient Escherichia coli mutant. They 
verified that this LOS is fully active as an endotoxin by stimulating RAW 264.7 
macrophage-like tumor cells to produce eicosanoids and TNF-α. One advantage of 
this molecule with respect to LPS is the high purity141. 
In this thesis, the activity of two different LOS was investigated. These LOS 
respectively named E. Coli LOS (Figure 10) and Xcc LOS (Figure 11) were 
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extracted from natural sources by the group of Professor Alba Silipo at the University 












































Figure 10: E. Coli LOS, the first LOS investigated in this thesis. 
The latter is a purified lipid obtained from the plant pathogen Xanthomonas 
campestris pv. campestris (strain 8004). Its structure presents a strong negative 
charge density in the lipid A-inner core region and has a number of interesting 
features, such as a galacturonyl phosphate attached at a 3-deoxy-D-manno-oct-2-
ulosonic acid residue and a unique phosphoramide group in the inner core region142. 
Besides that, it presents a 3-3 symmetry in the distribution of the acyl chains in the 
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Figure 11: Xcc LOS, the second LOS examined in this thesis. The dotted lines 
indicate nonstoichiometric substitutions. The dotted methyl groups on fatty acids are 
present as possible single substitutions. Adapted from142. 
 
1.2.3: Therapeutic TLR4 suppression 
TLR4 can be potentially used as a target for anti-cancer immunotherapy. 
Interestingly, PAMPs- and DAMPs-mediated overactivation of TLRs, TLR4 included, 
can be harmful since it unbalances immune homeostasis by sustained pro-
inflammatory cytokines and chemokines production. As a consequence, TLR4 can 
take part in the development of autoimmune diseases and inflammation143. From this 
point of view, TLR4 is related to a broad spectrum of contemporary diseases 
including allergies, asthma, chronic inflammations, autoimmune disorders. TLR4 has 
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also been suggested as a promising therapeutic target for depressive disorder and 
amyotrophic lateral sclerosis125. Especially, DAMPs have been implicated in TLR4 
overstimulation causing atherosclerosis, rheumatoid arthritis (RA) and 
neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral 
sclerosis (ALS) and many others144,145. 
Indeed, TLR4 activation and signaling contribute to the progression of the afore-
mentioned diseases and therefore inhibitors and/or antagonists targeting TLR signals 
may be beneficial to treat these disorders146,147. Amongst these diseases, the most 
severe one is sepsis, deriving from excessive TLR4 activation. It consists of a 
dysregulated response of the host organism to outer pathogens, leading to acute life-
threatening organ dysfunction. Sepsis has a very high fatality rate (20%) and 
accounts for 5.3 million deaths annually worldwide148.  Up until now, only two sepsis 
drugs made it to phase 3 clinical trials, Eritoran and TAK-242, but failed to show 
significant results and block acute sepsis145 and did not get the FDA approval125. 
Nevertheless, as the vast majority of the mentioned pathologies still lack a specific 
pharmacological treatment, molecules active in inhibiting TLR4 activation have 
attracted increasing interest in a wide range of possible clinical settings149. However, 
manipulation of TLR mediated immune responses needs to be balanced and 
requires further studies150,151. In this context, the manipulation or intervention of TLR-
mediated immune responses by nanomaterials is a potential approach to treat these 
diseases.  
 
1.2.3.1: TLR4 antagonists for immune suppression 
As already mentioned, the variable composition of natural products belonging to the 
LPS family are unpure or show different composition, which is an obstacle when 
determining the immune stimulating properties of such compounds126. As a result, 
different TLR4 antagonists have been developed also following a synthetic route.  
Amongst them, a notable example is Eritoran (E5564) (Figure 12), a synthetic 
analog of lipid A with four acyl chains of different length and nature. Structural 
studies of the TLR4–MD2 complexation to Eritoran showed that it binds directly to 
the hydrophobic pocket of MD2, competitively inhibits LPS from binding to MD2, and 
prevents dimerization of TLR4 and consequently TLR4-signaling, acting as a TLR4 
antagonist152. An interesting study was reported by Czeslick et al. in 2006, who 
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demonstrated that Eritoran inhibited the production of LPS-induced TNF-α and IL-6 
In human monocytes153. Despite the favorable results obtained in animal sepsis 
models152 and its safety in humans154, Eritoran did not reduce the patient mortality at 
28 days and 1 year from the statistical analysis143 and therefore didn’t get the FDA 
approval for use in the clinic to treat sepsis. Nonetheless, Eritoran could still be 
therapeutically beneficial for other inflammatory diseases. Indeed, it has been shown 
to prevent influenza-induced death in mice, to reduce cardiac hypertrophy in a 
mouse model and to attenuate inflammatory cytokine production and myocardial 
ischemia/ reperfusion injury in a rat model. 
 
Resatorvid (TAK-242) (Figure 12) is a small molecule with a chemical structure 
different from lipid A that directly targets TLR4 with a non-classical mechanism of 
action and made it to clinical investigations due to its preclinical success. 
Specifically, two phase III clinical trials for severe sepsis and for sepsis-induced 
cardiovascular and respiratory failure were performed. In the first trial, the results 
were unfortunately not satisfactory due to failure to effectively suppress serum 
cytokine levels (IL-6, IL-8, and TNF-α)149 when compared to controls, even with the 
drug showing a good tolerability profile155. The second trial, however, was terminated 
due to a business decision, and no further clinical development of this drug has been 
conducted ever since143. 
 
Lipid IVa (Figure 12) is a biosynthetic precursor that has been intensively studied 
and reported in 2003 by Onto et al.156 and pioneered the studies of the structural 
interaction amongst the TLR4 complex and its modulators. Interestingly, this 
molecule acts as an agonist in mice and antagonist in human, a difference which has 
been attributed to the difference in the shape between the human and murine MD2 
pocket and to variations in the electrostatic potential at the rim of the binding cavity of 
MD-2 and at the dimerization interface156,157. 
 
Ibudilast (AV411) (Figure 12), another small molecule TLR4 antagonist, has been 
shown to suppress pro-inflammatory cytokines such as TNF-α and IL-6 in 
neuroinflammation158 and is already used in Asia to treat asthma and post-stroke 
disorders88. Phase II clinical trials looking at AV411 for treatment of neuropathic pain 
in 2008 demonstrated that the antagonist was well tolerated in humans159. At 
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present, Ibudilast is in Phase II clinical trials for the treatment of asthma and 
poststroke disorders125. 
 
Perrin-Cocon et al.144 reported that FP7, a synthetic small-molecule TLR4 
antagonist, could modulate the “in vitro” secretion of proinflammatory cytokines (IL-6, 
IL-8, and MIP-1β) by monocytes and DCs (half maximal inhibitory concentration 
(IC50) < 1 μM) and prevented DC maturation upon TLR4 activation by ultrapure LPS 
and blocked influenza-induced lethality in a mice model. Its mechanism of action is 
based on the direct competition with LPS for MD-2 binding probably reinforced by 
direct binding to CD14 co-receptor125. 
 
Other compounds such as VIPER and NI-0101 have shown promising experimental 
results: the former is a peptide inhibitor derived from vaccinia virus protein A46 
described to inhibit TLR4-dependent signaling via blocking TIR–TIR domain 
interactions160, which showed the attenuation of blood pressure and inflammatory 
responses in hypertensive rats88. NI-0101 is a TLR4 targeted monoclonal antibody 
that inhibits dimerization reducing pro-inflammatory cytokine production and has 
several potential applications including in asthma. It is the first TLR4-targeting 









































































Figure 12: Structures of synthetic TLR4 antagonists. 
 
1.2.3.2: Structure-biological activity correlation in TLR4 antagonists 
The common features (or pharmacophore) that the TLR4 agonists have in common 
have already been discussed. New insights into the ligand-receptor interaction 
mechanisms were discovered recently by studying the structures of Eritoran and lipid 
IVa and the way these agonists bind to MD-2, which helped to understand the 
different mechanism of action of TLR4 agonists and adjuvants. Indeed, the molecular 
structures of Eritoran and lipid IVa, well known TLR4 antagonists, share four lipid 
chains that fit in and fill the available space in the hydrophobic MD-2 pocket. On the 
other hand, E. coli LPS and other TLR4 agonists have two or more additional lipid 
chains than these. It was proposed at first that some structural changes in the MD-2 
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pocket could account for the capacity of accommodating the extra lipid chain. 
However, Park et al.91 later found that the size of the MD-2 pocket doesn’t change 
and that additional space for lipid binding is generated by displacing the glucosamine 
backbone upwards by 5.5 A˚ (Figure 13). This repositions the phosphate groups so 
that they are allowed to interact with positively charged residues of the two TLR4 
heterodimers, TLR4 and TLR4*, therefore promoting dimerization and activation of 
the receptor complex. Hence, the total number of lipid chains is the most important 
factor in determining whether a TLR4 ligand is an agonist or an antagonist, according 
to Park et al. Indeed, molecules such as Eritoran featuring four lipid chains 
completely lack agonistic activity and are antagonists that prevent binding of agonists 
to TLR4. Increasing the number of chains, Lipid As with five lipid chains behave as 
agonists and Lipid A, with six lipid chains, has optimal inflammatory activity, 100 fold 
higher than five lipid chains lipid As161. Nonetheless, other molecules having different 
structures from the well-known lipids can inhibit the TLR4. For example, the 
aforementioned Resatorvid selectively inhibits TLR4 signal by covalently binding 
Cys747 in the intracellular domain of TLR4 which blocks the interaction between 
TLR4 and the adaptor proteins TIRAP and TRIF-related adaptor molecule (TRAM), 
thereby diminishing LPS-induced TLR4 signaling and inflammation149,143. An 
interesting example of synthesis and biological study of small structural differences 
was performed by Piazza et al.162, which reported the synthesis of six different 
glycolipids and a benzylammonium lipid rationally varying the chemical structure of a 
D-glucose-derived compound active as lipid A antagonist. In vitro studies confirmed 
their activity as lipid A antagonists on HEK cells, and the capacity to inhibit LPS-
induced septic shock “in vivo” upon injection of a lethal LPS dose per mice. 
Particularly, one of the reported compounds, IAXO 102 (Figure 14), could block the 
effect of the LPS injection and all the mice receiving compound 5 + LPS survived, 
while the control group mice, which only received LPS injection, died after 2 days. 
According to their data, IAXO 102 has a potency comparable to that of the best 
antisepsis agents developed to date such as Resatorvid, which showed comparable 
activity in the same in vivo test with a similar effective dose (ED).  In this thesis, the 
antagonistic activity of IAXO 102 was assessed in J774 murine macrophages, and 




Figure 13: Differences in the binding of Eritoran and LPS into the hydrophobic 


















1.3: Nanochemistry for drug delivery: an introduction 
Nanoparticles are of great interest for biomedical applications due to their unique 
physicochemical properties. The interest towards nanotechnology was kicked off by 
Richard Feynman’s talk in 1959 when he first pronounced the famous sentence 
‘‘there is plenty of room at the bottom’’, also stating that to complement the interest in 
‘‘big science’’ scientists should study and understand phenomena on a small 
scale163. The term "nanotechnology" itself was first defined by Norio Taniguchi in 
1974. This field of science deals with the development, handling, characterization, 
and use of materials, devices, and structures with at least one dimension less than 
100 nanometers 164. The FDA also refers to nanomaterials as “materials that have at 
least one dimension in the range of approximately 1 to 100 nm and exhibit 
dimension-dependent phenomena165 (Figure 15). 
 
 
Figure 15: Comparison of the size of nanomaterials with those of other common 
materials. 
Since the beginning of the 21st century, a plethora of nanomaterials have been 
reported in the literature due to their versatility (Figure 16), and the focus on such 
materials is expected to grow significantly in the future166, and nanotechnology 
promises to revolutionize cancer diagnosis and therapy167,168,169. 
Nanomaterials-based medicine hugely developed in the last years, with numerous 
nanomedicines approved by the FDA for different clinical applications170. Amongst 
nanomaterials, paramagnetic iron oxide nanoparticles, quantum dots, nanoshells, 
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and nanosomes have been extensively used for diagnostic purposes171. Many 
nanosystems for drug delivery have been used as therapeutic tools172,173, for early 
detection of cancer cells and/or specific tumor biomarkers174 and to enhance the 
efficacy of applied treatments175. The use of nanoparticles as delivery systems for 
cancer therapies176,177 and vaccine adjuvants178 also holds huge potential. 
 
Figure 16: A pictorial representation summarizing some of the nanoparticles’ 
shapes, compositions and surface properties. 
Improved drug delivery and reduced toxicity and side effects arise from a 
combination of unique properties such as their high loading surface area, their 
capacity to specifically present the payload to its binding sites, alter its biodistribution 
and slowly release it over time179,180,181,172,171. Indeed, small molecule therapeutics 
showed limited clinical efficacy due to many limiting factors such as poor solubility, 
inefficiently timed release and inability to target or directly accumulate in the desired 
locations182,183,184,169,185. Size, shape, composition and surface chemistry of 
nanoparticles are all factors that affect the toxicity, in vivo biodistribution, biological 
fate and targeting ability of these systems, thus being key factors to their use as 
carriers. Recent advances in nanochemistry, biomedicine and the concurrence of 
these disciplines have now expanded the ability to design and construct 
“multifunctional” nanoparticles, combining different functions such as targeted 
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therapy and diagnostic functions in a single entity allowing multimodal 
approaches112,174,173,186,187. Thus, nanotheranostics (nanotherapy + nanodiagnosis) 
emerged as an alternative to the separate administration of diagnostic probes and 
pharmacologically active molecules. Nanotheranostics provides an unprecedented 
opportunity to integrate various components along with customized therapeutic 
agents, controlled-release mechanisms, targeting strategies, and reporting 
functionality for therapeutic detection/ visualization within a nano-scaled 
architecture188. The combination of such different functionalities eventually looks to 
the establishment of “personalized nanomedicine”, which refers to the use of these 
nanosystems to elaborate specific and optimized treatment protocols fitting to each 
specific patient, or in administering “the right drug to the right patient”189. 
 
1.3.1: Different types and properties of theranostic nanomaterials 
Nanoparticles can be widely subdivided into inorganic and organic nanoparticles 
according to the chemical composition of their core190, or polymer and nonpolymer 
nanoparticles according to the presence or absence of a polymeric component. 
Although an astonishing variety of nanoparticles featuring different properties is 
available, the main objective of this thesis was to investigate specific types of 
metallic nanoparticles for their intrinsic imaging and therapeutic properties, which will 
be discussed in the following chapters. In general, it is considered that nanoparticles 
within a size of 10–100 nm are ideal for use as delivery vehicles or cancer 
therapeutics191,192,193 and in vivo applications194. Particles bigger than 200 nm can 
accumulate in the liver and spleen191, might not be uptaken at all195 or be lethal 
depending on the dose196. Zauner et al.197 and Rejman et al.198 discovered a trend in 
the uptake of differently sized nanoparticles in different kinds of cells: as the particle 
size increases beyond the range of 20- 50 nm, their likeliness to be uptaken in cells 
decreases. Additionally, Wilhelm et al. performed a literature survey and found that 
particles with a hydrodynamic diameter smaller than 100 nm tend to show higher 
delivery efficiency to solid tumors than larger particles (0.7% and 0.6% of the injected 
dose, respectively)199. Nanoparticles within a size of 25–40 nm penetrate tissue 
barriers and traffic to the draining lymph nodes more rapidly than nanoparticles 
larger than 100 nm in size200. The high surface-to-volume ratio is another advantage 
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of nanosized materials, especially when it comes to surface functionalization and 
drug delivery201. 
1.3.1.1: Iron oxide nanoparticles 
Within all the nanomaterials currently used for medical applications, 
superparamagnetic iron oxide nanoparticles (IONPs) are very versatile as they have 
been used for many in vivo applications such as hyperthermia, drug delivery, MRI 
contrast agents202,203,164, and cancer diagnosis and treatment173,204,205,166. Many 
magnetic nanoparticle-based cancer therapy systems are still at the research stage, 
but according to Yigit et al.206, their routine clinical application is getting near. This 
affirmation is supported by the number of IONPs-based nanomedicines that have 
been approved for use in humans as iron deficiency therapeutics and as MRI 
contrast agents by the FDA, such as Feraheme™/ferumoxytol, Feridex®/Endorem®, 
GastroMARK™/Lumirem® and by the European Medicines Agency (EMA) such as 
Endorem/Feridex170,207,204,208. Besides, it has been demonstrated that IONPs have a 
very good tolerance profile, by undergoing in vivo biotransformation to be turned into 
iron species stored into ferritin proteins209,210. Nowadays, the level of knowledge 
acquired in the field of nanoscience allows easy control over the size and shape of 
IONPs and fine-tuning of their properties and cargos211: It is considered important for 
those particles to be smaller than 100 nm to increase blood circulation time, and at 
the same time have a high surface area and a narrow particle size distribution212. 
The interest in IONPs derives from their magnetic properties, which are strongly 
depending on the size and morphology of the particles. In the bulk state, magnetic 
materials are constituted of multi-domains, but as particle size decreases to the sub-
micron range, the particles become monodomains, leading to a ferromagnetic 
behavior. If size is reduced even further, the resulting nanoparticles become 
superparamagnetic213: IONPs smaller than 25 nm are superparamagnetic, meaning 
that when a magnetic field is applied, the magnetic moments align to the magnetic 
field leading to a net magnetization214 (Figure 17). Indeed, when the particle size 
goes below 25 nm the nanoparticle acts as a single monodomain, with all the spins 
aligned in the same direction, and when the applied magnetic field disappears, 
magnetization is completely lost. These magnetic properties make IONPs ideal 
candidates as contrast agents for MRI and possible candidates for performing 
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hyperthermia therapy, a form of cancer therapy which will be explained deeper later 
in the introduction. Since imaging is not the main objective of this thesis, it is 
important to note that their biocompatibility, stability, and the possibility of modulating 
their surface according to the chemical needs also made them an ideal choice for 
this thesis’ purpose and for many other biomedical applications.215–217. 
 
Figure 17: Size-dependent properties of IONPs. 
 
1.3.1.2: Quantum dots 
Quantum dots (QDs) feature unique optical and electronic properties such as a 
narrow size-tunable emission spectrum with light emission, and a broad absorption 
spectrum enabling the simultaneous excitation of multiple fluorescence colors. QDs 
also show about 10 - 100 times brighter emission than organic fluorophores and are 
100 - 1000 times more stable against photobleaching218. These properties are well 
suited for dynamic imaging at the single-molecule level and for multiplexed 
biomedical diagnostics at ultrahigh sensitivity219. Different strategies have been 
developed to conjugate QDs to a variety of bioactive molecules such as enzymes, 
proteins, peptides, antibodies, and oligonucleotides220. QDs are thus widely used 
nanomaterials for biological applications221. Recent advances have led to the 
development of luminescent QDs for multiplexed molecular diagnosis and in vivo 
imaging222,223,224,225 and high specificity cancer targeting, as shown by Gao et al.226.  
The unique photophysical properties of QDs and their popularity derive from size-
dependent fluorescent emission (Figure 18):  their small size, which is close or even 
smaller than the energy level spacing between excited electrons and their 
corresponding electron holes, leads to discrete quantized energies. The band gap is 
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inversely proportional to the radius of the QDs (an effect also known as quantum 
confinement), with the emission wavelength shifting to the blue as QDs get smaller 
and changing their composition and crystal structure allows fine-tuning of their 
emission227.  
 
Figure 18: Size-dependent fluorescent emission of QDs. 
 
1.3.1.3: Upconverting nanoparticles 
Upconverting nanoparticles serve as an excellent substitute for traditional fluorescent 
labels, even for medical applications. Especially, rare earth-doped upconverting 
nanoparticles are able to turn long-wavelength radiation (e.g., NIR light) into short-
wavelength fluorescence (e.g., visible light) via a two-photon or multiphoton 
mechanism, thus emerging as a new class of fluorophores. These particles possess 
several advantages with respect to conventional fluorescent biolabels, such as the 
utilization of NIR excitation light which not only allows for deeper light penetration in 
tissues but also offer lower autofluorescence, reduced light scattering and 
phototoxicity228,229, an excellent signal to noise ratio (SNR) and improved detection 
sensitivity owing to the absence of autofluorescence. Additional advantages of 
upconverting nanoparticles include good chemical and physical stability, narrow 
emission peaks, resistance to photobleaching and low toxicity230,231,232. Lanthanide-
doped upconversion nanoparticles (UCNPs) have promisingly been used for 
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bioimaging, antigen-delivery233, photodynamic therapy234,235,236 and could potentially 
be used for targeted cancer therapy237,238.  
UCNPs feature the capacity of emitting visible light from near infrared radiation (NIR) 
by a process called upconversion (UC) (Figure 19). It is a nonlinear optical process 
by which excitation of lower electronic levels with low-energy radiation (NIR light) 
results in higher energy emission (visible or UV light) at higher electronic levels and 
can, therefore, be ascribed as an anti-Stokes mechanism, as opposed to a stokes 
mechanism, where excitation of electronic levels leads to a lower-energy emission. 
Anti-Stokes mechanisms require the sequential absorption of two or more photons to 
provide sufficient energy for the emission to occur232. Three different classes of UC 













Figure 19: Schematic representation of the upconversion process and graphical 
explanation. Solid, dotted and wavy arrows in the graph represent photon absorption 
or emission, energy transfer and relaxation processes, respectively. The blue wavy 
arrows denote the increased multiphonon relaxations caused by OH vibrations. 
Graph published by the Royal Society of Chemistry239. 
UCNPs are also advantageous because of the biocompatibility of their material 
composition and usefulness in optical diagnostic applications due to their high 
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photostability, weak background signal, and long luminescence lifetimes (micro- to 
milliseconds)237. 
1.3.1.4: Janus nanoparticles 
Janus particles (JanusNPs) are named after the Roman god Janus (typically 
represented by a double-faced head) and are characterized by the presence of two 
chemically different surface regions within a single particle,240,241 which generates 
asymmetry and confers properties unconceivable for homogeneous, core-shell and 
patchy nanoparticles. Indeed, JanusNPs are a special type of patchy particles 
presenting only one patch that covers half of the particle242. These are of particular 
interest in applications where a spatial separation of functionalities is required, such 
as interfaces stabilization, catalysis, assembly of higher order suprastructures with 
new properties arising by the collaborative effect of the nano-objects and biomedical 
application that could combine targeted drug delivery, molecular imaging or 
biomolecular biosensing in a single platform243. The interest in this kind of 
nanoparticles was promoted by the Nobel laureate P. G. de Gennes who talked 
about them in his Nobel lecture entitled “Soft Matter” in 1991244. Different particle 
architectures bridging from simple spherical to different kinds of dumbbell shapes to 
vesicles/capsules and highly anisotropic architectures, such as cylinders or disks 
have been attained so far240. Not only that, but diverse morphologies too have been 
reported for JanusNPs which combine gold with other nanomaterials, including iron 
oxides, QDs, and UCNPs245,246,247. 
In this thesis, JanusNPs composed of a spherical IONPs and a gold nanostar were 
used, due to the interesting surface functionalization possibilities of both gold and 
IONPs and the useful combination of magnetic and plasmonic properties. 
Nanoparticles with a branched gold structure, also known as nanostars, show a 
strong light absorption and plasmon resonance at the visible-NIR window and a high 
photothermal generation. The resulting JanusNPs allow photothermal therapy (PTT) 
together with the outstanding magnetic properties, multimodal imaging capabilities 
and biocompatibility of IONPs248. Moreover, both the heat coming from photothermal 




1.3.2: Nanoparticle-based delivery: functionalization strategies 
The surface of nanocarriers can be modified to introduce either functional groups, 
hydrophobic or hydrophilic ligands or targeting moieties and cargos like antibodies, 
small molecules, drugs or proteins depending on the specific needs, which can also 
allow controlled release strategies by using stimuli-responsive nanocarriers249,250. 
Three are the major conjugation strategies that have been adopted for cargo loading 
on nanoparticles: adsorption, encapsulation, and conjugation (Figure 20), all of 
which are dependent on the nature of both the carrier and the particle. Adsorption is 
generally based on either electrostatic or hydrophobic interactions retaining the drug 
in the nanoparticle251,252,253, while encapsulation is most commonly applied in the 
case of organic nanoparticles such as liposomes or polymeric nanoparticles254,255,256. 
 
Figure 20: Cartoon representing the different ligand loading strategies on 
nanoparticles. 
 
1.3.2.1: Covalent strategies for nanoparticle conjugation 
Conjugation of bioactive molecules (e.g. OVA as a tumor antigen) to nanostructures 
has been one of the objectives of this thesis. The conjugation approach consists of 
creating a chemical bond between the drug and the nanoparticle by the means of 
organic or click chemistry, usually mediated by chosen ligands or linker molecules. In 
all cases, the delivery vectors must not only transport the payload but also be able to 
release it in a specific location. 
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The first strategies developed for the conjugation of bioactive molecules to 
nanoparticles are the ones that drew inspiration from standard protein labeling 
chemistries: maleimide-thiol reaction, succinimidyl ester-amine reaction and 
carbodiimide activation followed by reaction to an amine257 (Figure 21).  
A popular cross-linking reaction is the one that uses amines and carboxylic acids as 
reactive functional groups, taking advantage of the process known as carbodiimide 
activation (e.g., 1-ethyl- 3-(3-dimethylaminopropyl) carbodiimide, or EDC). This 
method presents some disadvantages, one is the instability of the o-acylisourea 
intermediate formed through the activation of carboxylic acids, bringing to the use of 
a large excess of reagents and loss of colloidal stability. This has been only partially 
ameliorated by converting the o-acylisourea to a more stable reactive intermediate 
using N-hydroxysuccinimide (NHS), which helps maintain colloidal stability during the 
reaction258. Despite the improvement, this method is still limited by its sensitivity to 
reaction conditions such as pH and temperature. Furthermore, these reactions 
require very high concentrations of reagents, biomolecules, and nanoparticles, do 
not achieve control on the stoichiometry and display of the biomolecule loaded on 
the nanoparticles and can cause crosslinking and precipitation of the nanoparticles, 




Figure 21: Standard bioconjugation reactions, including maleimide-thiol, succinimidyl 
ester-amine, and carbodiimide-mediated coupling between carboxyls and amines. 
Another example is the monofunctional conjugation of avidin to pcQDs261: 
conjugation of large molecules to QDs is still challenging because steric hindrance, 
geometry, the stoichiometry of the conjugate, and its final functional activity have to 
be addressed.  
In the last few years, cleaner and more efficient biorthogonal chemistry has been 
used to tackle this challenge. It exploits functional groups not having significant 
reactivity toward the functional groups intrinsic to biomolecules such as amine, 
carboxyl, hydroxyl, and thiol groups. This approach offers the potential to eliminate 
undesirable side reactions, minimize nonspecific NP-bioconjugate activity, improve 
reproducibility in production, and maximize efficacy262,257. In particular, hydrazone 
ligations have proven to be chemoselective and fast, yielding stable products and 
reactions that can be monitored by UV-Visible spectroscopy due to the formation of 
the hydrazone cromophore263. Besides, this chemistry is suitable for applications in 
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the drug delivery field, since the hydrazone bond hydrolyzes at a pH of 5-6, 
corresponding with the one in the acidic environment of endosomes and lysosomes, 
releasing any biologically active molecule that is bound to the nanoparticle257.  
Different strategies have been used to achieve successful functionalization of 
nanoparticles with biomolecules and drugs. Some examples are reported below. 
Doxorubicin (DOX) is one of the main anticancer drugs that have been coupled to 
IONPs. This drug can both be covalently and electrostatically bound to functionalized 
IONPs. An example of the first approach is the paper by Wu et al.264 in which 1,2- 
ethanediamine (EDA)-azo (4,4-azobis (4-cyanovaleric acid))-functionalized magnetic 
nanoparticles were conjugated to DOX. When this system was injected in tumor 
challenged mice, the delivery of DOX by the nanoparticle reduced the tumor volume 
by 6.8 times compared with the free drug. Additionally, upon exposure to NIR 
irradiation, IONPs could reach a temperature of 43°C which could break the bond 
and achieve controlled release of DOX.  
Dutta et al.265 reported an example of sulfate moieties-mediated electrostatic 
conjugation of DOX to IONPs based on a self-assembled system consisting of an 
anionic surfactant and sodium dodecyl sulfate (SDS) on hydrophobic nanoparticles. 
These particles showed internalization in cells and heating ability under a magnetic 
field is thus suitable for hyperthermia treatment of cancer. 
 
A notable example is the yolk-shell Fe3O4@MgSiO3 nanoplatform developed by 
Wang et al.266, where the magnetic Fe3O4 core contributes to  magnetic targeting, the 
magnesium silicate shell provides a hollow cavity for drug loading and finally, the 
polymer poly(ethylene glycol) (PEG) guarantees in vivo biocompatibility and 
biostability. This nanocarrier was able to improve the activity of a conventional 
anticancer drug by taking advantage of the rational design. It was loaded with folic 
acid for targeting and the application of a magnetic field allowed to further enhance 
the delivery efficacy. Nevertheless, the presence of the nanoparticle alone without 
using the intrinsic properties could already improve the antitumor effect in mice 




Another interesting example of delivery is reported by Xiang et al.233, who took a 
model antigen, OVA, and loaded it via electrostatic interaction on the surface of dual-
polymer-coated UCNPs, forming nanoparticle-antigen complexes that were efficiently 
engulfed by DCs and induced DCs maturation and cytokine release.  
 
1.4: Nanotheranostics: exploiting the intrinsic therapeutic modalities of 
nanoparticles  
Even though this thesis focuses on the use of nanoparticles as delivery vehicles for 
immune therapies, it must be noted that the chosen nanoparticles feature different 
intrinsic properties that will allow them to be used for various therapeutic modalities 
and imaging (but these studies are beyond the scope of this thesis). This 
combination of intrinsic and extrinsic therapeutic elements, previously discussed in 
this chapter, is called nanotheranostics and aims in integrating various components 
along with customized therapeutic agents, controlled-release mechanisms and 
targeting strategies within a nano-scaled architecture188.  This section summarizes 
some of the applications that have been reported for IONPs, QDs, UCNPs and 
JanusNPs together with the most recent effects and results obtained with these 
nanoparticles within the nanotheranostics field. 
1.4.1: Photothermal therapy (PTT) 
Photothermal therapy (PTT) is a non-invasive cancer therapy approach utilizing 
visible or NIR light, performed in the presence of photo-absorbers such as 
nanoparticles that convert absorbed light energy into thermal energy. More 
specifically, the excited conduction band electrons decay to the ground state by 
releasing their energy as heat to the surrounding medium leading to thermal ablation 
of cancer267,268,269 (Figure 22). Compared with the conventional therapeutic 
modalities, PTT exhibits unique advantages in cancer therapy such as high 
specificity to biological tissues when coupled with targeting methods and drug 
delivery coming from the same nanoparticle270. Besides, minimal invasiveness and 
precise spatial-temporal selectivity constitute an improvement with respect to 
conventional therapies such as the use of visible lasers270,271.272,273.  
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In PTT, the cells can be killed by either necrosis or apoptosis depending on applied 
parameters such as laser power and time of exposure, which will, in turn, affect the 
temperature in the targeted area274. Right now, PTT is in a clinical trial, and 
AuroShell (Nanospectra Biosciences Inc., Texas), a gold nanoshells-based 
formulation (GNs), was recently approved for clinical evaluation in patients with 
refractory and/or recurrent tumors of the head and neck275,276. 
 
Figure 22: A cartoon illustrating photothermal therapy. 
IONPs can play important roles within nanosystems used for photothermal therapy. 
Zhou et al.277 reported PEGylated Fe@Fe3O4 nanoparticles, presenting a 
combination of targeting, PTT, and imaging in one entity. These nanocrystals 
demonstrated an excellent in vivo magnetic targeting effect upon application of an 
external magnetic field by MRI and showed a high photothermal conversion 
efficiency (~20%, comparable to gold nanorods). Strikingly, fourteen days after tumor 
challenge in mice, PBS-treated mice showed a 20-fold bigger tumor compared with 
the group treated using magnetically guided PEGylated Fe@Fe3O4 nanoparticles 
when photothermal treatment was applied276. 
UCNPs too have been used in the field of photothermal therapy. Lv et al.278 reported 
the preparation of mesoporous silica-coated core-shell UCNPs loaded with 
dopamine (abbreviated as UCNP@mSiO2-Dopa). Upon activation of the dopamine 
by the polyethyleneimine containing silica, this nanosystem is able to strongly absorb 
light under single 980 nm irradiation producing a photothermal effect and emitting 
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upconverted luminescence. The gadolinium core enabled the use of computed 
tomography (CT) and MRI. The UCNP@mSiO2-Dopa agent was shown to be 
reasonably biocompatible and could slow tumor growth two times better than the 
well-known anticancer drug DOX. 
Chu et al.279 showed an example of photothermal therapy using 10 nm silica-coated 
CdTe QDs emitting at a wavelength of 710 nm. Interestingly, scanning a series of 
increasing dimensions QDs, they found that the larger the QD sizes the higher the 
increase in temperature after irradiation is. To prove the “in vivo” efficiency, mice 
were challenged with A375 melanoma cells. Upon administration of QDs to mice and 
irradiation at 671 nm, they showed that the QDs significantly inhibited tumor growth.  
 
1.4.2: Hyperthermia 
Hyperthermia consists in the treatment of malignant diseases by administering heat 
in various ways280. This treatment modality also aims at improving the outcome of 
conventional treatment strategies within the framework of multimodal treatments. 
Indeed, its efficacy is not enough to replace the already established therapy 
modalities when applied alone but can work complementary to, for instance, 
chemotherapy in difficult to treat tumors281. Magnetic hyperthermia consists of raising 
the temperature of tumor tissues to 40–43°C282, but not higher than 46°C283. This 
temperature range might slightly change since the thermal dose-response relation 
varies among different cell lines and depends on microenvironmental factors such as 
pH284. This method is effective against cancer cells because of their higher sensitivity 
to elevated temperatures285. Hyperthermia with small magnetite nanoparticles was 
first reported by Gilchrist in 1957286 and further developed by Gordon 20 years 
later287. The first heating technique using magnetic nanoparticles to have entered 
clinical trials is called magnetic nanoparticle thermotherapy, a minimally invasive 
method developed for interstitial thermal therapy288. In this technique, a dispersion of 
IONPs is injected directly into the target tissue and heated in an alternating magnetic 
field. This technology, named NanoTherm®, is the only nanotechnology-based 
therapy approved by the European Union for the treatment of brain tumors289.  
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The heating efficiency of nanomaterials depends on different parameters such as the 
size and shape of magnetic nanoparticles: Fortin et al.290 discussed the effect of size 
in regulating the efficiency of maghemite nanoparticles as heat mediators and found 
that magnetization decreases with the size, being increased by 3 orders of 
magnitude (4 to 1650 W/g) for particles with sizes ranging from 5.3 to 16.5 nm. 
On the other hand, the effect of shape vas studied by Samia and co-workers which 
recently published a study comparing spherical and cubic IONPs (IONPsp and 
IONPc) as well as the effect of a zinc doped composition in both cases. Zn-doped 
IONPc were the most efficient heat producers, with a 5-fold improvement compared 
to undoped IONPsp291. 
Moreover, many applications have been reported in the literature where 
hyperthermia was combined with other strategies. Quinto et al.292 prepared 14 nm 
PEG-coated IONPs and showed their potential to concurrently deliver DOX and 
generate heat for an enhanced multimodal cancer treatment, reducing in half viability 
of a HeLa cell line with respect to the single effect of DOX being released from the 
particle and reducing it three times with respect to the drug free IONPs without using 
hyperthermia.  
 
1.4.3: Photodynamic Therapy 
Photodynamic therapy (PDT) is a minimally invasive and clinically approved cancer 
therapy exerting a selective cytotoxic activity toward malignant cells. It is constituted 
by the combination of non-toxic components known as photosensitizers (PS) and a 
laser source irradiating at a frequency corresponding to the absorption band of the 
photosensitizers. This activates the release of reactive oxygen species (ROS), but 
requires sufficient molecular oxygen to be present in the cells to work effectively 
(Figure 23). PDT acts in three steps: excitation of PS followed by  the activation of 
oxygen-species which ultimately lead to cell death by apoptosis, triggered by 
signaling pathways such as caspase activation or mitochondrial release of 
proapoptotic factors and cysteine-aspartic acid proteases activation293. It is different 
from PTT which utilizes heat for thermal ablation. Even though the therapeutic effect 
of light was known to the ancient Egyptian for repigmentation of Vitiligo, the first 
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clinical application of PDT was demonstrated in 1903 by Von Tappeiner and 
Jesionek using basal cell carcinomas and nowadays PDT has been approved to 
treat various cancers such as gastric cancer, esophagus, and melanoma294,295. 
A problem of PDT is in the PSs, which have limitations, such as limited delivery to 
target tissues and poor penetration of excitation wavelength, non-specific targeting, 
easy photodecomposition, hydrophobicity, and toxicity. NPs can be used to deliver 
the PS to effectively overcome these limitations296,297. Amongst them, IONPs can act 
as PS carriers for imaging-guided PDT overcoming most of the limitations of classic 
PS due to their diverse and non- toxic nature. IONPs can also be used with inorganic 
PS (TiO2) for PDT and imaging164. 
 
Figure 23: Pictorial representation of PDT.  
More relevant to this thesis, PDT could combine well with immunotherapy by 
compensating for ineffective antigen delivery or presentation and overcoming the 
intratumoral immunosuppressive microenvironment298. Exogenous light can be 
controlled by different means to ensure precise tumor tissue targeting299,300, 301,302 
and the in-situ release of tumor antigens due to PDT cytotoxicity could significantly 
initiate immune response298,303,297,304,305. Notable examples of PDT performed using 
nanoparticles have been reported in the literature recently.  
Cui et al. showed an UCNPs-based construct functionalized with a phthalocyanine 
zinc PS and coated by a folic acid modified chitosan (FASOC-UCNP-ZnPc). Upon 
intravenous injection in mice, the nanosystems accumulated mainly in the tumor 
thanks to folate receptors and were used to effectively perform PDT therapy to shrink 
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the tumors. Specifically, the mice treated with 660 nm PDT showed a tumor inhibition 
ratio of 77% with respect to the control group235.  
On the other hand, Xu et al.297 were capable of developing an UCNP combining PDT 
to the delivery of R837, a TLR7 agonist as an adjuvant, and adding CTLA-4 
checkpoint blockade to potentiate the anticancer activity. These multitasking 
nanoparticles could use NIR-induced PDT to destroy tumor cells and stimulate 
immune responses by triggering the maturation of DCs and secretion of cytokines. 
The combined activity of the nanoparticles and the checkpoint blockade strategy 
conferred complete immunity to a tumor challenge in a period of 60 days in the 
primary tumor and 44 days in secondary tumors (Figure 24). Besides, mice were 
protected from tumor reoccurrence from the development of a long-term immune 
memory297 by the development of CD8+ T cells and Tregs cells. 
 
Figure 24: Tumor challenge and primary and secondary tumor regression as shown 
in reference n.297. -Reprinted with permission from reference n.297. Copyright 2017 
American Chemical Society-. 
Park et al.234 showed a similar system using hexagonal-phase NaYF4:Yb,Er/NaGdF4 
core-shell UCNPs conjugated with Ce6, a PDT drug. UCNP–Ce6 nanoparticles were 
readily accumulated in tumor sites by the EPR effect. Upon irradiation by a 980 nm 
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laser, UCNPs were able to provide complete tumor protection until day 14 after 
tumor injection. UCNP–Ce6 could as well be used as dual-modal imaging probes for 
accurate diagnosis clearly making tumor visible by MRI and upconversion 
luminescence imaging. 
Another example of a combined activity is reported by Di Corato et al., that coupled 
PDT to magnetic hyperthermia. The authors prepared 9 nm magnetic nanoparticles-
filled liposomes and stimulated them both by an alternating magnetic field, to induce 
local hyperthermia, and by a light source, to generate highly toxic ROS, obtaining 
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Screening of nanoparticles for the delivery of TLR4 
ligands and their immunomodulatory properties 
In this chapter, different types of nanoparticles (IONPsp, IONPc, QDs, and UCNPs) 
were explored for the delivery of different TLR4 ligands (the TLR4 agonists E. Coli 
LOS, E. Coli LPS and Xcc LOS and the synthetic TLR4 antagonist IAXO 102) and 



















Combinatorial immunotherapy, and especially the combination of checkpoint 
blockade with vaccines and its promising applications in cancer treatment is 
increasingly being discussed in the scientific literature1. Since cancer vaccines can 
both generate new antigen-specific T cell responses against tumor cells and amplify 
existing responses, they can counterbalance one of the main drawbacks of 
checkpoint blockade, which is the requirement for continuous generation of T cells1.  
TLR agonists are of clinical relevance as vaccine adjuvants due to their capacity to 
modulate innate and adaptive immunity2,3, and nanoparticle delivery allows to 
overcome the limitations of conventional vaccines by presenting a ligand similarly to 
the way a pathogen would4,5. Nanoparticles can also promote cross-presentation and 
act as adjuvants on their own6. Besides, the usage of nanoparticles as carriers 
improves the therapeutic effectiveness of drugs by site-specific delivery and longer 
circulation half-life when compared to the free drug counterpart7,8,9. Additionally, the 
different intrinsic properties of nanoparticles allowing multimodal imaging and use in 
hyperthermia, photodynamic or photothermal therapy, further encourage their use as 
delivery vehicles for TLR ligands.  
There is a growing literature of nanoparticle-mediated delivery of TLR ligands. In 
relation to this thesis approach Ruiz-de-Angulo et al. described the preparation of 
CpG ODN-loaded IONPsp with ideal size for accurate delivery to DCs in the lymph 
nodes. IONPsp-mediated co-delivery of adjuvant and antigen was observed to 
enhance Th1-cytokine secretion and DC maturation, leading to strong CD8+ T cells 
activation, in turn developing enhanced protection against an aggressive melanoma 
tumor challenge10. 
Bocanegra-Gondan et al. used Zn-doped spherical iron oxide nanoparticles to deliver 
both poly(I:C) and imiquimod, co-administering this system with an OVA-loaded 
IONPsp. They took advantage of synergistic TLR stimulation and enhanced MRI 
properties to provide improved activation of macrophages and dendritic cells and in 
vivo tracking of the nanovaccine delivery. Immunization of mice with small amounts 
of OVA and poly(I:C)-imiquimod (5 µg) delivered by the different IONPsp lead to long 
term protection against melanoma, with 100 % of nanoparticle-immunized mice 
rejecting tumor re-challenge 70 days after the last immunization11.  
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The literature also reports some cases where nanoparticles were specifically 
functionalized with TLR4 ligands. Barr et al.12 loaded Kdo2-Lipid A on the surface of 
QDs reporting the first pathogen-like nanostructure. This delivery system was 
tracked in vitro by the use of confocal microscopy and exerted a strong 
immunostimulatory activity when injected together with the model antigen 
dinitrophenylated-ovalbumin (DNP-OVA) by increasing antibody titers (total Ab, IgG1 
and IgG2c) (Figure 1) in mice. This system proved to be a better adjuvant than LPS 
subcutaneously injected with the widely used incomplete Freund’s adjuvant (IFA), 
which is considered as the “gold standard” for T-cell vaccination but suffers from 
considerable adverse effects. 
 
Figure 1: Pathogen-like LPS-loaded QDs and their capacity to increase total Ab, 
IgG1 and IgG2 titers “in vivo”. Adapted from reference12. Reproduced by permission of 
The Royal Society of Chemistry 
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Another example in functionalization of nanoparticles with TLR4 agonists was 
reported by Piazza et al., which loaded IONPsp with LPS. The “in vitro” 
immunostimulatory properties of the nanoparticles were monitored by the 
accumulation of extracellular TNF-α using innate immune system cells, respectively 
murine bone marrow-derived dendritic cells (BMDCs) and bone marrow-derived 
macrophages (BMDMs). These LPS-loaded IONPsp produced dose- and TLR4-
dependent activation of both cell types derived from mice13. 
While the QDs used in this thesis were purchased, IONPsp and cubic iron oxide 
nanoparticles (IONPc) were prepared by Dr. Gomez-Blanco using the method known 
as thermal decomposition, due to the good size control and high crystallinity of the 
resulting product14. The synthesis and the characterization of UCNPs is reported in 
the results and discussion section of this chapter. 
Monodisperse IONPsp were obtained by thermal decomposition of a metallic 
precursor, Fe(acac)3, in the presence of oleic acid and oleylamine as surfactants in 
diphenyl ether (a high boiling point solvent) using 1,2 hexadecanediol as a reducing 
agent. This procedure has been used several times in our research group, yielding 
uniform and biocompatible 7 nm IONPsp that have been functionalized with TLR 
ligands and used for biomedical applications and in vivo imaging10,15. This synthetic 
method is very versatile since it allows precise control over the size of the final 
product by modulating the reaction conditions. The chosen solvent, reaction 
temperature, and temperature ramps affect the final size of the IONPsp obtained and 
are key factors to a monodisperse size distribution14. The size of the IONPsp used in 
this thesis was chosen to be 7 nm as this specific size yields hydrophilic micelles 
having a size between 20-100 nm, which is ideal for lymph node delivery16. Besides, 
these IONPsp exhibit superparamagnetic behavior at room temperature and their 
magnetization value (Ms) was measured by Dr. Cobaleda-Siles to be of 91 emu g–1, 
among the highest reported so far in the literature for IONPsp-based MR contrast 
agents of this size17,18,19. Moreover, the r2 relaxivity value of the drug-free 25 nm 
micellar IONPsp (mIONPsp), obtained from self-assembly of PEG-phospholipids 
around 7 nm IONPsp, was 68.8 mM–1s–1, at 11.7 T and 25 ºC20, which makes it a 
very good T2-weighted MRI contrast agent. Thus, a size of 7 nm was chosen as an 
ideal compromise between the hydrodynamic diameter of the resulting micelles, 
suitable for lymph node delivery, and magnetization value for MRI.  
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On the other hand, IONPc, despite being bigger than IONPsp, yielded mIONPc that 
were still within the ideal values for lymph node targeting but featuring more 
promising magnetic properties than IONPsp, which can be used to obtain improved 
MRI contrast. The improved magnetic properties of IONPc originate from the fact that 
IONPs bigger than 25 nm behave as randomly distributed stationary objects (static 
dephasing regime, SDR) and are predicted to exhibit the highest r2 relaxivity. 
However, the magnetic dipole interaction among these ferrimagnetic nanoparticles 
results in poor colloidal stability causing aggregation and impairing their use for 
biomedical applications. Therefore, obtaining single-core IONPc within the SDR is 
fundamental for this purpose21.  
The 27 nm IONPc used in this thesis were synthesized by thermal decomposition of 
iron (III) acetylacetonate in benzyl ether at high temperatures, with oleic acid as 
surfactant and 4-biphenyl carboxylic acid as reducing agent. This method has been 
widely used and yields highly uniform and monodisperse nanoparticles by a one-step 
reaction22. Moreover, Dr. Gomez-Blanco prepared 77 nm mIONPc incorporating 27 
nm IONPc in PEG-phospholipids and the r2 relaxivity of the resulting micelles was 
measured to be 408 mM–1s–1 (unpublished data). These are very promising results 
since this value is almost four times higher than the commercial and clinically used 
benchmarks23.  
The transmission electron microscopy (TEM) characterization of the synthesized 
IONPs (Figure 2) shows IONPsp with a mean core diameter of 6.6 ± 0.9 nm and 
IONPc with a mean edge of 26.68 ± 2.6 nm. The nanoparticles prepared by thermal 
decomposition resulted in hydrophobic materials that needed further 
functionalization to achieve the water solubility required for biomedical applications. 
Among all the polymers and ligands suitable, PEG and its derivatives are a very 
interesting class of polymers that have been widely used to impart water solubility 
and biocompatibility to hydrophobic nanoparticles24,25. These polymers have low 
toxicity and immunogenicity and several PEGylated products have been approved 
by the FDA for clinical use26 and many PEG-encapsulated nanoparticles have been 
used for biomedical applications. One of the advantages of PEG as a coating for 
nanoparticles is the increased resistance of the resulting nanoparticles to unspecific 
interactions with proteins ending up in the formation of the protein corona27, further 
affected by the density of the PEG grafting28. Additionally, PEG confers stealth 
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properties to nanoparticles increasing their circulation time and retention in the 




Figure 2: Representative TEM images of the hydrophobic IONPsp and IONPc used 
for micelle preparation. 
LOS, or R-form LPS, have been investigated less than LPS for various applications, 
despite showing very promising results as vaccine adjuvants, both against 
pathogens and diseases30,31,32. To the best of our knowledge, the nanostructures 
formed by the interaction of our nanoparticles with the two LOS (E. Coli LOS and Xcc 
LOS) haven’t been investigated previously. These LOS feature structural differences 
from the conventional LPS, such as the lack of the O-antigen chain and possess a 
shorter oligosaccharide core, with around ten saccharide units. 
The complete structure of Xcc LOS was determined by Silipo et al. and it was found 
to be a unique molecule with high negative charge in the lipid A-inner core region. 
The unique features include a galacturonyl phosphate attached at a 3-deoxy-D-
manno-oct-2-ulosonic acid residue and a unique phosphoramide group in the inner 
core region33. It also shows a 3+3 symmetry in the distribution of the acyl chains in 
the Lipid A moiety, while conventional LPS typically show a 2+4 distribution. 
Interested in exploring new TLR4 agonists and improving their adjuvanticity, and in 
how the structural differences of the two TLR4 agonists might affect their 
incorporation, these were loaded on different kinds of nanoparticles. Besides, the 
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structural differences that distinguish these two LOS from the known E. Coli LPS and 
the FDA approved MPLA yielded unique nanoplatforms with distinctive chemical and 
biological properties. 
This chapter will also report the attempts made towards the development of a light-
triggered delivery vehicle for suppression of TLR4 signaling. 
Recently, an interesting application of the TLR7 agonist imiquimod and TLR7/ 8 
agonist resiquimod has been reported in the literature. By applying a protecting 
group that could be cleaved by light, Ah Ryu et al. developed photo-controlled 
versions of both these immunomodulators34 which were biologically inactive and 
could be activated upon irradiation with UV light (Figure 3). We reasoned that 
UNCPs, with their UC emissions could potentially be used to trigger TLR4 signaling 
using NIR light. Indeed some recent studies have shown the utility of UCNPs for  the 
release of the active molecule, both by overcoming the pharmacokinetic problems of 
small molecules35 and the poor tissue penetration of UV light when compared to NIR 
irradiation36. 
To the best of our knowledge, prior to this thesis UCNPs had not been exploited for 
the delivery of TLR4 modulators.  
 
Figure 3: TLR7/8 activation and subsequent MyD88 signaling cascade by the 
deprotection of photocaged small-molecule agonists imiquimod and resiquimod. 




Core-shell UCNPs were chosen for their enhanced UC photoluminescence, as the 
addition of a shell creates a homogeneous interface between the core and the 
outer shell. This suppresses surface-related deactivations by the elimination of the 
quenching sites on the surface of the core nanoparticle as well as spatial isolation of 
the core from surrounding deactivators (ligands, solvents, etc.), increasing the 
efficiency of the upconversion process37. It is reported that the visible UC emissions 
in hexagonal phase NaYF4:Yb3+/Tm3+ were enhanced 29.6 times by growing a thin 
layer of NaYF438. 
The chosen TLR4 ligand for UCNPs functionalization, IAXO 102, was designed, 
synthesized and characterized by the Peri group at UNIMIB39. This molecule had 
showed promising results when tested as a TLR4 antagonist in vitro. 
Looking to ultimately develop a light-triggered system by photo-caging the synthetic 
TLR4 modulator IAXO 102, un-caged IAXO 102 was loaded onto UCNPs-filled 
micelles. The immunomodulatory activity of this system was studied in macrophages.  
 
2.2: Results and discussion 
 
2.2.1: Self-assembly of pathogen-mimicking TLR4 agonist-functionalized 
nanoparticle-filled micelles 
Hydrophobic IONPsp, QDs and IONPc were successfully encapsulated in PEG-
phospholipids with incorporation of the two TLR4 agonists Xcc LOS and E. Coli LOS 
(with a molar ratio of 20% Xcc LOS to PEG-phospholipids and 27.5% E. Coli LOS to 
PEG-phospholipids). The PEG-phospholipids and the LOS are amphiphilic 
molecules, which reduce NP/ water surface tension by associating with the surface 
of the original hydrophobic nanoparticles through interdigitation of their acyl chains 
by van der Waals attractive interactions. The organization of hydrophilic 
components/ precursors at the surfactant/ water interface through electrostatic and 
hydrogen bonding interactions resulted in the encapsulation of the nanoparticles in a 
shell formed by the polar head groups. The self-assembly process of the amphiphilic 
PEG-phospholipids and TLR4 agonists with the hydrophobic nanoparticles yielded 
pathogen-mimicking micellar nanoparticles (mNPs) that are soluble and stable in 
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water (Figure 4) and could be stored in aqueous solution for weeks without major 
aggregation and size changes. In contrast, the incorporation of the FDA approved 
MPLA immediately afforded insoluble aggregates.  Hence, it seems lack of the 
hydrophilic O-antigen polysaccharide and core oligosaccharide chain makes the 
micelle surface less hydrophilic and thus increases the surface hydrophobicity, 
leading to the formation of large and insoluble aggregates. To remove NP-free 
micelles the samples were centrifuged and the supernatants were kept for 
quantification of drug loading and the pelleted mNPs were redissolved in aqueous 
solution (3 cycles). The drug-free mNPs prepared as controls and the pathogen-
mimicking mNPs incorporating the TLR4 agonists were characterized by TEM, 
dynamic light scattering (DLS) and by measuring the ζ-potential of the particles 
(Figure 5, Figure 6 and Figure 7). The TEM images of these bacteria-like 
nanoplatforms show mNPs with size distributions corresponding to a number-
averaged hydrodynamic diameter of ca. 20 nm for IONPsp and QDs and of ca. 70 
nm for IONPc, which are in the ideal range (20-100 nm) for lymphatic delivery16 and 
with rather uniform size distribution (polydispersity index between 0.16 and 0.39). 
Moreover, they showed a more negative ζ-potential than the drug-free control 
mNPs, consistent with the high negative charge density of the LOS molecules 
provided by the high density of phosphate and carboxylate groups and the 
phosphoramide group uniquely present in Xcc LOS. Also consistent with their 
different structures, the bacteria-like mNPs functionalized with Xcc LOS had a more 
negative surface charge than mNPs functionalized with E. Coli LOS (-11.42 ± 2.17 
mV for mIONPsp-Xcc LOS, -8.17 ± 1.55 mV for mIONPsp-E. Coli LOS and -6.71± 
0.87 mV for drug free mIONPsp); (-7.48 ± 0.58 for mQDs-Xcc LOS, -3.91 ± 0.33 for 
mQDs-E. Coli LOS and -3.53 ± 0.11 for drug-free mQDs); (-9.10 ± 0.85 for mIONPc-
Xcc LOS, -8.68 ± 0.69 for mIONPc-E. Coli LOS and -4.44 ± 0.53 for drug-free 
mIONPc). Their negative surface charge constitutes an advantage for lymph node 
targeting. This is because negatively charged particles move faster through the 
interstitium and are accumulated more efficiently in draining lymph nodes40,41 due to 
the electrostatic repulsion with the negatively charged interstitial matrix. Moreover, 
hydrophobicity has been reported to facilitate uptake by antigen presenting cells and 
delivery to the lymph nodes40,42,43 and here bound LOS and the oleic acid chains of 
the nanoparticles provide hydrophobic components to the micelle, which upon 
exposure to the surface can facilitate interaction with the membrane of antigen 
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presenting cells. The mIONPsp-LOS, therefore, possess all the key features of 
materials that can effectively target lymph nodes, specifically a size of 20-100 nm, 
an appropriate level of hydrophobicity and a negative surface. 
Two sets of experiments were carried out to quantify TLR4 agonist loading onto the 
mNPs. After pelleting the mNP-LOS systems by three cycles of centrifugation, IL-6 
cytokine production in the macrophage cell line J774A.1 upon incubation with the 
supernatants was compared with the dose-response curves obtained with the 
corresponding LOS. To check the efficacy of the used quantification method, mNPs-
E. Coli LPS were prepared and characterized (Figure 8) and the LPS left in the 
supernatants was quantified using both the FDA-approved Limulus amebocyte 
lysate (LAL) test and the cell stimulation-based method, with the two assays 
producing almost identical results (Table 1). The prepared mNPs-E. Coli LPS 
showed uniform size distributions and negative ζ-potentials higher than the control 
micelles, proving the incorporation of the negatively charged LPS (-7.10 ± 1.04 mV 
for mIONPsp-E. Coli LPS and -6.71± 0.87 mV for drug free mIONPsp; -9.15 ± 2.71 
mV for mIONPc-E. Coli LPS and -4.44 ± 0.53 mV for drug-free mIONPc; -4.59 ± 
0.86 mV for mQDs-E. Coli LPS and -3.53 ± 0.11 mV for drug-free mQDs) (Figure 
8g).  Moreover, mIONPc-E. Coli LPS had a much bigger size than mQDs-E. Coli 
LPS and mIONPsp-E. Coli LPS (218.5 ± 47.29 for mIONPc-E. Coli LPS, 20.63 ± 
7.11 for mQDs-E. Coli LPS and 27.08 ± 9.30 for mIONPsp-E. Coli LPS), due to the 
bigger number of LPS molecules incorporated in the larger IONPc (78 ± 14 LPS 
molecules/ mIONPc vs. 53 ± 6 LPS molecules/ mIONPsp and 15 ± 3 LPS 






































Figure 4: a) Chemical structures of the TLR4 agonists and b) schematic of the self-
assembly process for the synthesis of the water-soluble mNPs incorporating Xcc or 

































































































































































































































































































































The results showed that Xcc LOS is incorporated in the mIONPsp and mIONPc 
better than E. coli LOS (76 ± 6 % vs 22.2 ± 5.1 % and 44 ± 11 % vs 25 ± 9 %, 
respectively, (Figure 9). The mIONPsp could be loaded with 79 ± 5 and 41 ± 2 
molecules of Xcc LOS and E. coli LOS per particle, respectively (Figure 5g). The 
larger NP core size of the mIONPc allowed to increase the loading to 240 ± 26 Xcc 
LOS molecules/particle and 76 ± 7 molecules of E. coli LOS/particle (Figure 7g). 
Both types of nanoparticles are stabilized with an oleic acid/ oleylamine surfactant 
layer. In contrast, the commercial QDs with a similar core size to the mIONPsp 
showed a preference for incorporating E. coli LOS over Xcc LOS (29 ± 1 Xcc LOS 
molecules/particle vs 155 ± 11 molecules of E. coli LOS/particle) (Figure 6g). 
 
Figure 5: Size and ζ-potential of mIONPsp with and without LOS incorporation. (a-c)   
TEM images and (d-f) DLS analysis. g) Main characterization data: IONPsp core 
diameter from TEM images and counting more than 200 nanoparticles, number-
average hydrodynamic diameter and polydispersity index obtained by DLS, ζ-






































































- potential (mV) / 
ratio
 ± 1.19  ± 3.53  ± 0.015 6.71 ± 0.86
-E. coli LOS  ± 1.19  ± 7.02  ± 0.017 8.17 ± 1.55  ± 2





Figure 6: Size and ζ-potential of mQDs with and without LOS incorporation.  (a-c) 
TEM images and (d-f) DLS analysis. g) Main characterization data: QDs core 
diameter from TEM images and counting more than 200 nanoparticles, number-
average hydrodynamic diameter and polydispersity index obtained by DLS, ζ-
potential and number of biomolecules per QDs based on n > 5 formulation replicates. 
These results might be explained in term of the differences in the hydrophobic 
chains, where specific chain lengths etc. contributed to forming more extensive van 


































































- potential (mV) / NP
 ± 1.64  ± 7.42  ± 0.010 3.53 ± 0.11
-E. coli LOS  ± 1.64  ± 9.95  ± 0.025 3.91 ± 0.33  ± 12







Figure 7: Size and ζ-potential of mIONPc with and without LOS incorporation.  (a-c)  
TEM images and (d-f) DLS analysis. g) Main characterization data: IONPc core 
diameter from TEM images and counting more than 200 nanoparticles, number-
average hydrodynamic diameter and polydispersity index obtained by DLS, ζ-




Table 1: Comparison of results from two LPS quantitation methods. IL-6 cytokine 
production in the macrophage cell line J774A.1 after incubation with the 
supernatants isolated from the purification of the different mNP-LPS systems: cell-
culture-based method and LAL assay. Data are presented as mean ± SEM of three 
independent experiments each performed in triplicate. 



































































- potential (mV) / NP
 ± 2.6  ± 31.75  ± 0.010 4.44 ± 0,53
-E. coli LOS  ± 2.6  ± 18.92  ± 0.003 8.68 ± 0.69  ± 7







Figure 8: Size and ζ-potential of mIONPsp, mIONPc and QDs with and without LPS 
incorporation. TEM images of a) mIONPsp-E. Coli LPS, b) mIONPc-E. Coli LPS and 
c) mQDs-E. Coli LPS and d), e), f) respective DLS analysis. g) Main characterization 
data: core diameters from TEM images and counting more than 200 nanoparticles, 
number-average hydrodynamic diameter and polydispersity index obtained by DLS, 








Figure 9: Quantitation of TLR4 loading in a, b) mIONPsp, c, d) mQDs and e, f) 
IONPc. After pelleting the mNPs-LOS by three cycles of centrifugation, IL-6 cytokine 
production in the macrophage cell line J774A.1 after 24 h incubation with the 
supernatants was compared with the dose-response curves obtained with the 
corresponding free LOS. Data are presented as mean ± SEM of independent 
experiments each performed in triplicate.  
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To assess the stability of the mIONPsp-Xcc LOS over time, their size was analyzed 
immediately after purification and over a 4-week period in 10 mM PBS. Although the 
results showed some aggregation over time, the size of the mIONPsp Xcc LOS was 
still within the ideal range for reaching the lymph nodes (Figure 10). To study the 
Xcc LOS molecules release over time, 10 mM PBS solutions of the mIONPsp-Xcc 
LOS were centrifugated at designed time points (week 0, 1 and 2), with the amount 
of Xcc LOS in the supernatants determined as described below. The results showed 
that only 5% of the Xcc LOS molecules are released. In the outer membrane of 
gram-negative bacteria the negatively charged LPS molecules cover most of the 
outer surface and divalent cations such as Mg2+ and Ca2+ are essential to neutralize 
this negative charge and allow strengthening of the lateral interactions between 
neighboring LPS molecules, which provides enhanced stability for the external 
bacterial membrane45–47. Similar electrostatic interactions and effects such as 
increased hydrogen bonding and tighter lipid packing and cross-linking exerted by 
divalent cation bridging can be expected to take place in the pathogen-mimetic mNP-
LOS nanostructures to provide the observed stability.   
 
Figure 10: Stability and Xcc LOS release for mIONPsp-Xcc LOS in 10 mM PBS.  
 
2.2.2: In vitro activity of the pathogen-mimicking mNPs 
Many studies have shown that the immune response to LPS is dictated by their 
chemical structure. Besides, it has been reported that LPS as amphiphilic molecules 
form supramolecular aggregates in aqueous environments and that these structures 
are the biologically active units of LPS.48 However, the type of supramolecular 
aggregates structures formed also depends strongly on the chemical structure of the 
LPS molecules. Incorporation into mNPs ensures the formation of supramolecular 
structures where multiple copies of the LPS molecules are clustered, and therefore 
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they would be equally or even more active than the mNP-free preparations. When 
stimulating the macrophage cell line J774A.1 with the different TLR4 ligands to 
produce IL-6, the biological activity of E. coli LPS showed greater IL-6 production in 
comparison to equal amounts of E. coli LOS or Xcc LOS, and lower cell viability. 
Comparison of IL-6 production and cell viability of the TLR4 ligands compared to 
TLR4 ligand-loaded mNPs showed that the immunostimulatory properties and 
cytotoxicity of the two ligands is modulated by each of the mNPs differently. 
Incorporation into mIONPsp enhanced IL-6 production and significantly reduced 
cytotoxicity for Xcc LOS (Figure 11b), while it did not affect the activity of E. Coli 
LOS. (Figure 11a).  
 
Figure 11: Immunostimulatory activity and cytotoxicity of a) mIONPsp-E. Coli LOS 
and b) mIONPsp-Xcc LOS in antigen presenting cells. J774A.1 macrophages were 
incubated for 24 h at 37 °C with the indicated formulations. Cytokines released in the 
supernatants were quantified by ELISA and cell viability was determined by the MTT 
assay. ****P<0.0001, ***P<0.001, **P<0.01, *P<0.05, ns = non significant by (a, b) 
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a b
E. coli LPS E. coli LOS mIONPsp-E. coli LOS E. coli LPS Xcc LOS mIONPsp-Xcc LOS
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In contrast, E. coli LOS incorporation into the mIONPc lead to reduced IL-6 
production and significantly increased cytotoxicity (Figure 12a), while incorporation 
of Xcc LOS into the mIONPc did not affect its toxicity but lowered the immune 
stimulating capacities of the ligand (Figure 12b). The mQDs enhanced IL-6 
production of the ligand E. Coli LOS without affecting its cytotoxicity (Figure 13a), 
while they did not significantly affect the activity and toxicity of the ligand Xcc LOS 
(Figure 13b). On the basis of these results, the mIONPsp-Xcc LOS system was 
selected for further studies. 
 
Figure 12: Immunostimulatory activity and cytotoxicity of a) mIONPc-E. Coli LOS 
and b) mIONPc-Xcc LOS in antigen presenting cells. J774A.1 macrophages were 
incubated for 24 h at 37 °C with the indicated formulations. IL-6 released in the 
supernatants was quantified by ELISA and cell viability was determined by the MTT 
assay. ****P<0.0001, **P<0.01, *P<0.05, ns = non significant by two-way ANOVA 
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Figure 13: Immunostimulatory activity and cytotoxicity of a) mQDs-E. Coli LOS and 
b) mQDs-Xcc LOS in antigen presenting cells. J774A.1 macrophages were 
incubated for 24 h at 37 °C with the indicated formulations. IL-6 released in the 
supernatants was quantified by ELISA and cell viability was determined by the MTT 
assay. ****P<0.0001, **P<0.01, ns = non significant by two-way ANOVA followed by 
Bonferroni’s test. Data show mean ± SEM of 3 independent experiments.  
 
2.2.3: Uptake of mIONPsp-Xcc LOS by antigen presenting cells  
The uptake of both drug-free mIONPsp and mQDs was assessed in J774A.1 murine 
macrophages by fluorescence microscopy. To enable tracking of the mIONPsp 
during cellular uptake a 5% rhodamine B-labeled phospholipid was incorporated 
during the micelle synthesis. The mIONPsp(Rho)-Xcc LOS was characterized and 
showed only a slight increase in size and a slight decrease in the ζ-potential 
compared to the mIONPsp-Xcc LOS system (Figure 14).  In the case of the mQDs, 
the bright red luminescence (620 nm) was used for tracking. The results show that 
both mIONPsp and mQDs are uptaken by the cells within 3 h at nanomolar 
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Figure 14: a) Size and ζ-potential of mIONPsp(Rho)-Xcc LOS and b)  main 











Figure 15: Stacked fluorescence microscopy images of a) mIONPs(Rho) and b) 
mQDs, showing uptake of the micelles in cells. 
 
TLR4 is the only TLR that activates both the MyD88- and TRIF-dependent 



























from the plasma membrane and endosomes, respectively. It has been shown that 
after TLR4 encounters LPS, endosomes showing LPS and TLR4 co-localization 
appear within 15 min50. As expected, mIONPsp(Rho)-Xcc LOS co-localized with 









Figure 16: In vitro uptake and trafficking of rhodamine-labeled mIONPsp-Xcc LOS. 
micelles. a) Fluorescence microscopy images of J774A.1 showing endocytic uptake 
of mIONPsp(Rho)-Xcc LOS after 3 h incubation. Cells’ nuclei were stained with 
Hoechst blue and lysosomes and endosomes with Lysotracker green. b) UV-vis 
absorption and fluorescence spectrum of mIONPsp(Rho)-Xcc LOS. 
2.2.4: Synthesis and characterization of core/shell NaYF4: Yb3+/ Tm3+@NaYF4 
UCNPs 
Herein, the steps made towards the preparation of a light-triggered nanoplatform for 
TLR4 modulation will be discussed.  
Hydrophobic core/shell UCNPs were prepared following the procedures already 
reported in the literature by our research group36. Core NaYF4 Yb3+/ Tm3+ 
(69.5/30/0.5 mol%) UCNPs were synthesized by thermal decomposition in the 
presence of oleic acid and 1-octadecene under inert nitrogen atmosphere and using 
standardized Schlenk techniques and next used as seeds for growing a protective 
NaYF4 shell, yielding core/shell (NaYF4: Yb3+/ Tm3+@NaYF4) UCNPs. These 
UCNPs displayed multiple emission maxima typical of Tm3+ electronic transitions: at 
Hoechst  
blue Lysotracker 































345 and 360 nm (3P0 → 
3F4 and 
1D2 → 








3H6) and at 800 nm (
3H4 → 
3H6)51 (Figure 17). These core-shell UCNPs were characterized by TEM, DLS, X-ray 
photoelectron spectroscopy (XPS) and infrared spectroscopy (IR). The TEM 
micrograph shows rod-like hydrophobic nanoparticles with an average length of 39.20 
± 6.64 nm and a uniform size distribution (Figure 18). 
 
Figure 17: Upconversion emission pattern of NaYF4: Yb3+/Tm3+@NaYF4 (0.5 mg/mL 
in THF) upon 980 nm excitation at different laser powers (3.4– 20.6 W/ cm-2). 
Adapted from reference36. Reproduced by permission of The Royal Society of 
Chemistry. 
 




XPS analysis was performed to study the composition of the obta ined UCNPs. 
The spectrum confirms the presence of the elements composing the prepared 
UCNPs being C, O, F, Na, Y, Yb and Tm as assigned by core levels and Auger 
electrons (Figure 19). 
 
Figure 19: XPS spectrum of the prepared core-shell NaYF4: Yb3+/ Tm3+@NaYF4 
UCNPs. 
The IR spectrum of the UCNPs was recorded and compared with that of the free 
ligands, and the IR analysis confirms the presence of oleic acid in both core and 
core-shell UCNPs and reveals its interaction with the nanoparticles (Figure 20). 
 
Figure 20: IR spectrum of oleic acid, core (NaYF4: Yb3+/ Tm3+) and core-shell 
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2.2.5: Functionalization of UCNPs with IAXO 102 
Both control UCNP-filled micelles (without any bioactive ligand) and UCNPs 
functionalized with the TLR4 antagonist IAXO 102 were prepared and characterized. 
UCNPs were solubilized in aqueous solutions using PEGylated phospholipids, 
adding the hydrophobic IAXO 102 and using the self-assembly process illustrated in 
Figure 21. The resulting mUCNPs were centrifuged and the pelleted mNPs were 
redissolved in aqueous solution (3 cycles) to remove nanoparticle-free micelles and 
any unbound ligand.  
The characterization of both mUCNPs and mUCNPs-IAXO 102 was performed by 
TEM and DLS, showing rod-like particles with uniform size distribution. For 
mUCNPs, the number-averaged size corresponds to ca. 65 nm (Figure 22). To 
prepare mUCNPs-IAXO 102, the same procedure was used but in the presence of 
the TLR4 ligand IAXO 102. Two different systems were prepared – one with 5% of 
IAXO 102 (measured in moles) relative to PEG-phospholipid (mUCNPs-IAXO 102-
5%), and another with 15% of IAXO (mUCNPs-IAXO 102-15%) to PEG-
phospholipid. These systems were characterized by TEM and DLS (Figure 23 and 
Figure 24). Both systems showed low polydispersity (0.20 and 0.18 for mUCNPs-







































Figure 21: a) Molecular structure of the TLR4 antagonist IAXO 102; b) Generic 
representation of the interactions between the PEG phospholipids, IAXO 102 and 













Figure 22: Characterization of mUCNPs. a-d): TEM images taken at different 
magnifications (12000x; 15000x; 20000x; 25000x); e) size distribution of 
mUCNPs; f) table summarizing the main mUCNPs characterization data: 
UCNPs length from TEM images and counting more than 200 nanoparticles, 
number-average hydrodynamic diameter and polydispersity index obtained by 
DLS. Data based on n > 3 formulation replicates. 
 
The number-averaged hydrodynamic diameter of both the mUCNPs-IAXO 102 
was higher than the hydrodynamic diameter of mUCNPs (81.00 ± 50.34 for 
mUCNPs-IAXO 102-5% and 99.91 ± 41.14 for mUCNPs-IAXO 102-15% versus 
65.40 ± 38.03 for mUCNPs) (Figure 23g, Figure 24g and Figure 22g 
respectively).  The hydrodynamic diameter of the UCNPs-filled nanosystems is 






Figure 23: Characterization of mUCNPs-IAXO 102-5%. a-d) TEM images at 
different magnifications (15000x; 20000x; 25000x; 30000x); e) mUCNPs-IAXO 
102-5% size distribution; f) table summarizing the main mUCNPs-IAXO 102-5% 
characterization data: UCNPs length from TEM images and counting more than 
200 nanoparticles, number-average hydrodynamic diameter and polydispersity 
index obtained by DLS. Data based on n > 3 formulation replicates. 
 
Figure 24: Characterization of mUCNPs-IAXO 102-15%. a-d) Transmission 
electron microscopy (TEM) images at different magnifications (15000x; 20000x; 
25000x; 30000x); e) mUCNPs-IAXO 102-15% size distribution; f) table 
 
131 
summarizing the main mUCNPs-IAXO 102-15% characterization data: UCNPs 
length from TEM images and counting more than 200 nanoparticles, number-
average hydrodynamic diameter and polydispersity index obtained by DLS. 
Data based on n > 3 formulation replicates. 
 
2.2.6: In vitro activity of IAXO 102 
 
The biological activity of IAXO 102 and IAXO 102-functionalized UCNPs as 
antagonists of LPS was tested in murine J774A.1 macrophages by measuring 
its capacity to inhibit the L P S - i n d u c e d  production of IL-6 and compared to 
the LPS antagonist polymyxin B (PmB) as a positive control. While the highly 
cationic PmB forms electrostatic interactions with the negatively charged LPS 
inhibiting its capacity to bind to TLR452, IAXO 102 is expected to compete53,39 
with LPS for the binding sites on the TLR4 hydrophobic pocket. Both 
mechanisms should decrease the IL-6 release in the supernatants of the LPS 
stimulated cells. Cells were stimulated with three different concentrations of 
LPS (66, 6.6 and 0.66 nM) and three different concentrations of PmB and IAXO 
102 (both 10, 5 and 1 μM) as antagonists.   
 
Both IAXO 102 and PmB without any LPS stimulation did not show 
immunostimulatory properties or toxicity in J774A.1 cells at the explored 
concentrations (Figure 25). When administered with LPS, IAXO 102 did not 
show any antagonist activity. On the contrary, at most of the IAXO 102 and 
LPS concentrations tested, IAXO 102 seems to turn LPS into a more powerful 
immunostimulant (Figure 26). In contrast, PmB suppressed stimulation by 
LPS effectively. These results in macrophages are in disagreement with the 
results reported by Piazza et al.39, which show effective TLR4 inhibition by 
compound IAXO 102 in a model using HEK-Blue-4 cells. This model is based 
on HEK293 cells stably transfected with TLR4, MD2, CD14 genes and 
engineered to stably express an optimized alkaline phosphatase gene, sAP, 
which allows monitoring of the activation of TLR4 signal pathway by endotoxin. 
The difference in the experimental settings played a role, but in the chosen 
experimental model, no meaningful modulation of the endotoxin’s activity was 









Figure 25: Administration of IAXO 102 and PmB to J774A.1 macrophages. a) 
Cytotoxicity and b) immunomodulatory activity of IAXO 102 and PmB in the 
absence of LPS. *P<0.05, ns = non significant by two-way ANOVA followed by 
Bonferroni’s test. Data shown as Mean ± SEM of triplicates of a representative 













































































































































































































































































































































































































































Figure 26: Cytotoxicity and immunomodulatory activity of LPS are modulated 
by IAXO 102 and PmB. a, b) IL-6 production and cell Viability in J774A.1 
macrophages when stimulated with 66 nm LPS and different concentrations of 
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IAXO 102 and PmB; c, d) IL-6 production and Cell Viability in J774A.1 
macrophages when stimulated with 6,6 nm LPS and different concentrations of 
IAXO 102 and PmB; e, f) IL-6 production and Cell Viability in J774A.1 
macrophages when stimulated with 0,66 nm LPS and different concentrations of 
IAXO 102 and PmB; ****P<0.0001, ***P<0.001, **P<0.01, *P<0.05, ns = non 
significant by two-way ANOVA followed by Bonferroni’s test. Data shown as 
Mean ± SEM of triplicates of a representative experiment out of three 
independent ones. 
 
2.2.7: In vitro activity of IAXO 102-functionalized UCNPs 
The prepared mUCNPs and mUCNPs-IAXO 102 were tested in J774A.1 
mouse macrophages to assess their cytotoxicity and immune-
suppressive/stimulatory activity. Prior to using mUCNPs-IAXO 102, the immune 
stimulating activity and cytotoxicity of the drug-free mUCNPs were measured, 
and the results showed that they are not toxic at the administered 
concentrations (Figure 27a) and do not induce any IL-6 production (Figure 
27b). When administer together with LPS, mUCNPs can slightly increase LPS' 
toxicity (Figure 27c), on the other hand the immune stimulating activity of LPS 
is affected by the presence of drug-free mUCNPs which can slightly suppress 
the IL-6 release (Figure 27d). 
J774A.1 cells were thus stimulated with LPS and the two mUCNPs-IAXO 102 
prepared, respectively mUCNPs-IAXO 102-15% and mUCNPs-IAXO 102-5% 
(herein named A and B for clarity purposes). At the tested concentrations of 
mUCNPs-IAXO 102, it seems that the IAXO 102-loaded systems and drug-free 
UCNPs are more effective at suppressing the LPS-induced activity than free 
IAXO 102. but induce more cell death (Figure 28). One hypothesis might be 
that the mUCNPs could degrade in the lysosomes, releasing the hydrophobic 
nanoparticles, and the alkyl chains belonging to the oleic acid coating the 
UCNPs could act on their own as TLR4 modulators by insertion in the 






Figure 27: Effect (IL-6 release and viability) of core-shell mUCNPs on J774.1 
mouse macrophage cells. a) toxicity and b) immunostimulatory activity of 
UCNPs, c) toxicity and d) immunostimulatory activity of UCNPs administered 
wuth LPS. ****P<0.0001, ***P<0.001, **P<0.01, *P<0.05, ns = non significant by 
two-way ANOVA followed by Bonferroni’s test. Data shown as Mean ± SEM of 


















Figure 28: a) IL-6 release and b) cell viability of mUCNPs-IAXO 102-15% and 
mUCNPs-IAXO 102-5% on J774.1 mouse macrophage cells. **** P<0.0001, 
***P<0.001, **P<0.01, *P<0.05 by two-way ANOVA followed by Bonferroni’s 
test. Data shown as Mean ± SEM of triplicates of a representative experiment 



































































































































































In summary, a nanoplatform based on pathogen-mimicking TLR4 agonist 
functionalized structures was designed and developed. The system is 
comprised of IONPsp encapsulated in phospholipid micelles where the LOS 
derived from the plant pathogen Xcc as TLR4 agonist was adhered by 
hydrophobic interactions. Unlike MPLA, both E. Coli LOS and the structurally 
unique Xcc LOS allowed effective interaction with IONPsp-, IONPc- and QDs-
filled micelles for the generation of stable pathogen-mimicking nanostructures 
with size, charge and hydrophobicity ideal for lymph node delivery. Each of the 
new prepared nanosystems, namely mIONPsp-Xcc LOS, mIONPsp-E. Coli 
LOS, mIONPc-Xcc LOS, mIONPc-E. Coli LOS, mQDs-Xcc LOS, and mQDs-E. 
Coli LOS were administered to J774A.1 macrophages to select the best 
adjuvant based on their toxicity profile and immune stimulating capacities. The 
results showed that each nanoparticle modulates the ligand’s activity in a 
different manner. Amongst the generated nanostructures, the mIONPsp-Xcc 
LOS showed the best size, stability, toxicity profile, and immune response. This 
system encapsulated the type of IONPs for which previous studies have shown 
effective in vivo tracking by multimodal imaging10,15 and ability to potentiate 
other cancer immunotherapies approaches such as DC-based vaccination54 
and macrophage polarization into pro-inflammatory M1 phenotypes55. This 
system was investigated as a cancer vaccine adjuvant (described in chapter 4) 
together with newly developed antigen-loaded nanoparticles (described in 
chapter 3). 
With the idea to develop a light-triggered nanoplatform for delivery of TLR4 
modulators, core-shell NaYF4: Yb3+/ Tm3+@NaYF4 UCNPs were prepared by 
thermal decomposition and characterized by DLS, TEM, and XPS, obtaining 
uniform rod-like nanoparticles featuring an upconversion emission at different 
wavelengths in the UV-Vis range36, triggered by NIR irradiation at 980 nm. 
These UCNPs were encapsulated in PEG-phospholipid micelles obtaining 
water-soluble mUCNPs of ~65 nm, a size suitable for drug delivery. The 
incorporation of two different ratios of IAXO 102, a TLR4 antagonist, yielded two 
different nanoplatforms, respectively mUCNPs-IAXO 102-5% and mUCNPs-
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IAXO 102-15%, featuring hydrodynamic diameters of ~81 and ~99 nm 
approximately and with a uniform size distribution, ideal for use in drug delivery. 
Prior to testing the mUCNPs-IAXO 102, the antagonist activity of the ligand 
IAXO 102 was tested in J774A.1 murine macrophages and compared to the 
well-known LPS inhibitor PmB. As expected, both molecules proved to be non-
toxic in J774A.1 cells at the concentrations used. However, it was discovered 
that while all the PmB concentrations can effectively inhibit 66 nM and 6,6 nM 
LPS, at these LPS concentrations IAXO 102 seemed to enhance the immune 
stimulating activity of endotoxin as measured by IL-6 release, thus acting as an 
agonist, contrarily to what had been seen in the literature39. Thus, the activity of 
IAXO 102 is too complex, since it switches from stimulatory to inhibitory at 
different concentrations. Interestingly both drug free mUCNPs and the 
mUCNPs-IAXO 102 systems inhibited the immunostimulatory activity of LPS but 
with higher toxicity. Taken together, these findings did not encourage any 














2.4: Materials and methods 
Materials: Unless otherwise specified all commercially available reagents were 
used without further purification. Both Xcc LOS and E. Coli LOS were received 
from the research group of Prof. Alba Silipo at the University of Naples Federico 
II. The lipooligosaccharide of Xcc was extracted and purified from dried cells as 
described previously33. The ligand IAXO 102 was obtained by the group of Prof. 
Francesco Peri at the University of Milano Bicocca and synthesized as 
described39. Iron (III) acetylacetonate (99 %) was purchased from STREM 
chemicals; Oleic acid (90 %), Oleylamine (70 %), Dibenzylether (80 %), 
CdSe/ZnS core/shell quantum dots (λem 600 nm), Yttrium(III) acetate hydrate 
(99.9%), Ytterbium(III) acetate tetrahydrate (99.9%), Thulium(III) acetate 
hydrate (99.9%), 1-octadecene (technical grade, 90%), Sodium hydroxide (≥ 
97%), Ammonium fluoride (98%), Tetrahydrofuran (THF), Dimethyl sulfoxide 
(DMSO) and Polymyxin B (PmB)  were all purchased from Sigma Aldrich; 1, 2- 
hexadecanediol (98 %) was purchased from TCI Europe; 4-biphenylcarboxylic 
acid (95%) was purchased from Acros; CHCl3 (0,005 % water), Methanol 
(MeOH) and HNO3 were purchased from MACRON fine chemicals; 1,2-
distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-
2000] (ammonium salt) (DSPE-mPEG) and 1,2 dipalmitoyl-sn-glycero-3-
phosphoethanolamine-N-(lissaminerhodamine B sulfonyl) (ammonium salt) 
(Rho-PE) were purchased from Avanti polar lipids. 0.45 µm syringe filters were 
purchased from Pall life sciences; Pierce LAL chromogenic endotoxin 
quantitation kit, Hoechst 33342 (Hoechst blue) and Lysotracker green DND-26 
were purchased from Thermo Fisher. Dulbecco’s Modified Eagle Medium 
(DMEM), Fetal Bovine Serum (FBS), Penicillin/Streptomycin (P/S) and L- 
glutamine (L-Glu) were all purchased from Gibco; Cell culture plates were 
purchased from Nunc; MTT cell proliferation kit was purchased from Roche, IL-
6 sandwich ELISA kit was purchased from R&D. 
Synthesis of iron oxide nanoparticles (IONP): Hydrophobic spherical IONP 





Nanoparticle- filled nanomicelles preparation: 1 mg of IONPsp and 2 mg of 
DSPE-mPEG methoxy were dissolved in 100 μL and 200 μL of chloroform 
respectively, combined in a 4 mL round-bottomed glass vial with 100 μL of 
chloroform and let to evaporate overnight at RT. LOS- and LPS- loaded 
micelles were prepared in the same way, with the exception that 0.2 mg of LOS 
or LPS were added to the latter 100 μL of chloroform and dissolved thoroughly 
using a vortex mixer (5 minutes) and an ultrasonic cleaner (30 minutes).  
Fluorescent micelles were prepared in the same way adding a 5% of 1,2-
dimyristoyl-sn-glycero-3-phosphoethanolamine-N-lissamine Rhodamine B 
sulfonyl-ammonium salt to the phospholipids mixture. The flask was placed in a 
water bath at 80 °C for 30 s, after which micelles were re-dissolved in 1 mL of 
MilliQ water. This solution was centrifuged at 5000 xg for 5’ and passed through 
a 0.45 µm syringe filter to remove non-soluble particles. Then, the micelles were 
centrifuged at 108600 xg for 50 minutes; the supernatant was discarded and 
washed with MilliQ water to remove empty PEG micelles (3 cycles). Finally, the 
pellet was dissolved in 400 μL of MilliQ water (or 10 mM Phosphate Buffered 
Saline, PBS, when injected in vivo). Micelles were stored at 4ºC. In order to 
quantify the concentration of iron, ICP analysis was carried out. Briefly, 10 µL of 
micelles were digested in concentrated HNO3 over a minimum of three days. 
Prior to the measurement, the samples were diluted up to 8 mL in MilliQ water 
(final acid concentration: 1-2 %). ICP-AES analyses were carried out on a 
Perkin Elmer Optima 5300 DV (Perkin Elmer, Santa Clara, CA, USA) at CIC 
BiomaGUNE by the Mass spectrometry platform. A range of calibration 
standards was prepared using single element 1000 mg/L stock solutions (Fisher 
Scientific UKLTD) and a Merck multielement standard (ICP Multi element 
standard solution, VICertiPUR) was employed as a reference standard.  
QDs- filled nanomicelles preparation: The procedure reported for the 
preparation of IONPs- filled nanomicelles was followed, with a variation: after 
filtering the micelles through a 0.45 µm syringe filter, the micelles were 
centrifuged at a speed of 108600 xg for 45 min. QDs concentration vas 
determined by UV-Vis spectroscopy following the procedures reported in the 
literature56,57. UV–Vis absorption spectra were recorded on a V-630Bio 
Spectrophotometer (JASCO Analytical Instruments). 
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IONPc- filled nanomicelles preparation: The procedure reported for the 
preparation of IONPs- filled nanomicelles was followed, with some slight 
variations: after re-dissolving the micellar film in 1 mL of MilliQ water, the 
solution was centrifuged at 300 xg for 5 min. Besides, after filtering the micelles 
through a 0.45 µm syringe filter, they were centrifuged at a speed of 88200 xg 
for 25 min (3 cycles). 
Transmission electron microscopy (TEM) studies were performed using a JEOL 
JEM-2011 electron microscope operating at 120 kV. The samples were 
prepared by deposing a drop of a solution of nanoparticles (1 mg/mL in THF) 
onto Pelco 150 mesh grid (Ted Pella) and allowing it to dry. For the preparation 
of hydrophilic samples, TEM grids were polarized using a Quorum technologies 
K100X glow discharge system. Nanoparticles’ size was determined from TEM 
images, measuring a minimum of 200 nanocrystals with the software ImageJ.  
Hydrodynamic diameter and ζ-potential of the micelles were measured using a 
Z-Sizer (Malvern Nano-Zs, UK). To determine the stability, mIONPsp-Xcc LOS 
were dissolved at a concentration of approx. 5 mM in 10 mM PBS and the 
hydrodynamic diameter analyzed by Z-Sizer immediately after purification and 
over a 4 weeks period. To measure the ζ-potential, the samples were dissolved 
at a concentration of approx. 0, 5 mM in 10 mM NaCl and analyzed by Z-sizer 
immediately after purification. 
Quantification of LOS loading on IONPsp micelles: The amount of LOS 
incorporated on micelles was measured using a calibration curve prepared 
plotting the immune stimulating activity of the pure ligand (measured 
determining the amount of IL-6 released) on cell cultures versus its 
concentration, and the amount of ligand bound to the nanoparticle was 
determined indirectly, measuring the amount of ligand that wasn’t incorporated 
to the micelles and remained in the supernatants from the micelles workup. 
Briefly, in a typical determination, a calibration curve is prepared administering 
Xcc LOS concentrations ranging from 36 μM to 3.6 nM to cells and the 
corresponding IL-6 production is measured by Sandwich ELISA and plotted 
against the ligand’s concentration to get a calibration curve, used to extrapolate 
the concentration of unincorporated Xcc LOS from the supernatants upon 
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measurements of their immune stimulating activity, by IL-6 concentration. The 
efficiency of this method was double checked by loading LPS on the mNPs 
developed and reported in the supporting information section (iron oxide 
nanospheres and nanocubes and quantum dots) and comparing the results 
obtained with the “supernatants quantification” method to the ones obtained 
with a commercial kit (Pierce LAL chromogenic endotoxin quantitation kit) for 
determination of LPS concentration. The ratio of ligand to nanoparticles was 
calculated following these calculations for IONPsp: Assuming a completely 
spherical nanoparticle and the known density of magnetite structure, the 
number of iron atoms per nanoparticle can be determined: 
 
VIONPsp = 4/3 · (D/2)3 · π = 1.505 · 10-25 m3; 
ρ(Fe3O4) = 5.17 · 106 g·m3; 
m = ρ(Fe3O4) · VIONPsp = 7.783 · 10-19 g; 
nFe = m/ MW (Fe3O4) · 3 = 1.009 · 10-20 mol; 
Featoms/IONPsp = nFe · NA = 6076 atoms; 
MW (Xcc LOS): 2750 Da and MW (E. Coli LOS): 2000 Da. 
In order to calculate the ratio of ligand to IONPc, the same logic was followed, 
using the side length of nanocubes: 
VIONPc = (l)3= 1.899 · 10-23 m3; 
ρ(Fe3O4) = 5.17 · 106 g·m3; 
m = ρ(Fe3O4) · VIONPc= 9.818 · 10-17 g; 
nFe = m/ MW (Fe3O4) · 3 = 1.272 · 10-18 mol; 
Featoms/IONPc = nFe · NA = 766120 atoms; 
MW (Xcc LOS): 2750 Da and MW (E. Coli LOS): 2000 Da. 
 
Quantification of LPS loading on IONPsp, IONPc, and QDs micelles: The 
analysis was performed using a Pierce LAL chromogenic endotoxin quantitation 
kit (Thermofisher) following the instructions given by the kit’s manufacturer. The 
assay was performed in aseptic conditions. Briefly, 50 μL of standards or 
samples were put on a 37ºC 96 well microplate (in duplicates), incubated for 5 
min. at 37ºC after which the LAL reagent was added to each well. Following a 
10 min. incubation at 37ºC, 100 μL of substrate solution were added, stirred and 
incubated for 6 min. at 37ºC. Then, 25 μL of stop solution were added and the 
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absorbance at 405 nm was immediately measured using a Varioskan LUX 
multimode plate reader (Thermo Fisher). The concentration of LPS in the 
unknown samples was determined using a calibration curve. 
Xcc LOS release studies: Ligand loading on the nanoparticles was measured 
immediately after preparation. 1 or 2 weeks after, mIONPsp-Xcc LOS 
nanoparticles were centrifuged at a speed of 108600 xg for 50 min.  and the 
supernatant was removed and analyzed following the fore mentioned 
procedures for quantification of the ligand loading.  
Fluorescence microscopy: J774A.1 cells were seeded in an Ibidi μ-Slide VI0.4 at 
a density of 30000 cells/ well in DMEM supplemented with 10% Fetal Bovine 
Serum and 1% Penicillin/Streptomycin and let to adhere overnight in an 
incubator maintained at 37 °C and 5% CO2. The day after, the medium was 
removed and cells were administered with 1 μg/ mL Hoechst blue to stain the 
nuclei and incubated for 30 minutes. Cells were washed with PBS three times in 
order to get reed of the unbound dye and then stained with ~200 nM 
mIONPsp(Rho)-Xcc LOS or mIONPs(Rho) or mQDs (the latter at a 
concentration of ~150 nM) and incubated for three hours. Cells were washed 
again and stained with 1 mM Lysotracker green, incubated for 30 minutes, 
washed with PBS and finally images were taken using ZEISS Axio Observer 
inverted microscope for the experiments carried out at CIC BiomaGUNE and a 
Zeiss 200M Axiovert for the experiments at UNIBI. In the latter case, a built-in 
deconvolution program was used to overlap images of cells obtained from 
different focal planes and deconvolute the images. Fluorescence and 
absorbance spectrum of the Xcc LOS-loaded micelles were recorded using a 
Fluorometer Horiba Fluoromaster 3 and UV–Vis absorption spectra were 
recorded on a V-630Bio Spectrophotometer (JASCO Analytical Instruments) 
respectively. 
Cell viability experiments: The J774A.1 mouse macrophage cell line was 
obtained from the American Type Culture Collection (ATCC). Cells were grown 
at 37 °C in a humidified atmosphere of 5 % CO2 using Dulbecco’s Modified 
Eagle Medium (DMEM, Gibco) supplemented with 10 % Fetal Bovine Serum 
(FBS, Gibco) and 1 % Penicillin/Streptomycin (P/S, 50 U/mL, Gibco). Cells were 
 
144 
detached when reached 70% confluence by removing them from the culture 
flask via gentle scraping and then resuspended in medium and seeded at a 
density of 3·104 cells/ well in 96-well plates and allowed to adhere overnight. 
Then, cells were administered with ligands, micelles or ligand-loaded micelles 
solutions diluted accordingly in medium, in triplicates, in a final volume of 200 
μL (of which 100 from cell seeding and 100 from the administered solution, split 
into 50 for LPS and 50 for IAXO 102, IAXO 102-loaded mUCNPs or PmB) and 
incubated for 24h at 37ºC after which supernatants were removed and stored at 
-20ºC until analysis. Cell viability was determined using a MTT assay (Roche). 
Briefly, cells were administered with 100 μL/well of a MTT solution diluted in 
medium and incubated for 1h at 37ºC, after which supernatants were discarded 
and MTT crystals dissolved in 200 μL/well of Dimethyl sulfoxide (DMSO). The 
absorbance of the wells was measured using a TECAN Genios Pro 96/384 
multifunction microplate reader at 550 nm and data represented as the cell 
viability compared to control wells. 
  
Quantification of Cytokine Production by ELISA: Cytokines were measured in 
cells’ supernatants using IL-6 (R&D) sandwich ELISA. A 4-parameter logistic 
standard curve was generated using Graph Pad Prism 5 and used to get the 
cytokines concentrations. Results are expressed as mean ± SEM in pg/mL or 
ng/mL, compared to untreated control wells.  
 
Synthesis of Upconverting nanoparticles: Hydrophobic core-shell                        
NaYF4 upconverting nanoparticles doped with Yb and Tm (NaYF4: Yb
3+/ 
Tm3+@NaYF4) were prepared following the procedure reported in the literature 
by our research group36.  
Synthesis of core NaYF4: Yb
3+/ Tm3+: Yttrium(III) acetate hydrate (2.1 mmol, 
555 mg), ytterbium(III) acetate tetrahydrate (0.90 mmol, 380 mg) and 
thulium(III) acetate hydrate (0.015 mmol, 5.2 mg) were added in 1-octadecene 
(25 mL) and oleic acid (15 mL) in a round-bottomed flask. The suspension was 
heated up to 120 ºC with a temperature ramp of 3.2 ºC/min under stirring and 
vacuum. Once the reaction mixture reached such temperature, it was kept in 
these conditions for 30 min in order to eliminate residual water and oxygen. The 
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system was then let to cool to 50 ºC under a flow of nitrogen gas. A solution of 
sodium hydroxide (7.5 mmol, 300 mg) and ammonium fluoride (12.0 mmol, 444 
mg) dissolved in methanol (8 mL) was added dropwise to the reaction flask. The 
reaction mixture was stirred at 50ºC for 30 min and at 70ºC for 30 min under 
nitrogen. Then, the system was heated up to 300ºC with a temperature ramp of 
13.5 ºC/min under stirring and nitrogen and maintained in such conditions for 90 
min. Next, the flask was left cooling to room temperature, and nanoparticles 
were purified by centrifugation (3000 xg, 15 min). The white pellet was washed 
once with of ethanol (40 mL) and once with THF/ethanol (5/35 mL) and 
recollected by centrifugation. Upconversion nanoparticles were dried at room 
temperature overnight.  
Synthesis of core-shell NaYF4: Yb
3+/ Tm3+@NaYF4: The previously prepared 
core NaYF4: Yb
3+/ Tm3+ nanoparticles were used as seeds to grow a NaYF4 
shell. Yttrium (III) acetate hydrate (0.9 mmol, 240 mg) was added in 1-
octadecene (15 mL) and oleic acid (6 mL) in a round-bottomed flask. The 
suspension was heated up to 120 ºC with a temperature ramp of 3.2 ºC/min 
under constant stirring and vacuum, and kept in such conditions for 30 min. 
Afterwards, the solution was let to cool to 80 ºC and placed under a flow of 
nitrogen gas. Meanwhile, a suspension of NaYF4:Yb3+/Tm3+ (260 mg) in hexane 
(10 mL) was prepared and added to the reaction flask dropwise. The reaction 
mixture was heated up to 110 ºC (3.2 ºC/min) under vacuum to eliminate the 
hexane. After 30 min the solution was let to cool to 50 ºC and a solution of 
sodium hydroxide (2.2 mmol, 88 mg) and ammonium fluoride (3.5 mmol, 130 
mg) in methanol (5 mL) was added to the system drop wise. The flask was kept 
at 50 ºC for 30 min and at 70 ºC for 30 min under nitrogen to evaporate the 
entire amount of methanol from the reaction mixture. Afterwards, the reaction 
flask was heated up at 300 ºC with a temperature ramp of 13.5 ºC/min and kept 
for 90 min. The solution was then cooled to room temperature. The obtained 
core-shell nanoparticles were purified by centrifugation (3000 xg, 15 min). The 
pellet was washed with ethanol and THF and dried overnight.  
UCNPs- filled nanomicelles preparation: 2 mg of UCNPs and 2 mg of DSPE-
mPEG were dissolved in 200 μL and 200 μL of chloroform respectively, 
combined in a 4 mL round-bottomed glass vial with 100 μL of chloroform and let 
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to evaporate overnight at RT. IAXO 102-loaded UCNPs micelles were prepared 
as above described, with the exception that 0.1 mg or 0.3 mg of IAXO 102 (to 
prepare mUCNPs-IAXO 102-r1 and mUCNPs-IAXO 102-r2 respectively) were 
added to the latter 100 μL of chloroform. The flask was placed in a water bath at 
80 °C for 30 s, and micelles were re-dissolved in 1 mL of MilliQ water. This 
solution was centrifuged at 5000 xg for 5’ and passed through a 0.45 µm 
syringe filter to remove non-soluble particles. Then, the micelles were 
centrifuged at 72000 xg for 30 minutes; the supernatant was discarded and 
washed with MilliQ water to remove empty PEG micelles (3 cycles). Finally, the 
pellet was dissolved in 400 μL of MilliQ water and micelles were stored at 4ºC. 
The concentration of UCNPs was measured assuming that 100% of the 
nanoparticles used ended up in the micelles. 
Fourier Transform Infrared (FTIR) FTIR spectra of oleic acid, NaYF4: Yb3+/ 
Tm3+, NaYF4: Yb3+/ Tm3+@NaYF4, and oleic acid were recorded on a Nicolet 
FTIR 6700 spectrometer as KBr pellet, obtained by mixing 0.5 mg of core-shell 
upconverting nanoparticles with 2 mg of dry KBr and using the hydraulic press.  
XPS experiments were performed in a SPECS Sage HR 100 spectrometer 
with a non- monochromatic X-ray source Magnesium Kα line of 1253.6eV 
energy and an applied power of 250 W. It was calibrated using the 3d5/2 line of 
Ag with a full width at half maximum (FWHM) of 1.1 eV. All measurements were 
made in an ultra-high vacuum (UHV) chamber at a pressure below 8·10–8 
mbar. To prepare the sample, 3 mg of nanoparticles were dissolved in THF, 
carefully sonicated and put in a Titanium coated glass slide (previously 
prepared). The acquisition time was 150 minutes. 
Cell viability and cytokine production experiments: The J774A.1 mouse 
macrophage cell line was obtained from the American Type Culture Collection 
(ATCC). Cells were grown and split following the procedures already reported in 
the materials and method section. Then, cells were administered with ligands, 
micelles or ligand-loaded micelles solutions diluted accordingly in medium, in 
triplicates, in a final volume of 200 μL (of which 100 from cell seeding and 100 
from the administered solution, split into 50 for LPS and 50 for IAXO 102, IAXO 
102-loaded mUCNPs or PmB) and incubated for 24h at 37ºC after which 
supernatants were removed and stored at -20 ºC until analysis. Cell viability 
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was determined using a MTT assay (Roche). Cytokine production was 
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Covalent binding of the model antigen ovalbumin 
(OVA) to IONPsp and JanusNPs: 
Here, several ways to improve the delivery of OVA were investigated, by 
preparing mIONPsp-HyNic-FB-OVA, mJanusNPs-HyNic-FB-OVA and the 
adjuvant- and antigen- loaded mIONPsp-E. Coli LPS/HyNic-FB-OVA systems 


















The use of nanoparticles for antigen delivery has several advantages over the 
use of  conventional antigens as they can protect antigens from degradation 
and improve their delivery and presentation to the immune system1. Besides, 
nanostructures can be loaded with multiple antigenic epitopes or both antigen 
and adjuvant in a single carrier and also reduce systemic side effects2. 
Moreover, coordinated delivery of adjuvant and antigen to the lymph nodes is 
necessary for the immune system to unleash a strong immune response3,4,5 and 
is a desirable feature for every vaccine candidate. 
A central aspect of antigen delivery leading to a protective immune response is 
the antigen presentation to dendritic cells, which will in turn present it on MHC 
class I or II molecules and subsequently promote T cells expansion. Uto et al. 
showed that poly(γ-glutamic acid) nanoparticles (γ-PGA NPs) loaded with OVA 
can be taken up much more efficiently by dendritic cells than OVA alone or its 
Alum-associated form, and the use of nanoparticles improved the uptake 
efficiency of up to 30-fold6.  
Another important factor improving antigen delivery is the depot effect, which 
can provide long-term antigen release from a vaccination site, and polylactide-
co-glycolide (PLGA) micro- or nanoparticles have been used for this purpose 
since they have a history of safe use in humans7. However, the literature also 
reported that antigens encapsulated and released from PLGA micro- or 
nanoparticles suffered from degradation and that because of low antigen 
encapsulation efficiency and scale-up issues these particles never moved into 
clinical trials as controlled-release delivery vehicles for vaccines7,8,9. 
Another type of nanoparticle that has been exploited for antigen delivery are 
lipid-based vesicles or liposomes. These particles have been investigated 
intensively in recent years due to being  relative ease to make and tune their 
properties, efficient uptake in APCs and lack of toxicity10. However, Epaxal® is 
the only liposome-based vaccine approved for use in humans against hepatitis 
A infection11. The low stability characteristic of liposomes hinders the  
application of these particles12. 
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Another antigen delivery approach is represented by the use of metallic 
nanoparticles. Recently, there has been enough evidence to suggest that these 
might act not only as antigen carriers, but also as immunostimulatory entities, 
by inducing cytokine production, APCs activation, and humoral immune 
responses13.  
Another fundamental aspect of antigen delivery by nanoparticles is the strategy 
employed to conjugate the antigen to nanoparticles, and many different 
approaches have been reported in the scientific literature. Among them, are the 
EDC coupling chemistry14,15,16, and the reductively labile disulphide-based 
antigen conjugation17. Herein, hydrazone ligation was utilized to prepare the 
nanoparticle-antigen conjugates. The bis-aryl-hydrazone-linking conjugation 
strategy offers high chemoselectivity, high yields at low concentrations, 
enhanced reaction rates and easy reaction monitoring. Its selectivity arises from 
the fact that the linkers, introduced separately in the molecules that have to be 
conjugated, are not reactive towards the common functional groups found in 
biological molecules such as amino groups, allowing to avoid cross-linking 
which could ultimately lead to aggregation. 
 
3.2: Results and discussion 
3.2.1: Synthesis and characterization of mIONPsp linked to OVA via 
hydrazone bond (mIONPsp-HyNic-FB-OVA)  
 
Since mIONPsp-Xcc LOS were selected as the best adjuvant system, IONPsp 
were also chosen for the delivery of the model antigen OVA. The preparation 
and the characteristics of the hydrophobic IONPsp were already discussed in 
chapter 2. 
To introduce the required functional groups onto the mIONPsp, the terminal 
amine group of the mIONPsp prepared using 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[amino(polyethylene glycol)-2000] (DSPE-aPEG) was 
modified to an aromatic aldehyde at a pH of 7 by reaction with the activated 
ester of the linker succinimidyl 6-hydrazinonicotinate acetone hydrazone (S-
HyNic) (Figure 1a). The resulting HyNic-modified mIONPsp (mIONPsp-HyNic) 
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were purified by a desalting column and spin filtration to get rid of the unreacted 
starting material. The average molar substitution ratio of the mIONPsp with the 
HyNic linker was ca. 10, which was determined by reacting mIONPsp-HyNic 
with 4-nitrobenzaldehyde and measuring the formation of the bis-aryl hydrazone 
bond at 345 nm. On the other hand, lysine residues of OVA were modified to an 
aromatic aldehyde by reacting them with the activated ester of the linker 
succinimidyl 4-formylbenzoate (4FB) at pH 7 (Figure 1a) and the product was 
purified by a desalting column and spin filtration. The substitution ratio of the 
OVA with the 4FB linker was determined by reaction with 2-hydrazinopyridine-
2HCl and measuring the formation of the bis-aryl hydrazone at 350 nm, and 
was of 2-3 molecules of 4FB per OVA (Figure 1b) out of 20 lysine residues. 
The ligation reaction of the aromatic aldehyde functionalized 4FB-OVA (20-30 
μM) with hydrazine activated mIONPsp-HyNic (0.5-3 μM IONPs) carried out at 
pH 6.2 in the presence of 100 mM aniline as a nucleophile catalyst and 
monitored by the hydrazone chromophore formation achieved a high level of 
conjugation (ca. 85-90%) in 2 h with an 80% conversion already within the first 
10 min of the reaction (Figure 1c). Quantitative analysis of protein content by 
the commercial test BCA showed conjugation of ~6 molecules of OVA per 
IONPsp. TEM and DLS studies confirmed that this conjugation strategy 
preserves the 20-100 nm size for lymph node targeting (Figure 1d, e), and that 



































Figure 1. a) General strategy for the conjugation of the antigen (OVA) to 
mIONPsp. b, c) UV monitoring of the chemical ligations. b) The substitution ratio 
of the OVA with the 4-FB linker was determined by reaction of the FB-OVA with 
2-hydrazinopyridine-2HCl. c) The formation of the FB-modified OVA and the 
ligation reaction of FB-OVA (20-30 μM) to mIONPsp-HyNic (0.5-3 μM 
mIONPsp) in presence of ~100 mM of aniline. d-g) Size and stability of 


















































































































































































































































































analysis of size and size distribution over time. Data are representative of n > 5 
formulation replicates. 
 
3.2.2: Uptake of mIONPsp-HyNic-FB-OVA by antigen presenting cells. 
The uptake of mIONPsp-HyNic-FB-OVA was assessed in J774A.1 murine 
macrophages by fluorescence microscopy. To enable tracking of the mIONPsp 
during cellular uptake a 5% rhodamine B-labeled phospholipid was incorporated 
during the micelle synthesis. The results show that mIONPsp(Rho)-HyNic-FB-










Figure 2. In vitro uptake and trafficking of rhodamine labeled mIONPsp-HyNic-
OVA micelles. a) Fluorescence microscopy images of J774A.1 macrophages 
showing endocytic uptake of mIONPsp-HyNic-FB-OVA after 3 h incubation. 
Cells’ nuclei were stained with Hoechst blue and lysosomes and endosomes 




3.2.3: Preparation of hydrophilic Fe3O4-Au JanusNPs (mJanusNPs) 
Hydrophilic (Fe3O4-Au) JanusNPs were synthesized in two consecutive seed-




































BiomaGUNE. In order to obtain JanusNPs, gold nanospheres were prepared 
and used as seeds for the growth of gold- iron oxide nanodumbbells. 
Afterwards, these nanodumbbells were used as seeds for the directional growth 








Figure 3. Synthesis of JanusNPs. a) Synthesis of Au nanoparticles. b) Growth 
of an IONP and subsequent oxidation. c) Growth of an Au nanostar using the 
nanodumbbells as seeds. 
 
The growth of a gold nanostar is performed in presence of polyvinylpyrrolidone 
(PVP) which acts both as reducing agent and shape-directing capping agent. 
The nanoparticles were further functionalized selectively with a thiol-
functionalized PEG (PEG thiol) and alendronic acid (Figure 4a). The thiol group 
provides affinity to the gold surface whereas the alendronic acid binds to the 
iron oxide surface, and both interactions increase the overall colloidal stability of 
the nanoparticles. Moreover, the amino group of the alendronate ligands can be 
used for the covalent attachment of ovalbumin. TEM images show uniform 
nanoparticles with an average equivalent diameter of around 37.4 ± 2.8 nm for 
the core and featuring a distinctive Janus morphology where the smaller iron 
oxide lobe protrudes from the gold nanostar (Figure 4b, c). The mJanusNPs 
showed a low polydispersity of 0.16 and a number-averaged hydrodynamic 
diameter of 45.67 ± 15.43 nm (Figure 4d) due to the branched morphology of 
the particle, the organic coating and hydration water around the nanoparticle. 
Finally, elemental analysis by ICP was used to determine the [Au] and [Fe] 
concentrations showing a molar ratio of [Au] / [Fe] = 3.83. 




Figure 4. a) Representation of the ligand substitution reaction. b), c) TEM 
images at different magnifications and d) Size distribution of mJanusNPs. 
 
3.2.4: Synthesis and characterization of mJanusNPs linked to OVA via 
hydrazone bond (mJanusNPs-HyNic-FB-OVA)  
 
In order to contribute to the development of JanusNPs as new vaccine 
nanoplatforms, OVA was bound to the iron oxide patch of these JanusNPs by 
using the hydrazone strategy, obtaining a new antigen-loaded nanoplatform. 
Conjugation of OVA to the linker 4FB yielded 4FB-OVA, and an aromatic 
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aldehyde was introduced onto the mJanusNPs at the terminal amine group of 
the alendronic acid on the iron oxide patch at a pH of 7 yielding mJanusNPs-
HyNic. By reacting 4FB-OVA with mJanusNPs-HyNic at a pH of 6.2 and in 
presence of aniline as nucleophile catalyst, mJanusNPs-HyNic-FB-OVA were 
obtained, which formation could be monitored by UV-Vis following the formation 
of the chromophore hydrazone (Figure 5c). mJanusNPs-HyNic-FB-OVA 
showed a number-averaged hydrodynamic diameter of 44.16 ± 14.17 nm, ideal 
for lymph node delivery (Figure 5b) and a low polydispersity of 0.25. The 
hydrazone conjugation achieved a loading ratio of ~1 OVA molecule per 2000 
Fe atoms and the resulting nanoparticles showed no signs of aggregation for up 













Figure 5. a) General strategy for the conjugation of OVA to mJanusNPs. b) size 
distribution of mJanusNPs-HyNic-FB-OVA. c) Monitoring of the conjugation 
reaction between mJanusNPs-HyNic and FB-OVA in presence of ~100 mM of 




3.2.5: Co-functionalization of mIONPsp with E. Coli LPS and OVA 
Next, the attempts made for creating nanoparticles carrying both the antigen 
and the adjuvant will be discussed. mIONPsp-E. Coli LPS were prepared using 
DSPE-aPEG, and following the same procedures described in chapter 2. Then, 
the conjugation to OVA was performed using the hydrazone strategy already 
used for the synthesis of mIONPsp-HyNic-FB-OVA. The resulting nanosystem, 
mIONPsp-E. Coli LPS/HyNic-FB-OVA (Figure 6a), was characterized using 
TEM, DLS and by measuring the ζ-potential of the particles (Figure 6b, c, d). 
The mIONPsp-E. Coli LPS/HyNic-FB-OVA showed a uniform size distribution 
with a number-averaged size of 27.08 ± 9.30 nm, which is still within the size 
range of 20-80 nm ideal for lymph node delivery. The ζ-potential of -7.10 mV, 
which is more negative than the one of the control nanomicelles, is consistent 
with the incorporation of the negatively charged E. Coli LPS in the micelles and 
should contribute to promoting accumulation in the lymph nodes, as shown in 
the literature19,20. The OVA payload was quantified using the commercial BCA 
kit to determine protein concentration and a loading of 2 molecules of OVA per 
NP was detected. The particles formed were soluble in water and did not show 











Figure 6. a) Pictorial representation of the final product and b-d) 
characterization of mIONPsp-E- Coli LPS/HyNic-FB-OVA. b) DLS analysis of 
size, c) representative TEM micrograph and d) main characterization data. Data 







3.2.6: Antigen cross-presentation by mIONPsp-E. Coli LPS/HyNic-FB-OVA 
in bone marrow-derived dendritic cells 
 
MHCI-mediated antigen presentation, also known as cross-presentation, is 
fundamental in cancer immunotherapy since it allows to initiate CD8+T cell 
responses, yielding an effective cytotoxic immune response against tumor 
cells21.  
Since naïve antigen-specific CD8+ T cells cannot directly recognize and 
eliminate cancer cells, they need to be activated by professional APCs to 
become active CTLs. Among APCs, DCs can process a variety of antigens and 
are in charge of activating naïve T cells. On their own, DCs need to acquire and 
internalize exogenous antigens, and have the capability of presenting it in both 
MHC class II molecules and MHC class I molecules, the so-called cross-
presentation. By this mechanism, tumor antigens can be presented to CD8+ T 
cells. Upon maturation, DCs migrate to the lymphoid organs where they present 
the antigen to naïve T cells. The activated T cells subsequently proliferate and 
leave the lymph nodes in search of cells to kill in an antigen-dependent 
manner22. Although various types of APC can cross-present model antigens in 
vitro, most studies indicate that DCs are the main cross-presenting APCs in 
vivo, and that cross-presenting DC subsets thus have a major role in antitumor 
immune responses23. 
After TLR stimulation, cross presentation by some subsets of mice DC has 
been observed “ex vivo” and its dependence upon the TRIF signaling pathway 
induced by this molecule has been reported24,21. Loading of the LPS adjuvant 
and OVA on the same particle could improve the delivery timing and thus boost 
the immune responses due to an improved cross-presentation. For instance, 
this was demonstrated using aluminum hydroxide polymer nanoparticles loaded 
with OVA and CpG as an adjuvant, which resulted in effective cross-
presentation of antigen and improved CD8+ T cell responses that led to 
prolonging survival in  B16‐OVA tumor‐bearing mice25. In order to test the 
possibilities attainable by the delivery of the antigen and adjuvant loaded 
together on a single particle, cross-presentation experiments were performed at 
the VIB-UGent Center for Inflammation Research in Ghent. BMDCs were 
administered and incubated overnight (17 h) with mIONPsp-E. Coli LPS, 
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mIONPsp-HyNic-FB-OVA (here reported as LPS-mIONPsp and OVA-mIONPsp 
respectively), the combination of mIONPsp-E. Coli LPS + mIONPsp-HyNic-FB-
OVA, mIONPsp-E. Coli LPS/HyNic-FB-OVA (here reported as OVA-LPS-
mIONPsp) LPS, OVA, and LPS + OVA. All the formulations used showed a 
similar activity at inducing both CD86 production and MHC I expression, and the 
expression of these markers was not affected differently by the use of 
mIONPsp-E. Coli LPS + mIONPsp-HyNic-FB-OVA versus mIONPsp-E. Coli 
LPS/HyNic-FB-OVA. The used concentrations of LPS might have been already 
quite high to detect differences between the different systems (14 µg/ mL when 
[OVA] = 2 µg/mL and 1.8 µg/ mL when [OVA]= 250 ng/mL). Song et al reported 
that a concentration of 1 µg/ mL of LPS can already induce twice as much 
CD80 and CD54 expression than different PLGA NPs loaded with OVA in 
dendritic cells26. On the other hand, it was found that mIONPsp-HyNic-FB-OVA 
can slightly enhance CD86 and MHC class I with respect to OVA alone at the 
highest concentration, a behavior that might be explained by the nanoparticle 










































Figure 6: mIONPsp- E. Coli LPS/HyNic-FB-OVA doesn’t improve cross-
presentation with respect to the mIONPsp-E. Coli LPS + mIONPsp-HyNic-FB-
OVA system. a): expression of MHCI at an [OVA]= 2 µg/mL; b): expression of 
MHCI at an [OVA]= 250 ng/mL; c): expression of CD86 at an [OVA]= 2 µg/mL; 








































































































































































































































In this chapter different types of nanoplatforms for antigen delivery and co-
delivery with TLR4 agonists have been designed, developed and characterized. 
An aniline-catalyzed hydrazone ligation strategy was used for the conjugation of 
the tumor antigen OVA to these nanoplatforms, enabling a highly efficient, 
monitorable and stable covalent conjugation to create multi-functional 
nanovaccines under physiological conditions at very low concentrations. The 
simplest platform developed, mIONPsp-HyNic-FB-OVA, was obtained in high 
yield at micromolar concentrations yielding a stable product which showed 
uniform size distribution. This construct was rapidly taken up by antigen 
presenting cells. This system was used in “in vivo” experiments as a 
nanovaccine together with the mIONPsp-Xcc LOS developed in chapter 2 and 
the obtained results are discussed in the following chapter. A platform where 
OVA and the adjuvant LPS were bound to the same nanoparticle was also 
developed and investigated for improving antigen cross-presentation in dendritic 
cells. Finally, an asymmetrical or “Janus” nanoplatform was developed, 
mJanusNPs-HyNic-FB-OVA, which combines the properties of iron oxide 
nanoparticles and gold nanoparticles and allows a different surface chemistry 
for each material “patch” to be used, allowing different (bio)functionalization. 
OVA was anchored to the alendronate ligands bound to the IONPs side of the 
Janus particle using the covalent hydrazone chemistry strategy. This 
sophisticated nanoplatform was characterized by TEM, DLS and measuring the 
ζ-potential and OVA payload and represents a highly promising platform for 
antigen delivery which can be further functionalized and used in different 








3.4: Materials and Methods 
Materials: Unless otherwise specified all commercially available reagents were 
used without further purification. DSPE-aPEG and Rho-PE were purchased 
from Avanti polar lipids. Hydrogen tetrachloroaurate(III) trihydrate (99.99%) was 
purchased from Alfa Aesar, oleylamine (80-90%) was purchased from Acros 
organics, 1- octadecene (90%), oleic acid (90%), iron(0) pentacarbonyl 
(99.99%), 1,2-hexadecanediol (90%), methoxypolyethylene glycol acetic acid 
(80%, Mn = 5000 g/mol), 4- mercaptobenzoic acid (90%) and PVP (MW = 10 
Kg/mol) were all purchased from Sigma-Aldrich, thiol- terminated PEG (Mn = 
750 g/mol), was purchased from Polymer Source. Endo-Ova (Endotoxin-free 
Ovalbumin) was purchased from Hyglos GmbH; Succinimidyl 6-
hydrazinonicotinamide acetone hydrazone was purchased from Solulink; 
Succinimidyl 4-Formylbenzoate was purchased from Santa Cruz biotechnology; 
2-hydrazinopyridine-2HCl was purchased from Fluorochem. 
Lipopolysaccharides from Escherichia coli O55:B5 and poly(ethylene glycol) 
methyl ether thiol (average Mn 2000) were purchased from Sigma-Aldrich. 0.45 
µm syringe filter were purchased from Pall life sciences; PD MiniTrap G-10 
desalting column were from GE Healthcare; Amicon Ultra-0.5 mL Centrifugal 
filters (100 KDa Molecular weight cut-off) and Amicon Ultra-4mL (10 KDa 
Molecular weight cut-off) were purchased from Merck; Pierce LAL chromogenic 
endotoxin quantitation kit, Hoechst 33342 (Hoechst blue) and Lysotracker green 
DND-26 were purchased from Thermo Fisher. Dulbecco’s Modified Eagle 
Medium (DMEM), Fetal Bovine Serum (FBS), Penicillin/Streptomycin (P/S) and 
L- glutamine (L-Glu) were all purchased from Gibco; Cell culture plates were 
purchased from Nunc; Red blood cells (RBC) lysis buffer was purchased from 
BD Biosciences; 100 mm bacteriological Petri dishes were purchased from 
Falcon; Granulocyte-macrophage colony-stimulating factor (GM-CSF) was 
purchased from Peprotech; FC block, Amcyan-labelled L/D staining, APC-
labelled anti-CD11c, PE-Cy7-labelled anti-CD86 and PE-labelled MHCI 
antibodies were all purchased from BioLegend; Ibidi μ-Slides VI0.4 were 
purchased from Ibidi.  
Synthesis of iron oxide nanoparticles (IONPsp): Hydrophobic spherical IONP 
(IONPsp) were prepared as described in chapter 2.  
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Preparation of Janus NPs: The synthesis of the asymmetric dumbbell seeds 
was performed as previously reported by a one-pot two-step method27.  
Briefly, for the 20 nm iron oxide part, a solution in 1-octadecane (47 mL) was 
prepared containing oleic acid (6 mmol, 1.90mL), oleylamine (6 mmol, 1.97mL) 
and 1,2-hexadecanediol (10 mmol, 2.58g) and stirred for 15 min at 160 ºC 
under N2. Fe(CO)5 (2 mL) was then injected and after 3 min a solution 
containing HAuCl4·3H2O (0.1 mmol) dissolved in a mixture of oleylamine (0.5 
mL) and 1-octadecane (3 mL) was injected and heated up to 310 °C at 
approximately 3 °C/min. The solution was left to react for 45 min under 
magnetic stirring. After cooling down, the dispersion was exposed to air for 30 
min to cause Fe oxidation. To purify the nanoparticles, 50 mL of isopropanol 
were added and the solution was centrifuged at 4500 xg for 30 min. The 
nanoparticles were cleaned two more times after redispersion with hexane and 
aggregation with isopropanol. Finally, oleylamine (100 μL) was added to store 
the nanoparticles for long periods of time in a hexane-chloroform solution.  
The nanodumbbells were cleaned three times in ethanol and redispersed in 
chloroform to remove as much as oleylamine as possible. Then, they were 
redispersed in chloroform at a concentration of approximately 2 mg/mL. A small 
quantity of carboxyl terminated PEG-PL (PEG-COOH) was added to the 
solution (to have approximately 2 mg/mL of polymer) and left for 1 h. This step 
was performed to obtain a good dispersion when the seeds were added to the 
DMF gold solution. 
A solution of HAuCl4·3H2O (2.184 mL, 50 mM) was added to a solution 
containing PVP (40 g) dissolved in DMF (400 mL). The solution was left stirring 
to allow gold salt prereduction from Au3+ to Au+ as described elsewhere28 (this 
time was highly dependent on the PVP batch and needed to be adjusted by UV-
vis, in this case it was 5 min). The dumbbell nanoparticle solution (at different 
volumes) was then quickly added and the reaction was left reacting for 1 h, 
showing a fast color change into blue. The nanoparticles were purified in 4 
centrifugation cycles, redispersed 2 times in ethanol and 2 times in water and at 
a relative centrifugation force of 2500-4000 xg, depending on the nanoparticle 
size. The nanoparticles were finally redispersed in 40 mL of ultrapure water.  
Ligand exchange: Janus nanoparticles were incubated overnight with PEG-thiol 
(50 ligands/nm2 assuming a spherical particle). Then the particles were 
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centrifuged twice at 600 xg for 10 min to remove the unbound PEG-thiol. 
Alendronic acid (1000 ligands/nm2) was added to the nanoparticles and they 
were incubated overnight with 0.83 mM NaOH. Finally, the nanoparticles were 
centrifuged twice at 600 xg for 10 min and the pellet was redissolved in water. 
Calculation of the number of ligands/nm2: The amount of Au was determined by 
UV-vis using a calibration curve. The [Au] / [Fe] ratio was determined previously 
by ICP and used to calculate the concentration of Fe. The surfaces of the IONP 
and Au patch were determined using the known densities and the sizes of the 
magnetite and Au patches.  
 
IONPsp- filled nanomicelles preparation: 1 mg of IONPsp and 2 mg of PEG 
phospholipid (DPPE-aPEG) were dissolved in 100 μL and 200 μL of chloroform 
respectively, combined in a 4 mL round bottomed glass vial with 100 μL of 
chloroform and let to evaporate overnight at RT. LPS loaded micelles (for 
mIONPsp-E. Coli LPS/HyNic-FB-OVA) were prepared as above described, with 
the exception that 0.2 mg of or LPS were added to the latter 100 μL of 
chloroform and dissolved thoroughly using a vortex mixer (5 minutes) and an 
ultrasonic cleaner (30 minutes). Fluorescent micelles were prepared adding a 
5% of 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine-N-lissamine 
Rhodamine B sulfonyl-ammonium salt to the phospholipids mixture. The flask 
was placed in a water bath at 80 °C for 30 s, after which micelles were re-
dissolved in 1 mL of MilliQ water. This solution was centrifuged at 5000 xg for 5’ 
and passed through a 0.45 µm syringe filter to remove non-soluble particles. 
Then, the micelles were centrifuged at 108600 xg for 50 minutes; the 
supernatant was discarded and washed with MilliQ water to remove empty PEG 
micelles (3 cycles). Finally, the pellet was dissolved in 400 μL of MilliQ water. 
Micelles were stored at 4ºC. In order to quantify the concentration of iron, ICP 
analysis was carried out. Briefly, 10 µL of micelles were digested in 
concentrated HNO3 over a minimum of three days. Prior to the measurement, 
the samples were diluted up to 8 mL in MilliQ water (final acid concentration: 1-
2 %). ICP-AES analyses were carried out on a Perkin Elmer Optima 5300 DV 
(Perkin Elmer, Santa Clara, CA, USA) at CIC BiomaGUNE by the Mass 
spectrometry platform. A range of calibration standards were prepared using 
single element 1000 mg/L stock solutions (Fisher Scientific UKLTD) and a 
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Merck multielement standard (ICP Multi element standard solution, VICertiPUR) 
was employed as a reference standard. 
Transmission electron microscopy (TEM) studies were performed using a JEOL 
JEM-2011 electron microscope operating at 120 kV. The samples were 
prepared by deposing a drop of a solution of IONPs (1 mg/mL in THF) onto 
Pelco 150 mesh grid (Ted Pella) and allowing it to dry. For the preparation of 
hydrophilic samples, TEM grids were polarized using a Quorum technologies 
K100X glow discharge system. IONPs size was determined from TEM images, 
measuring a minimum of 200 nanocrystals with the software ImageJ.  
Hydrodynamic diameter and ζ-potential of the micelles were measured using a 
Z-Sizer (Malvern Nano-Zs, UK). To determine the stability, mIONPsp-HyNic-FB-
OVA was dissolved at a concentration of approx. 5 mM in 10 mM PBS and the 
hydrodynamic diameter analyzed by Z-Sizer immediately after purification and 
over a 4 weeks period. To measure the ζ-potential, the samples were dissolved 
at a concentration of approx. 0, 5 mM in 10 mM NaCl and analyzed by Z-sizer 
immediately after purification and over a 4 weeks period. 
Conjugation of IONPsp to HyNic (Succinimidyl 6-hydrazinonicotinamide acetone 
hydrazone): In a typical synthesis, IONPsp micelles (~3- 0.5 µM) were added to 
a 50 mM NaPi buffer (pH 7.4) and coupled to a 100 mM HyNic solution in 
CH3CN (420 µL total volume). The reaction mixture was stirred overnight (~14 
h) at room temperature and the product was purified using both a desalting 
column and a 0.5 mL centrifugal filter (100 KDa MW cut-off) (10000 xg, 5 min.) 
and kept at 4ºC until further use. 
Conjugation of Ovalbumin to FB (Succinimidyl 4-Formylbenzoate): a 450 µM 
Endotoxin-free OVA solution in 50 mM NaPi buffer (pH 7.4) was added to a 100 
mM FB solution in DMSO (550 µL total volume) and stirred overnight (~14 h) at 
room temperature. Purification was carried on using a desalting column and a 4 
mL centrifugal filter (10 KDa MW cut-off) (2000 xg, 15 min.). The product was 
stored at 4ºC. 
Covalent attachment of Ovalbumin to IONPsp micelles: HyNic modified IONPsp 
(~3- 0.5 µM) were first mixed to a 50 mM NaPi buffer (pH 6.2) and conjugated 
to FB modified OVA (30- 20 µM). Finally, 100 mM Aniline was added (250 µL 
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total volume). The reaction mixture was stirred overnight (~14 h) at room 
temperature and the product was purified by a desalting column and a 0.5 mL 
centrifugal filter (100 KDa MW cutoff) (10000 xg, 5 min.). The obtained product 
was centrifuged at 17400 g for 20’ and the pellet washed with MilliQ water to 
remove any unbound OVA. The number of OVA molecules bound to the 
nanoparticle was determined using a commercial BCA kit (ThermoFisher). 
Conjugation of JanusNPs to HyNic: (Succinimidyl 6-hydrazinonicotinamide 
acetone hydrazone): In a typical synthesis, mJanusNPs (~1 mM Fe) were 
added to a 50 mM NaPi buffer (pH 7.4) and coupled to a 100 mM HyNic 
solution in CH3CN (300 µL total volume). The reaction mixture was stirred 
overnight (~14 h) at room temperature and the product purified using a 0.5 mL 
centrifugal filter (100 KDa MW cut-off) (600 xg, 10 min.)  and kept at 4ºC until 
further use. 
Covalent attachment of Ovalbumin to mJanusNPs-HyNic: HyNic modified Janus 
NPs (~0.5 mM Fe) were first mixed to a 50 mM NaPi buffer (pH 6.2) and 
conjugated to FB modified OVA (30- 20 µM). Finally, 100 mM Aniline was 
added (180 µL total volume). The reaction mixture was stirred overnight (~14 h) 
at room temperature and the product was purified by a desalting column and a 
0.5 mL centrifugal filter (100 KDa MW cutoff) (600 xg, 10 min.). The obtained 
mJanusNPs-HyNic-FB-OVA were centrifuged at 600 xg for 15’ and the pellet 
washed with MilliQ water to remove any unbound OVA. The number of OVA 
molecules bound to the nanoparticle was determined using a commercial BCA 
kit (ThermoFisher). In order to quantify the concentration of iron, ICP analysis 
was carried out, as already reported. 
 
Monitoring of the mJanusNPs-HyNic to 4FB-OVA coupling reaction: 0.5 µM 
mJanusNPs-HyNic were added to 20 μM 4FB-OVA in 50 mM NaPi buffer (pH 
6.2) in a quartz cuvette (500 μL total volume). Aniline (3 µL) was added drop 
wise to the reaction mixture and the reaction was monitored at a wavelength of 
354 nm using a UV-Vis spectrometer.  
 
Estimation of HyNic groups linked to mIONPsp-HyNic micelles: 1.5 μM 
mIONPs-HyNic micelles were mixed with 0.5 mM 4-nitrobenzaldehyde and 100 
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mM Aniline in 50 mM pH 6.2 NaPi buffer (500 μL total volume) in a quartz 
cuvette and thoroughly stirred. The formed hydrazone bond was monitored by 
UV-Vis at 345 nm and the molar substitution ratio was obtained using the 
absorption coefficient (ɛ= 18000) found in the literature.  
Estimation of 4-FB groups linked to Ovalbumin: 45 µM functionalized 4FB-OVA 
was mixed to a 0.5 mM solution of 2-hydrazinopyridine-2HCl and 100 mM 
Aniline in 50 mM pH 7.4 NaPi buffer (500 μL total volume), put in a quartz 
cuvette, stirred and finally the absorbance was measured. The reaction kinetics 
of the hydrazone bond formation were monitored for 120 min at 345 nm using a 
UV-Vis spectrophotometer and the 4FB-OVA molar substitution ratio was 
obtained using the extinction coefficient at 24600 for the hydrazone 
chromophore.  
Monitoring of the mIONPsp-HyNic to 4FB-OVA coupling reaction: 3 μM 
mIONPsp-HyNic were added to 20 μM 4FB-OVA in 50 mM NaPi buffer (pH 6.2) 
in a quartz cuvette (500 μL total volume). 3 µL of aniline were added drop wise 
to the reaction mixture and the reaction was monitored at a wavelength of 354 
nm using a UV-Vis spectrometer.  
Fluorescence microscopy: J774A.1 cells were seeded in an Ibidi μ-Slide VI0.4 at 
a density of 30000 cells/ well in DMEM supplemented with 10% Fetal Bovine 
Serum and 1% Penicillin/Streptomycin and let to adhere overnight in an 
incubator maintained at 37 °C and 5% CO2. The day after, the medium was 
removed and cells were administered with 1 μg/ mL Hoechst blue to stain the 
nuclei and incubated for 30 minutes. Cells were washed with PBS three times in 
order to get reed of the unbound dye and then stained with ~200 nM 
mIONPsp(Rho)-HyNic-FB-OVA and incubated for three hours. Cells were 
washed again and stained with 1 mM Lysotracker green, incubated for 30 
minutes, washed with PBS and finally images were taken using a ZEISS Axio 
Observer inverted microscope. 
 
Preparation of mIONPsp- E. Coli LPS/HyNic-FB-OVA: 1 mg of IONPsp, 2 mg of 
PEG phospholipid (PEG-NH2) and 0.2 mg of LPS were dissolved in 100, 200 
and 100 μL of chloroform respectively, added to a 4 mL round bottomed glass 
vial and let to evaporate overnight at RT. Upon adding LPS to the latter 100 μL 
 
176 
of chloroform, it was dissolved thoroughly using a vortex mixer (5 minutes) and 
an ultrasonic cleaner (30 minutes). The flask was placed in a water bath at 80 
°C for 30 s and micelles were re-dissolved in 1 mL of MilliQ water. This solution 
was centrifuged at 3000 xg for 5’ and passed through a 0.45 µm syringe filter to 
remove non-soluble particles. Micelles were then centrifuged at 108600 xg for 
50 minutes; the supernatant was discarded or kept for LPS quantification and 
washed with MilliQ water to remove empty PEG micelles (3 cycles). Finally, the 
pellet was dissolved in 200 μL of MilliQ water. Micelles were stored at 4ºC.  
Quantification of LPS loading on mIONPsp-E. Coli LPS/HyNic-FB-OVA 
micelles: The amount of LOS incorporated on micelles was carried out before 
conjugation with OVA and measured as previously described for LOS- and 
LPS- loaded micelles. Briefly, a calibration curve was prepared plotting the 
immune stimulating activity of the pure ligand on cell cultures versus its 
concentration and used to determine the amount of ligand bound to the 
nanoparticle indirectly, measuring the amount of ligand that remained in the 
supernatants from the micelles’ workup. The efficiency of this method was 
double checked using a commercial kit (Pierce LAL chromogenic endotoxin 
quantitation kit) and following the instructions given by the kit’s manufacturer. 
The assay was performed in aseptic conditions. Briefly, 50 μL of standards or 
samples were put on a 37ºC 96 well microplate (in duplicates), incubated for 5 
min. at 37ºC, after which the LAL reagent was added to each well. Following a 
10 min. incubation at 37ºC, 100 μL of substrate solution were added, stirred and 
incubated for 6 min. at 37ºC. Then, 25 μL of stop solution were added and the 
absorbance at 405 nm was immediately measured using a Varioskan LUX 
multimode plate reader (Thermo Fisher). The concentration of LPS in the 
unknown samples was determined using a calibration curve. 
Conjugation of mIONPsp-E. Coli LPS to HyNic (Succinimidyl 6-
hydrazinonicotinamide acetone hydrazone): The procedure previously 
described was followed, with slight variations: mIONPsp-E. Coli LPS micelles 
(~0.5- 0.2 µM) were added to a 50 mM NaPi buffer (pH 7.4) and coupled to a 
100 mM HyNic solution in CH3CN (300 µL total volume). The reaction mixture 
was stirred overnight (~14 h) at room temperature and the product was purified 
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using both a desalting column and a 0.5 mL centrifugal filter (100 KDa MW cut-
off) and kept at 4ºC until further use. 
Covalent attachment of Ovalbumin-FB to mIONPsp- E. Coli LPS/HyNic 
micelles: HyNic modified mIONPsp- E. Coli LPS (~ 0.5- 0.2 µM) were first mixed 
to a 50 mM NaPi buffer (pH 6.2) and conjugated to FB modified OVA (30- 20 
µM) (prepared as previously described). Finally, 100 mM Aniline was added 
(180 µL total volume). The reaction mixture was stirred overnight (~14 h) at 
room temperature and the product was purified by a desalting column and a 0.5 
mL centrifugal filter (100 KDa MW cutoff). The obtained product was centrifuged 
at 17400 xg for 20’ and the pellet washed with MilliQ water to remove any 
unbound OVA. The number of OVA molecules bound to the nanoparticle was 
determined using a commercial BCA kit (ThermoFisher). In order to quantify the 
concentration of iron, ICP analysis was carried out, as already reported. 
BMDC primary culture establishment: C57BL/6J mice (6–12 weeks old) were 
sacrificed by cervical dislocation and intact femurs and tibiae of hind limbs were 
removed aseptically as described elsewhere.29 After washing the bones in cold 
PBS (10 mM), the bone marrow was obtained by tearing apart the bones, 
putting them in a small Eppendorf tube and centrifuging at 2000 xg until it came 
out. The obtained bone marrow cells were flushed with same buffer using a 
syringe. After the erythrocytes were lysed with a commercial RBC lysis buffer 
(BD Biosciences), the cells were washed and resuspended in RPMI-1640 
medium supplemented with 10 % FBS, 1 % P/S and 1 % L-glutamine (200 mM, 
Gibco). On day zero cells were plated at a concentration of 2·106 cells per 100 
mm bacteriological Petri dish (Falcon) in 10 mL of medium supplemented with 
20 ng/mL of murine GM-CSF (Peprotech) and maintained at 37 °C and 5% 
CO2. On day 3, 10 mL of complete RPMI-1640 medium containing GM-CSF (20 
ng/mL) was added to each Petri dish. On day 6, half of the supernatant was 
collected, centrifuged and cell pellet resuspended in 10 mL of fresh complete 
RPMI-1640 with GM-CSF (10 ng/mL) and added again to each Petri dish. 
Finally, at day 8 of the differentiation process, BMDCs were plated in 96-well 
plates (2·105 cells/well) and incubated overnight (17h) (in triplicates) with the 
different stimuli. All experiments were carried out two times. 
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Analysis of DCs’ maturation markers by flow cytometry: After overnight 
incubation with the different stimuli, 96-well plates containing the BMDCs were 
centrifuged (400 xg, 5 min, 4°C) and supernatants removed. Cells were washed 
with cold PBS, centrifuged again and the supernatants were removed. Cells 
were stained with FC block, Amcyan-labelled L/D staining, APC-labelled anti-
CD11c, PE-Cy7-labelled anti-CD86 and PE-labelled MHCI antibodies (all from 
BioLegend). Cells were incubated with the stains for 20 min after which they 
were centrifuged and washed using cold PBS. Finally, cells were fixed using BD 
cytofix-cytoperm solution, washed using BD-wash/perm and finally analyzed. 
The expression of the different markers was analyzed using the FACS Fortessa 
flow cytometer. BMDCs were electronically gated based on the forward and 
side scatter parameters and the not-single events left out based on forward 
area and height scatter parameters. DCs were gated based on positive staining 
for CD11c population marker and the expression of the chosen maturation 
markers was analyzed within this population. Results were expressed as mean 
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Anticancer activity of OVA- and LOS- loaded 
mIONPsp in a mouse melanoma model 
 
In this chapter, the efficacy of the formulation composed by mIONPsp-HyNic-
FB-OVA and mIONPsp-Xcc LOS was assessed in a prophylactic setting against 
B16-F10(OVA) melanoma. Moreover, two formulation composed respectively 
by mIONPsp-HyNic-FB-OVA co-injected with mIONPsp-E. Coli LPS and 
mIONPsp-HyNic-FB-OVA co-injected with mIONPsp-Poly(I:C)-imiquimod were 













Immunotherapy has emerged in the last years as one of the main pillars of 
cancer treatment alongside radiotherapy, surgery, and chemotherapy1. An 
exciting discovery in this field is represented by checkpoint blockade therapy, 
which has emerged as a promising option for treatment of cancer2,3,4. The 
release of negative regulators of immune activation in tumor cells allows 
evasion of immune surveillance, and checkpoint blockade can effectively inhibit 
such mechanisms unleashing the full potential of tumor-reactive T cells5. 
Cancer vaccines constitute an ideal immunotherapeutic partner for checkpoint 
blockade therapy since they can provide a continuous supply of antigen-specific 
T cells and long-lasting immune responses6. To the best of our knowledge, the 
adjuvant properties of Xcc LOS for vaccine development and immunotherapy 
have not been investigated previously, while other TLR4 ligands such as LPS 
and in particular the FDA-approved MPLA have been extensively investigated 
as vaccine adjuvants7,8. TLR agonists, and in particular TRL4 agonists, have 
the potential to develop Th1 immune responses9,10,11, but can induce systemic 
cytokine production leading to acute toxicity12, and can induce immune 
inhibitory factors13. The combination of checkpoint blockade with TLR4 agonists 
could compensate for the release of these immune suppressing factors 
releasing the full therapeutic potential of LPS and LOS. Moreover, TLR ligands 
have shown ineffective targeting of tumor and lymph nodes14, and nanoparticle 
delivery could be used to further improve their therapeutic effectiveness15,16,17,18.  
The use of nanoparticles for vaccine delivery in combinatorial immunotherapy 
has been already reported in the literature. One example is from Yang et al., 
who reported imiquimod-loaded PLGA nanoparticles coated with mannose-
modified B16-OVA cancer cell membranes (NP-R@M-M) acting as tumor-
specific antigens. These nanoparticles showed enhanced uptake in APCs and 
could effectively target the lymph nodes. When administered in mice bearing 
B16-OVA tumors, a combination of NP-R@M-M and immune checkpoint 
inhibition with anti-PD-1 antibodies could improve survival of mice to 45 days 
with 3/6 mice completely rejecting the tumor from 25-27 days and no mice 




4.2: Results and discussion 
4.2.1: Adjuvanticity of mIONPsp-Xcc LOS administered with mIONPsp-
HyNic-FB-OVA in a prophylactic setting 
After having evaluated the potential of Xcc LOS and mIONPsp-Xcc LOS in vitro, 
the adjuvanticity of the ligand was assessed in vivo and antigen-specific 
responses were evaluated. The B16-F10(OVA) subline was chosen for murine 
tumor immunotherapy studies as a poorly immunogenic, highly aggressive and 
widely used melanoma model. To compare the adjuvant properties, C57BL/6 
mice were immunized subcutaneously with OVA (5 µg) alone or with OVA (5 
µg) + E. coli LPS (1 µg), OVA (5 µg) + MPLA (1 µg), and OVA (5 µg) + Xcc LOS 
(1 µg) at days 0 and 14. At day 21, mice were challenged with 3 × 105 B16-
F10(OVA) cells injected subcutaneously in the right flank, and tumor growth 
was monitored until they reached the limits of the established endpoint (Figure 
2a). Despite a weaker capacity of Xcc LOS to induce IL-6 production in the 
J774A.1 macrophages than E. Coli LPS (shown in chapter 2 of this thesis), Xcc 
LOS was found to be as effective as E. coli LPS and the clinically approved 
MPLA (Figure 2b, c). To evaluate the utility of nanoparticle delivery, another 
group of mice was immunized with mIONPsp-HyNic-FB-OVA (5 µg OVA) 
formulated with pathogen-mimicking mIONPsp-Xcc LOS (1 µg Xcc LOS) as an 
adjuvant. All animals vaccinated with the TLR4 agonists showed reduced tumor 
growth and provided survival benefits (median survivals of 34-38 days) 
compared to the OVA-treated (median survival of 28 days) even with the 
ultralow adjuvant doses used (1 µg). Compared to the nanoparticle-free 
treatments, the immunization with mIONPsp-HyNic-FB-OVA formulated with 
pathogen-mimicking mIONPsp-Xcc LOS effectively slowed tumor growth in 

































Figure 2: Protective immunity against B10-F10(OVA) melanoma cells induced 
by the use of the different TLR4 agonists as adjuvants when co-administered 
with tumor antigen OVA. a) Vaccination scheme. C57BL/6J mice were 
subcutaneously immunized with the indicated formulations (5 µg of OVA, 1 µg 
of TLR4 agonist per mouse, 25-70 µg of IONP on day 0 and 14 and 
subcutaneously challenged with 3 × 105 B16-F10(OVA) cells/mouse on day 21. 
b-d) Average and individual tumor growth curves and Kaplan–Meier survival 
curves. The data show mean ± SEM from a representative experiment (n= 5–
10) from 2–3 independent experiments. 
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To understand the enhancement in the anti-melanoma response to the 
nanovaccines, the induction of tumor antigen-specific CD8+ T cells effector and 
memory response in mice’s blood were analyzed. Although generating antibody 
production has been commonly achieved with conventional vaccine strategies 
such as Cervarix, generating protective memory CD8+ T cells has proven more 
difficult to achieve20. It was therefore analyzed if the immunization with OVA + 
Xcc LOS and mIONPsp-HyNic-FB-OVA formulated with pathogen-mimicking 
mIONPsp-Xcc LOS was able to drive antigen-specific CD8+ T cell responses. 
For this, the frequency of the OVA257-264 peptide (SIINFEKL)-specific CD8+ T 
cells was monitored by H-2Kb/SIINFEKL dextramer staining followed by FACS 
analysis. The highest frequency of SIINFEKL-specific CD8+ T cells was found in 
mice immunized with OVA antigen delivered by mIONPsp-HyNic-FB-OVA and 
formulated with pathogen-mimicking mIONPsp-Xcc LOS (Figure 3a). 
In the event of infection or vaccination, naive CD8+ T cells are primed in 
secondary lymph nodes by DCs and consequently proliferate and differentiate 
into ‘effector memory’ cells (TEM) and ‘central memory’ (TCM) cells, which exhibit 
distinct functional abilities playing a different role in adaptive immunity.21. 
Whereas TEM are localized in peripheral non-lymphoid tissues (e.g., lung, liver, 
intestine), spleen, and blood and can immediately recognize and kill the target 
virally infected/cancer cells, TCM cells can rapidly traffic into lymph nodes 
directly from the blood and are thought to provide a sustained and robust CTL 








Figure 3. Immunization with the mIONPsp-based vaccines triggers a higher-
level tumor antigen-specific cytotoxic T lymphocyte (CTL) effector responses. a) 





































































































Analysis of frequency of circulating OVA257-264 (SIINFEKL)-specific CD8+ T cells 
isolated from blood. b, c) Frequency of SIINFEKL-specific CD8+ TEM and TCM 
cells. TCM cells are defined as CD3+CD8+CD62L+CD44+ and TEM as 
CD3+CD8+CD62L-CD44+. Data presented as mean ± SEM. n = 5 mice per 
group. ***P<0.001, **P<0.01, *P<0.05 by two-way ANOVA followed by 
Bonferroni’s test. 
The frequency of circulating SIINFEKL-specific CD8+ TEM-cells 
(CD44+CD62Llow) and TCM-cells (CD44+CD62Lhigh) was analyzed over time (t = 
0, 7, 14, 21, 28 and 35 days). mIONPsp-vaccinated mice had a much greater 
frequency of both antigen-specific TEM and TCM cells. The TEM population 
peaked at day 7 after the first vaccination and the levels increased drastically on 
day 35, i.e. after boost and tumor challenge (Figure 3b). The highest frequency 
of the SIINFEKL-specific CD8+ TCM-cells was observed on day 35 (Figure 3b). 
The results demonstrate that our nanovaccine generates more effectively 
protective memory CD8+ T cells than the other conventional therapies used. 
 
4.2.2: Combinatorial immunotherapy of PD-L1 checkpoint blockade and 
mIONPsp-Xcc LOS administered with mIONPsp-HyNic-FB-OVA as 
anticancer vaccine  
The B16-F10(OVA) melanoma model used is an ideal candidate for PD-L1 
checkpoint inhibition since it is characterized by high PD-L1 expression22. The 
use of anti-PD-L1 blocking antibodies requires multiple doses and PD-L1 is 
expressed on many immune system cells such as B and T lymphocytes and 
blocking it can bring to toxicity and uncontrolled auto reactivity23,24. Checkpoint 
blockade was thus performed at the level of the cancer cell using B16-
F10(OVA) melanoma cells with silenced PD-L1. This achieves the same effects 
than knocking out PD-L1 in cancer cells as demonstrated previously. The PD-
L1–deficient B16-F10(OVA) cells (B16-F10(OVA) ∆PD-L1) were generated at 
Navarrabiomed by the research group of David Escors by using CRISPR/Cas9 
genome editing and lentiviral particles. This genetically modified cell line, B16-
F10(OVA) ∆PD-L1, was used in the prophylactic immunization assay (Figure 
4a). C57BL/6 mice were subcutaneously vaccinated with OVA + Xcc LOS and 
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mIONPsp-HyNic-FB-OVA + mIONPsp-Xcc LOS (day 0 and 14) and inoculated 
with 2 × 106 B16-F10(OVA) ∆PD-L1 cells (day 21). All the mice treated with 
PBS developed melanoma tumors within 10 days. The tumor growth kinetics 
following inoculation of 2 × 106 B16-F10(OVA) ∆PD-L1 and inoculation of 3 × 
105 B16-F10(OVA) cells was very similar for mice treated with PBS. However, 
in the case of mice immunized with OVA + Xcc LOS, mice remained tumor-free 
for 20 days and 40% did not develop tumor past 100 days after the challenge 
with B16-F10(OVA) ∆PD-L1 cells, compared to all the mice developing tumor by 
day 20 after the challenge with the B16-F10(OVA) cells. In the case of mice 
immunized with mIONPsp-HyNic-OVA + mIONPsp-Xcc LOS 100% of the 
animals were free of tumor 110 days after the challenge with B16-F10(OVA) 
∆PD-L1 cells (Figure 4b, c, e). Furthermore, analysis of SIINFEKL-specific 
CD8+ T cells corroborated the enhanced protection against the melanoma cells 
(Figure 4d). Hence mIONPsp delivery combined to the permanent PD-L1 
checkpoint blockade remarkably improved the efficacy of the vaccination. The 
immune responses 100 days after the boosting immunization were thus 
investigated to assess the efficacy and longevity of memory recall responses in 
the mIONPsp-vaccinated mice. The frequency of circulating SIINFEKL-specific 
CD8+ T cells was analyzed in the blood previous to the recall immunization and 
comparing immunized mice with mice of the same age that had not been 
immunized/challenged with the melanoma cells and no SIINFEKL-specific cells 
were found neither within the CD8+ nor in the TCM cell population. Mice received 
a recall immunization 103 days after the boost and the capacity to clear a tumor 
re-challenge (2 × 106 B16-F10(OVA) ∆PD-L1 cells subcutaneously implanted on 






















Figure 4. Protective immunity against B16-F10(OVA) melanoma cells with 
knocked-down expression of PD-L1 (B16-F10(OVA) ∆PD-L1). a) Vaccination 
scheme. C57BL/6J mice (n = 5) were subcutaneously challenged with 2 × 106 
B16-F10(OVA) ∆PD-L1 cells seven days after the last vaccination with 5 μg of 
OVA, 1 μg Xcc LOS per mouse, 25 μg of IONP). b-e) Average (b) and individual 
(e) tumor growth curves and (c) Kaplan–Meier survival curves. d) Circulating 
SIINFEKL-specific CD8+ T cells 35 days after the first immunization (two weeks 
after tumor inoculation). **P<0.01, *P<0.05, ns = non significant by one-way 
ANOVA followed by Tukey’s test. CR = fraction of complete tumour rejection. 
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Whereas the control mice developed melanoma tumors within 10-15 days, 
100% of the mIONPsp-vaccinated mice remained tumor-free until the end of the 
experiment on day 139 (Figure 5b). Further analysis of the TEM subset revealed 
that mice immunized with mIONPsp-HyNic-FB-OVA + mIONPsp-Xcc LOS had 
high levels of SIINFEKL-specific CD8+ TEM cells even 100 days after the first 
immunization (Figure 5c). At this point, the frequency of circulating antigen-
specific T cells was analyzed to assess the magnitude and quality of the 
memory response generated after the recall. The frequencies of the SIINFEKL-
specific CD8+ T cells in peripheral blood were high 5.9 ± 2.0 % (n = 5) 
(compared to 1.2 ± 0.5% at day 35 after the 1st boost and 1st tumor challenge). 
The immunization recall (day 117) rapidly increased the antigen-specific TEM 
and TCM cell percentages up to the frequencies observed on day 35 after first 
immunization and boost, indicating that mIONPsp-based vaccines induced T 
cell memory and effective recall responses.  
Next, to evaluate the quality of CD8+ T cell responses, cellular extracts from 
spleens were cultured ex vivo by 5h incubation with the antigenic peptide 
SIINFEKL, and the IFN-γ and TNF-α intracellular production and the 
degranulation marker CD107a were analyzed by FACS. The data demonstrated 
that mice immunized with the nanoparticles generate T lymphocytes with 
enhanced cytolytic activity (Figure 5e, f, g).  Also, the cells collected from the 
spleen showed significantly enhanced ability to release IFN-γ following ex vivo 
re-stimulation with SIINFEKL (over 48 h). Taken together, the results show how 
a potent and long-lasting antitumor immunity can be achieved when combining 


































Figure 5. Tumor protection and rapid activation of the immune system upon 
recall of mIONPsp-based vaccines (n = 5). a) 103 days after the first tumor 
inoculation, T cell memory was recalled with the nanovaccines (same 
antigen/adjuvant concentrations). Five days after, a tumor re-challenge with 2 
×106 B16-F10(OVA) ∆PD-L1 cells was carried out. At day 17 after the second 
tumor challenge, mice were sacrificed and blood and spleens collected for 
further immune analysis. b) Average tumor growth curves. c, d) SIINFEKL-
specific CD8+, TEM and TCM cell percentages before (c) and (d) after recall 
injection. e, f) Intracellular IFN-γ and TNF-α production and CD107a expression 
after 5 h of incubation with 10 µg/mL of SIINFEKL peptide. g) Extracellular IFN-
γ production after 48 h of incubation with the peptide. ***P<0.001, **P<0.01, 
*P<0.05, ns = non significant by (c, d) two-way ANOVA followed by Bonferroni’s 
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4.2.3: Adjuvanticity of mIONPsp-E. Coli LPS administered with mIONPsp-
HyNic-FB-OVA in a therapeutic setting 
 
The adjuvanticity of LPS has been already explored intensively in vaccine 
development and immunotherapy as TLR4-dependent vaccine adjuvant, and 
this ligand showed toxicity and systemic cytokine production leading to 
undesired side effects and eventually death by sepsis12. Hence, the 
effectiveness of LPS delivery by mIONPsp was assessed in vivo using an 
ultralow adjuvant dose (5 µg). To compare the anticancer properties of the 
different nanosystems developed, C57BL/6 mice were injected subcutaneously 
in the right flank with 3 × 105 B16-F10(OVA) cells at day 0. Then, mice were 
vaccinated subcutaneously with OVA (10 µg) + E. coli LPS (5 µg), OVA (10 µg) 
+ Alum (25 µL) as a conventional therapy, and mIONPsp-HyNic-FB-OVA (10 µg 
OVA) + mIONPsp-E. Coli LPS (5 µg Ligand) at days 7, 10, and 13, and tumor 
growth was monitored until they reached the limits of the established endpoint 
(Figure 6a, b). The median survival of E. Coli LPS-treated mice was of 26 days 
and the median survival for mIONPsp-E. Coli LPS-treated mice was of 24 days, 
which overall proved that OVA + E. Coli LPS, also when delivered by mIONPsp, 
worked as weak cancer therapies. Both E. Coli LPS- and mIONPsp-E. Coli 
LPS-treated mice showed a similar survival to Alum-treated mice, which 
boasted a median survival of 22 days (Figure 6c). Moreover, the mice in the 
OVA + E. Coli LPS and mIONPsp-HyNic-FB-OVA + mIONPsp-E. Coli LPS 
groups showed ulceration on the tumor when compared to the control group 
confirming that E. Coli LPS as a therapy shows side effects as reported in the 
literature25. All the treatments used did not cause a weight change in the treated 
mice (Figure 7). The therapy using LPS was not effective at delaying tumor 
growth when compared to the control group and the OVA + Alum-treated group, 



























Figure 6. Therapeutic anticancer effect of different adjuvants administered with 
OVA antigen. a) Vaccination scheme. C57BL/6J mice were subcutaneously 
challenged with 3 × 105 B16-F10(OVA) cells/ mouse on day 0 and treated with 
the indicated formulations (10 µg of OVA, 5 µg of E. Coli LPS and 30 µg of 
IONP per mice on day 7, 10 and 13. b) Average tumor growth and c) Kaplan–
Meier survival curves. Data are shown as mean ± SEM from an experiment (n= 
5). 
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Figure 7. Animal weight after tumor injection and therapy. Data are shown as 
mean ± SEM from an experiment (n= 5). 
 
4.2.4: Formulation of mIONPsp-HyNic-FB-OVA with mIONPsp-Poly(I:C)-
imiquimod for improved antigen delivery in a therapeutic setting 
Next, the efficacy of the covalent conjugation of OVA to the mIONPsp 
(mIONPsp-HyNic-FB-OVA) was compared with the mIONPsp-OVA formed by 
electrostatic interaction previously developed in our laboratory as delivery 
vehicle for OVA. These electrostatic nanoparticles were conjugated by simply 
mixing OVA and mIONPsp and were purified using spin filtration to get rid of the 
unbound OVA, and showed an average OVA loading of 7 OVA/ IONPsp, similar 
to that of the covalent mIONPsp-HyNic-FB-OVA system. To compare the 
covalent and electrostatic OVA delivery strategies with IONPsp, a synergistic 
combination of TLR agonists made up of Poly(I:C) and imiquimod (Figure 8), 









































Figure 8. Poly(I:C) and imiquimod. 
 
mIONPsp-Poly(I:C)-imiquimod were coupled with the two different OVA-loaded 
nanoparticles developed, the covalent mIONPsp-HyNic-FB-OVA and the 
electrostatic mIONPsp-OVA and the two resulting nanovaccines were 
subcutaneously injected in the B16-F10(OVA) mice tumor model (Figure 9a). 
The FDA-approved adjuvant alum showed a median survival of 22 days and did 
not work as an effective antitumor therapy when injected with OVA. The use of 
the electrostatic mIONPsp-OVA as antigen delivery vehicle improved the 
median survival of the injected mice to 31 days, with 1 mouse out of 5 rejecting 
the tumor (Figure 9b). Compared to the electrostatic mIONPsp-OVA, the 
covalent mIONPsp-HyNic-FB-OVA significantly delayed tumor growth, with a 
median survival of 51 days and 3/5 mice tumor-free at day 51 after tumor 
injection (Figure 9c). At the administered concentrations, no meaningful 
decrease in the weight of mice administered with our treatments was noticed 























Figure 9. Therapeutic anticancer effect of the adjuvant 
mIONPsp-Poly(I:C)-imiquimod administered with covalent mIONPsp-HyNic-FB-
OVA. a) Vaccination scheme. C57BL/6J mice were subcutaneously challenged 
with 3 × 105 B16-F10(OVA) cells/ mouse on day 0 and treated with mIONPsp-
Poly(I:C)-imiquimod (10 µg of OVA, 4 µg of Poly(I:C), 2 µg of imiquimod and 30 
µg of IONP per mouse on day 7, 10 and 13. b) Average tumor growth and c) 
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Kaplan–Meier survival curves. Data are shown as mean ± SEM from an 
experiment (n= 5). 






















Figure 10. Animal weight after tumor injection and therapy. Data are shown as 
mean ± SEM from an experiment (n= 5). 
 
These results showed that the developed mIONPsp-HyNic-FB-OVA work 
effectively as an antigen delivery vehicle and that vaccine efficacy is strongly 
dependent upon the antigen conjugation strategy used. Moreover, the covalent 
bonding in mIONPsp-HyNic-FB-OVA is acid-labile, which contributes to 
releasing the antigen payload into the lysosomes at a pH of 526. The mIONPsp-
HyNic-FB-OVA is therefore an optimised antigen delivery system based on 











After having developed the two adjuvant-loaded nanoparticle-based delivery 
systems and the antigen loaded mIONPsp-E. Coli LPS, mIONPsp-Xcc LOS, 
and mIONPsp-HyNic-FB-OVA, in vivo experiments were performed to evaluate 
the efficacy of these systems. It was first proved that the adjuvant Xcc LOS 
elicits as potent in vivo immune responses as MPLA (FDA-approved TLR4 
agonist) for the development of anti-cancer vaccines. It was also found that the 
Xcc LOS-, E. Coli LPS- and MPLA- treated mice had a median survival of 34- 
38 days, compared to 28 days in OVA-treated mice. Besides, the formulation 
obtained by combining mIONPsp-Xcc LOS with mIONPsp-HyNic-FB-OVA led to 
enhanced protection against highly aggressive and poorly immunogenic OVA-
expressing B16-F10 murine melanomas, slowing down tumor growth when 
compared to the nanoparticle-free treatments. Moreover, when this formulation 
was combined with abrogation of PD-L1 expression in the melanoma cells, it 
achieved complete tumor rejection in 100 % of the immunized mice. This 
showed the general utility of creating vaccines based on pathogen-mimicking 
nanostructures and the hydrazone ligation reaction for antigen binding, as well 
as the importance of PD-L1 blockade for a significant upgrade of vaccines 
exploiting TLR4 agonists. The developed nanosystems were also tested in a 
therapeutic vaccination setting with a formulation composed by 
mIONPsp-E. Coli LPS and mIONPsp-HyNic-FB-OVA. mIONPsp-E. Coli LPS did 
not show a strong adjuvanticity at the low concentrations used (5 µg LPS/ 
mouse). On the other hand, the antigen delivery system developed in this 
thesis, mIONPsp-HyNic-FB-OVA, was found to work very well and be much 
more effective than mIONPsp-OVA formed by electrostatic interactions. The 
covalent mIONPsp-HyNic-FB-OVA system co-administered with 
mIONPsp-Poly(I:C)-imiquimod as adjuvant led to major improvement of the 
median survival from 31 to 51 days. Moreover, the covalent mIONPsp-HyNic-
FB-OVA improved tumor rejection to 3/5 mice compared with 1/5 in the case of 
the mIONPsp-OVA. This demonstrates the potential of this covalent binding 





4.4: Materials and methods 
Materials: Unless otherwise specified all commercially available reagents were 
used without further purification. Endo-Ova (Endotoxin-free Ovalbumin) was 
purchased from Hyglos GmbH; 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[carboxy(polyethylene glycol)-2000] (DSPE-cPEG) 
was purchased from Avanti polar lipids, Dulbecco’s Modified Eagle Medium 
(DMEM), Fetal Bovine Serum (FBS), Penicillin/Streptomycin (P/S) L- glutamine 
(L-Glu) and collagenase/DNase were all purchased from Gibco; Poly(I:C) and 
Imiquimod were purchased from Invivogen. Cell culture plates and flow 
cytometry tubes were purchased from Nunc; Matrigel® Matrix from Corning, All 
the fluorescently labeled antibodies were obtained from BioLegend, unless 
otherwise specified and SIINFEKL OVA peptide was obtained from Peptides 
International, red blood cells (RBC) lysing buffer, Golgi Stop and 
Cytofix/Cytoperm-fixation and permeabilization kit from BD Biosciences. 
 
Preparation of mIONPsp-Xcc LOS: synthesis of mIONPsp-Xcc LOS was carried 
out as described in chapter 2 of this thesis. 
Preparation of mIONPsp-HyNic-FB-OVA: synthesis of mIONPsp-HyNic-FB-
OVA was carried out as described in chapter 3 of this thesis. 
Preparation of mIONPsp-E. Coli LPS: synthesis of mIONPsp-E. Coli LPS was 
carried out as described in chapter 3 of this thesis. 
Preparation of mIONPsp-OVA: mIONPsp were prepared following a similar 
procedure to the one described in chapter 2 using a different PEG-phospholipid, 
DSPE-cPEG. Briefly, 1 mg of IONPsp and a mixture of 2 mg of PEG 
phospholipids (1 mg DSPE-cPEG and 1 mg DPPE-mPEG) were dissolved in 
500 μL of chloroform in a 4 mL round bottomed glass vial and let to evaporate 
overnight at RT. The flask was placed in a water bath at 80 °C for 30 s, after 
which micelles were re-dissolved in 500 μL of MilliQ water. This solution was 
centrifuged at 9700 xg for 5’ and passed through a 0.45 µm syringe filter to 
remove non-soluble particles. Then, the micelles were centrifuged at 369000 xg 
for 45 minutes; the supernatant was discarded and washed with MilliQ water to 
remove empty PEG micelles (3 cycles). Finally, the pellet was dissolved in 400 
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μL of MilliQ water (or 10 mM Phosphate Buffered Saline, PBS, when injected in 
vivo). Characterization of the so-prepared micelles (mIONPsp-Carboxy) was 
performed using the techniques previously described. 
Electrostatic attachment of OVA: The solution of mIONPsp-Carboxy (3 μM) was 
incubated overnight with endotoxin-free OVA (molar ratio 15:1 OVA to 
mIONPsp) in a final volume of 300 μL of MilliQ water. The unbound OVA was 
eliminated by spin filtration at 1844 xg for 5 min (4 cycles) using 100 KDa 
MWCO Amicons. The pellet (mIONPsp-OVA) was resuspended in the initial 
volume of nanopure water or PBS and stored at 4 °C.  
Preparation of mIONPsp-Poly(I:C)-imiquimod: mIONPsp were prepared 
following a similar procedure to the one described in chapter 2 using a different 
PEG-phospholipid (DPPE-mPEG). Briefly, 1 mg of IONPsp and 2 mg of DPPE-
mPEG were dissolved in 500 μL of chloroform in a 4 mL round bottomed glass 
vial and let to evaporate overnight at RT. The flask was placed in a water bath 
at 80 °C for 30 s, after which micelles were re-dissolved in 1 mL of MilliQ water. 
This solution was centrifuged at 9700 xg for 5’ and passed through a 0.45 µm 
syringe filter to remove non-soluble particles. Then, the micelles were 
centrifuged at 369000 xg for 60 minutes; the supernatant was discarded and 
washed with MilliQ water to remove empty PEG micelles (3 cycles). Finally, the 
pellet was dissolved in 1 mL of MilliQ water (or 10 mM Phosphate Buffered 
Saline, PBS, when injected in vivo). Characterization of the so-prepared 
micelles (mIONPsp-Methoxy 16C) was performed using the techniques 
previously described. 
Electrostatic attachment of Poly(I:C) and imiquimod: Poly(I:C) and imiquimod 
functionalized mIONPsp were developed through a two-step process as 
reported in the literature22. Poly(I:C) and Imiquimod were dissolved in 
endotoxin-free water to a final concentration of 1000 μg/mL and 500 μg/mL 
respectively. After, mIONPsp were mixed with Poly(I:C) and the mixture was 
stirred overnight at room temperature using a benchtop shaker set at 700 rpm. 
The excess of unbound Poly(I:C) was removed by three cycles (5 minutes at 
1475 xg) of spin filtration with NanoSep 100k (MWCO 100 kDa) centrifugal 
devices (Pall Life Sciences). Then, Poly(I:C)-loaded mIONPsp were 
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resuspended in an imiquimod solution, keeping the final volume constant. This 
mixture was stirred and purified as described above. The final pellet was 
resuspended in MilliQ water or phosphate buffered saline (PBS) and stored at 4 
°C.  
Assessment of antitumor prophylactic effect: C57BL/6 mice (6−8 weeks old) 
were immunized subcutaneously in the flanks twice with an interval of 2 weeks 
between injections (100 µL, 50 µL/flank, 1 μg of TLR4 ligands, 5 μg of OVA and 
ca. 25-70 μg of IONPsp per mice). On day 21 after first immunization, 3.5 × 105 
B16-F10(OVA) cells or 2 × 106 B16-F10(OVA) ∆PD-L1 cells diluted in 
PBS:Matrigel® (1:1) were injected subcutaneously in the right back. Animals 
were monitored for tumor growth using an electronic digital caliper 779A series 
(Starrett). Criteria for humane endpoint included tumors greater than 1.5 cm 
diameter and ulceration. Results were expressed as mean ± SEM of at least 5 
mice per group. Blood was taken (50 μL) at several time points after the first 
immunization for analyzing the generated immune response. In the case of 
antibodies production, blood was diluted in PBS and centrifuged (13000 xg, 5 
min) to separate the serum (supernatant) from blood cells (pellet). Blood sera 
were stored at -20 °C. In order to analyze the circulating cellular response, 
blood was diluted up to 4 mL in cold PBS. After centrifugation (1028 xg, 5 min at 
4 °C), the pellet was resuspended in 2 mL of commercial RBC lysing buffer and 
incubated at RT. After washing the cell suspensions twice with 5% FBS in PBS 
via centrifugation, cells were resuspended in complete RPMI-1640, ready for 
further analysis. Secondary lymphoid organs such as spleens were also 
harvested for the analysis of local cellular response. Briefly, spleens were 
harvested and perfused with tissue dissociating mix (3 mL of 
collagenase/DNase I diluted in RPMI-1640 medium), cut into small pieces and 
incubated for 30 min at RT in a sterile Petri dish. The reaction was stopped with 
36 μL of 500 mM EDTA and organs were dissociated with the plunger of a 
syringe. RBC lysis was performed as previously described and the resulting cell 
suspensions were resuspended in complete RPMI-1640. Primary immune cells 
were analyzed for CD8+ T cells, TCM and TEM cells specific for the OVA epitope 
SIINFEKL; extracellular and intracellular TNF-α and IFN-γ production and 
CD107a degranulation marker expression were also analyzed. The 
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quantification of extracellular IFN-γ production was performed by seeding 8 × 
105 splenocytes/well, followed by incubation over 48 h with 10 μg/mL of 
SIINFEKL peptide and analyzing the supernatants by sandwich ELISA, as 
described in the chapter 2. For flow cytometry assays, 1 × 106 splenocytes or 
peripheral blood cells were placed in round-bottom 96-well plates and stained 
with different antibodies. SIINFEKL-specific T cells were stained with Brilliant 
Violet™ 421-labelled anti-CD3, PE-Cy7-labelled anti-CD8, APC-labelled anti-
CD44, FITC-labelled anti-CD62L and PE-labelled H-2kb-OVA257−264 dextramer 
(Immudex). SIINFEKL specific cell percentage was analyzed in the CD8+ T cell 
population (CD3+ and CD8+ double positive); in the TCM cell population (cells 
showing a phenotype of CD44low and CD62Llow within CD3+ and CD8+ double 
positive population); and in the TEM population (CD44high and CD62Llow). To 
study intracellular TNF-α and IFN-γ and the expression of the degranulation 
marker CD107a, cells were placed in 100 μL of RPMI-1640 medium in the 
presence of Golgi Stop, PE-labelled anti-CD107a and 10 μg/mL SIINFEKL 
peptide. After 5 h of incubation at 37°C, cells were washed twice and stained 
with the surface markers Brilliant Violet™ 421-labelled anti-CD3, Brilliant 
Violet™ 510-labelled anti-CD4 and FITC-labelled anti-CD8. Then, cells were 
fixed and permeabilized using the Cytofix/Cytoperm-fixation and 
permeabilization kit, after which intracellular cytokine staining was performed 
(APC-labelled anti-INF-γ and PE-Cy7-labelled anti-TNF-α). T cells were gated 
based on double positive for CD3 and CD8 markers, excluding CD4+ cells if 
needed. Results were represented as IFN-γ and CD107a double positive or 
TNF-α positive cell percentage of total CD3+ CD8+ T cells. Isotype controls were 
added when needed but were not included in the figures for clarity purposes. 
Results were expressed as mean ± SEM of 5 mice per group of immunization, 
analyzed individually and compared to unstimulated wells. 
Statistical analysis: All data presented were expressed as mean ± SEM. The 
differences between the control and the experimental groups were assessed 
using one- or two-way ANOVA followed by Tukey’s test or Bonferroni’s test 
(GraphPad Prism, GraphPad Software, La Jolla, CA). P values of less than 0.05 





Assessment of antitumor therapeutic effect: C57BL/6 mice (6−8 weeks old) 
were subcutaneously injected 3.5 × 105 B16-F10(OVA) cells diluted in 
PBS:Matrigel® (1:4) in the right flank (Day 0). At day 7, 10 and 13 mice were 
injected with a dose of therapeutic (50 µL subcutaneously injected in the hock) 
of PBS, OVA (10 µg) + E. coli LPS (5 µg), OVA (10 µg) + Alum (25 µL), 
mIONPsp-HyNic-FB-OVA (10 µg OVA) + mIONPsp-E. Coli LPS (5 µg Ligand), 
mIONPsp-HyNic-FB-OVA (10 µg OVA) + mIONPsp-Poly(I:C)-imiquimod (10 µg 
of OVA+ 4 µg of Poly(I:C) + 2 µg of Imiquimod per mouse), mIONPsp-OVA + 
mIONPsp-Poly(I:C)-imiquimod, 30 µg of IONP per injection. Animals were 
monitored for tumor growth using an electronic digital caliper 779A series 
(Starrett). Criteria for humane endpoint included tumors greater than 1.5 cm 
diameter and ulceration. Results were expressed as mean ± SEM of at least 5 
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• Different TLR4-agonists loaded nanoplatforms have been synthesized 
and characterized taking advantage of the self-assembly process of 
hydrophobic nanoparticles, PEG-phospholipids and the amphiphilic TLR4 
ligands, resulting in IONPsp-, IONPc-, QDs- and UCNPs- filled 
nanomicelles. These constructs showed a uniform size distribution and 
their hydrodynamic diameters were within the 20-100 nm range ideal for 
lymph node uptake, and their negative ζ-potentials and hydrophobicity 
further contributes to their uptake in the lymph nodes.  
• These nanoparticles could modulate the immunostimulatory activity and 
toxicity of the ligands E. Coli LOS and Xcc LOS in antigen presenting 
cells, with each of the different nanoplatforms affecting these 
characteristics differently. Among the different systems developed, 
mIONPsp-Xcc LOS was selected and used for further in vivo studies. 
• Hydrophobic UCNPs were synthesized, characterized and used to 
prepare two different UCNPs-filled nanomicelles loaded with different 
amounts of the TLR4 antagonist IAXO 102, both showing uniform size 
distribution and a hydrodynamic diameter within the 20-100 nm range for 
lymph node delivery. This was able to suppress LPS induced activation 
of macrophages. 
• mIONPsp were covalently bound to the model antigen OVA using 
hydrazone chemistry, a high-yield, fast, selective and monitorable 
conjugation reaction. The obtained mIONPsp-HyNic-FB-OVA had a low 
polydispersity, a hydrodynamic diameter of ~50 nm suitable for lymph 
node delivery and were stable for weeks in PBS. 
• The hydrazone conjugation chemistry was used to bind OVA to 
mJanusNPs and to prepare mIONPsp-E. Coli LPS/HyNic-FB-OVA both 
characterized by low polydispersity and a hydrodynamic diameter 
suitable for lymph node delivery.  
• Both mIONPsp-Xcc LOS and mIONPsp-HyNic-FB-OVA were 
functionalized with a rhodamine-phospholipid and tracked by 
fluorescence microscopy and were uptaken in the lysosomes in antigen 
presenting cells in 3 h at nanomolar concentrations. 
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• A formulation composed of mIONPsp-Xcc LOS and mIONPsp-HyNic-FB-
OVA was investigated in a mice prophylaxis model against the 
aggressive B16-F10(OVA) melanoma and when coupled to PD-L1 
checkpoint blockade led to complete tumor rejection of even after a re-
challenge, with FACS analysis confirming induction of antigen-specific T 
cells and long-lasting antitumor responses. 
• A formulation composed of mIONPsp-HyNic-FB-OVA and mIONPsp-
Poly(I:C)-imiquimod was injected in mice challenged with B16-F10(OVA) 
melanoma as a therapy. When compared to the electrostatic mIONPsp-
OVA, mIONPsp-HyNic-FB-OVA could enhance the median survival of 

















AD: Alzheimer’s disease  
AGP: Aminoalkyl glucosamidine-4-
phosphates  
ALS: Amyotrophic lateral sclerosis  
APC: Antigen-presenting cells  
BCG: Bacillus Calmette-Guérin 
BECC: Bacterial enzymatic 
combinatorial chemistry  
BMDCs: Bone marrow-derived 
dendritic cells  
BMDMs: Bone marrow-derived 
macrophages  
CD14: Cluster of differentiation 14  
CpG ODN: CpG oligodeoxynucleotide  
CT: Computed tomography  
CTLA-4: Cytotoxic T-lymphocyte-
associated protein 4   
DAMPs: Damage-associated molecular 
patterns  
DCs: Dendritic cells 
DLS: Dynamic light scattering 










(ammonium salt)  
DPPE-mPEG: 1,2-Dipalmitoyl-sn-
glycero-3-phosphoethanolamine-N-
[methoxy (polyethylene glycol)-2000]  
DSPE-aPEG: 2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-




(ammonium salt)  
ED: Effective dose  
EDC: 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide  
EMA: European Medicines Agency   
FDA: American food and drug 
administration  
GLA: Glucopyranosyl lipid A  
HMGB1: High-mobility-group box 1 
alarmin protein  
HNSCC: Head and neck squamous cell 
carcinoma  
IC50: Half maximal inhibitory 
concentration  
IFA: Incomplete Freund’s adjuvant  
IFNs: Interferons 
IL: Interleukin  
IONPc: Iron oxide nanocubes  
IONPs: Iron oxide nanoparticles 
IONPsp: Iron oxide nanospheres 
IR: Infrared spectroscopy (IR). 
JanusNPs: Janus nanoparticles 
Kdo2-Lipid A: 3-deoxy-D-manno-
octulosonic acid-lipid A  




LPS: Lipopolysaccharide  
MHC: Major histocompatibility complex  
mNPs: Nanoparticle-filled micelles  
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MRI: Magnetic resonance imaging 
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MyD88: Myeloid differentiation factor 88  
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NK: Natural killer cell 
NKT: Natural killer T cell  
NSCLC: Non-small cell lung cancer  
RCC: renal cell carcinoma  
OVA: Ovalbumin 
PAMPs: Pathogen-associated 
molecular patterns  
PCho: Phosphorylcholine  
PDT: Photodynamic therapy  
PD-1: Programmed cell death protein 1  
PD-L1: Programmed death-ligand 1  
PEG: Poly(ethylene glycol)  
PEG thiol: Thiol-functionalized PEG  
PLGA: Polylactide-co-glycolide micro- 
or nanoparticles  
PmB: Polymyxin B  
Poly(I:C): Polyinosinic: polycytidylic 
acid  
PRRs: Transmembrane pattern 
recognition receptors  
PS: Photosensitizers  
PTT: Photothermal therapy  
QDs: Quantum dots  
RA: Rheumatoid arthritis  
Rho-PE: 1,2 dipalmitoyl-sn-glycero-3-
phosphoethanolamine-N-
(lissaminerhodamine B sulfonyl) 
(ammonium salt)  
ROS: Reactive oxygen species  
SDS: Sodium dodecyl sulfate  
SDR: Static dephasing regime  
SNR: Signal to noise ratio  
TAAs: Tumor-associated antigens  
TEM: Transmission electron 
microscopy   
TICAM2: TIR-containing adapter 
molecule 2  
TILs: Tumor-infiltrating lymphocytes  
TIR:  Toll-interleukin 1 receptor 
TIRAP: TIR-domain containing adaptor 
protein   
TNF-α: Tumor necrosis factor α  
TLRs:  Toll-like receptors  
TLR4: Toll-like receptor 4   
TRAM: TRIF-related adaptor molecule  
TRIF: TIR-domain-containing adapter-
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UC: Upconversion  
UCNPs: Upconverting nanoparticles  
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